{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:54:07Z","timestamp":1792853647545,"version":"4.5.0"},"reference-count":1624,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Pruritus is a frequent symptom in medicine. Population-based studies show that one in five persons in the general population has suffered from chronic pruritus (CP) at least once in their lifetime, with a 12-month incidence of 7%. CP, which can affect all age groups, is associated with numerous, often interdisciplinary medical conditions. It needs a precise diagnostic work-up to identify causes and relevant comorbidities. Management of CP comprises treatment of the underlying disease as well as topical and systemic therapies. Treating CP needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. In recent years, novel on-label therapies have been approved for CP, including therapies for chronic prurigo and cholestatic pruritus. We present the updated European guideline on chronic pruritus by a team of European pruritus experts from different disciplines.<\/jats:p>","DOI":"10.2340\/actadv.v105.44220","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T09:53:50Z","timestamp":1755856430000},"page":"adv44220","source":"Crossref","is-referenced-by-count":27,"title":["European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)"],"prefix":"10.2340","volume":"105","author":[{"given":"Elke","family":"Weisshaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Garcovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kupfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gimenez-Arnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mettang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Misery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekin","family":"Savk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Tschachler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Wallengren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"122362","doi-asserted-by":"crossref","unstructured":"Abella, B. S., W. E. Berger, M. S. Blaiss, I. G. Stiell, J. P. Herres, J. J. Moellman, S. Suner, A. Kessler, H. A. Klausner, J. M. Caterino and J. Du (2020). \u201cIntravenous Cetirizine Versus Intravenous Diphenhydramine for the Treatment of Acute Urticaria: A Phase III Randomized Controlled Noninferiority Trial.\u201d Ann Emerg Med 76(4): 489\u2013500.","DOI":"10.1016\/j.annemergmed.2020.05.025"},{"key":"122363","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annemergmed.2020.05.025","DOI":"10.1016\/j.annemergmed.2020.05.025"},{"key":"122364","doi-asserted-by":"crossref","unstructured":"Aboeldahab, S., F. Khalil and R. Ezz Eldawla (2021). \u201cClinical and Laboratory Characteristics of Elderly Patients with Pruritus.\u201d Clin Cosmet Investig Dermatol 14: 1009\u20131015.","DOI":"10.2147\/CCID.S322527"},{"key":"122365","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CCID.S322527","DOI":"10.2147\/CCID.S322527"},{"key":"122366","doi-asserted-by":"crossref","unstructured":"Aboeldahab, S. S., F. J. Khalil and R. E. Eldawla (2021). \u201cClinical and Laboratory Characteristics of Elderly Patients with Pruritus.\u201d Clin Cosmet Investig Dermatol 14: 1009\u20131015.","DOI":"10.2147\/CCID.S322527"},{"key":"122367","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CCID.S322527","DOI":"10.2147\/CCID.S322527"},{"key":"122368","doi-asserted-by":"crossref","unstructured":"Acevedo Ribo, M., J. M. Moreno Planas, C. Sanz Moreno, E. E. Rubio Gonzalez, E. Rubio Gonzalez, E. Boullosa Grana, V. Sanchez-Turrion, D. Sanz Guajardo and V. Cuervas-Mons (2005). \u201cTherapy of intractable pruritus with MARS.\u201d Transplant Proc 37(3): 1480\u20131481.","DOI":"10.1016\/j.transproceed.2005.02.002"},{"key":"122369","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.transproceed.2005.02.002","DOI":"10.1016\/j.transproceed.2005.02.002"},{"key":"122370","doi-asserted-by":"crossref","unstructured":"Ada, S., D. Seckin, I. Budakoglu and F. N. Ozdemir (2005). \u201cTreatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study.\u201d J Am Acad Dermatol 53(1): 149\u2013151.","DOI":"10.1016\/j.jaad.2004.12.052"},{"key":"122371","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2004.12.052","DOI":"10.1016\/j.jaad.2004.12.052"},{"key":"122372","unstructured":"Adams, S. (1989). \u201cIron deficiency, serum ferritin, generalized pruritus and systemic disease: a case control study.\u201d Br J Dermatol 121(s34): 15."},{"key":"122373","doi-asserted-by":"crossref","unstructured":"Adreev, V. C. and I. Petkov (1975). \u201cSkin manifestations associated with tumours of the brain.\u201d Br J Dermatol 92(6): 675\u2013678.","DOI":"10.1111\/j.1365-2133.1975.tb03148.x"},{"key":"122374","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1975.tb03148.x","DOI":"10.1111\/j.1365-2133.1975.tb03148.x"},{"key":"122375","doi-asserted-by":"crossref","unstructured":"Afifi, Y., F. Aubin, E. Puzenat, A. Degouy, D. Aubrion, B. Hassam and P. Humbert (2004). \u201c[Pruritus sine materia: a prospective study of 95 patients].\u201d Rev Med Interne 25(7): 490\u2013493.","DOI":"10.1016\/j.revmed.2003.12.015"},{"key":"122376","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.revmed.2003.12.015","DOI":"10.1016\/j.revmed.2003.12.015"},{"key":"122377","doi-asserted-by":"crossref","unstructured":"Agrawal, D., K. Sardana, S. R. Mathachan and A. Ahuja (2023). \u201cA Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib.\u201d Indian Dermatol Online J 14(4): 564\u2013566.","DOI":"10.4103\/idoj.idoj_508_22"},{"key":"122378","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/idoj.idoj_508_22","DOI":"10.4103\/idoj.idoj_508_22"},{"key":"122379","doi-asserted-by":"crossref","unstructured":"Aguilar-Bernier, M., J. Bassas-Vila, C. Sanz-Munoz and A. Miranda-Romero (2005). \u201cSuccessful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis.\u201d Br J Dermatol 152(4): 808\u2013809.","DOI":"10.1111\/j.1365-2133.2005.06498.x"},{"key":"122380","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06498.x","DOI":"10.1111\/j.1365-2133.2005.06498.x"},{"key":"122381","doi-asserted-by":"crossref","unstructured":"Ahmed, A., L. Solman and H. C. Williams (2018). \u201cMagnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.\u201d Br J Dermatol 178(3): 659\u2013662.","DOI":"10.1111\/bjd.16046"},{"key":"122382","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16046","DOI":"10.1111\/bjd.16046"},{"key":"122383","doi-asserted-by":"crossref","unstructured":"Al-Ansari, R. Y., M. Al-Sharari and T. Al-Saadi (2021). \u201cPalms and soles itchiness as a side effect of COVID-19 vaccination.\u201d J Infect Public Health 14(10): 1389\u20131391.","DOI":"10.1016\/j.jiph.2021.08.006"},{"key":"122384","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jiph.2021.08.006","DOI":"10.1016\/j.jiph.2021.08.006"},{"key":"122385","doi-asserted-by":"crossref","unstructured":"Alsakaan, N. A. G., S. Abd-Elsalam, M. M. Fawzy and N. M. Elwan (2022). \u201cEfficacy and safety of oral methotrexate versus oral mini pulse betamethasone therapy in the treatment of lichen planus: a comparative study.\u201d J Dermatolog Treat 33(7): 3039\u20133046.","DOI":"10.1080\/09546634.2022.2104446"},{"key":"122386","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2022.2104446","DOI":"10.1080\/09546634.2022.2104446"},{"key":"122387","doi-asserted-by":"crossref","unstructured":"Ambros-Rudolph, C. M., R. R. Mullegger, S. A. Vaughan-Jones, H. Kerl and M. M. Black (2006). \u201cThe specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients.\u201d J Am Acad Dermatol 54(3): 395\u2013404.","DOI":"10.1016\/j.jaad.2005.12.012"},{"key":"122388","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2005.12.012","DOI":"10.1016\/j.jaad.2005.12.012"},{"key":"122389","doi-asserted-by":"crossref","unstructured":"Amirkhanlou, S., A. Rashedi, J. Taherian, A. A. Hafezi and S. Parsaei (2016). \u201cComparison of Gabapentin and Ketotifen in Treatment of Uremic Pruritus in Hemodialysis Patients.\u201d Pak J Med Sci 32(1): 22\u201326.","DOI":"10.12669\/pjms.321.8547"},{"key":"122390","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.12669\/pjms.321.8547","DOI":"10.12669\/pjms.321.8547"},{"key":"122391","doi-asserted-by":"crossref","unstructured":"Andersen, H. H., J. B. Marker, E. A. Hoeck, J. Elberling and L. Arendt-Nielsen (2017). \u201cAntipruritic effect of pretreatment with topical capsaicin 8% on histamine- and cowhage-evoked itch in healthy volunteers: a randomized, vehicle-controlled, proof-of-concept trial.\u201d Br J Dermatol 177(1): 107\u2013116.","DOI":"10.1111\/bjd.15335"},{"key":"122392","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15335","DOI":"10.1111\/bjd.15335"},{"key":"122393","doi-asserted-by":"crossref","unstructured":"Andersson, N., H. E. Poulsen and J. T. Andersen (2020). \u201cDesloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study.\u201d J Allergy Clin Immunol Pract 8(1598\u20131605).","DOI":"10.1016\/j.jaip.2020.02.017"},{"key":"122394","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2020.02.017","DOI":"10.1016\/j.jaip.2020.02.017"},{"key":"122395","doi-asserted-by":"crossref","unstructured":"Andersson, N. W., C. Torp-Pedersen and J. T. Andersen (2020). \u201cAssociation Between Fexofenadine Use During Pregnancy and Fetal Outcomes.\u201d JAMA Pediatr 174(8): e201316.","DOI":"10.1001\/jamapediatrics.2020.1316"},{"key":"122396","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamapediatrics.2020.1316","DOI":"10.1001\/jamapediatrics.2020.1316"},{"key":"122397","doi-asserted-by":"crossref","unstructured":"Andoh, T., Y. Asakawa and Y. Kuraishi (2018). \u201cNon-myelinated C-fibers, but not myelinated A-fibers, elongate into the epidermis in dry skin with itch.\u201d Neurosci Lett 672: 84\u201389.","DOI":"10.1016\/j.neulet.2018.02.034"},{"key":"122398","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.neulet.2018.02.034","DOI":"10.1016\/j.neulet.2018.02.034"},{"key":"122399","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, F. and B. C. B\u00f6ckle (2022). \u201cSj\u00f6gren\u2019s syndrome.\u201d J Dtsch Dermatol Ges 20(7): 980\u20131002.","DOI":"10.1111\/ddg.14823"},{"key":"122400","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14823","DOI":"10.1111\/ddg.14823"},{"key":"122401","doi-asserted-by":"crossref","unstructured":"Ang-Tiu, C. U., C. F. Meghrajani and C. C. Maano (2012). \u201cPimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials.\u201d Expert Rev Clin Pharmacol 5(1): 91\u201397.","DOI":"10.1586\/ecp.11.68"},{"key":"122402","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1586\/ecp.11.68","DOI":"10.1586\/ecp.11.68"},{"key":"122403","doi-asserted-by":"crossref","unstructured":"Aperis, G., C. Paliouras, A. Zervos, A. Arvanitis and P. Alivanis (2010). \u201cThe use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients.\u201d J Ren Care 36(4): 180\u2013185.","DOI":"10.1111\/j.1755-6686.2010.00190.x"},{"key":"122404","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1755-6686.2010.00190.x","DOI":"10.1111\/j.1755-6686.2010.00190.x"},{"key":"122405","doi-asserted-by":"crossref","unstructured":"Apfelbacher, C. J., E. J. van Zuuren, Z. Fedorowicz, A. Jupiter, U. Matterne and E. Weisshaar (2013). \u201cOral H1 antihistamines as monotherapy for eczema.\u201d Cochrane Database Syst Rev 2: CD007770.","DOI":"10.1002\/14651858.CD007770.pub2"},{"key":"122406","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD007770.pub2","DOI":"10.1002\/14651858.CD007770.pub2"},{"key":"122407","doi-asserted-by":"crossref","unstructured":"Appleby, V. J., J. M. Hutchinson and M. H. Davies (2015). \u201cSafety and efficacy of long-term nasobiliary drainage to treat intractable pruritus in cholestatic liver disease.\u201d Frontline Gastroenterol 6(4): 252\u2013254.","DOI":"10.1136\/flgastro-2014-100489"},{"key":"122408","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/flgastro-2014-100489","DOI":"10.1136\/flgastro-2014-100489"},{"key":"122409","doi-asserted-by":"crossref","unstructured":"Aquino, T. M. O., K. A. C. Luchangco, E. V. Sanchez and V. M. e. a. Verallo-Rowell (2020). \u201cA randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus.\u201d Int J Dermatol 59(8): 955\u2013961.","DOI":"10.1111\/ijd.14953"},{"key":"122410","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.14953","DOI":"10.1111\/ijd.14953"},{"key":"122411","doi-asserted-by":"crossref","unstructured":"Argoff, C. E., N. Katz and M. Backonja (2004). \u201cTreatment of postherpetic neuralgia: a review of therapeutic options.\u201d J Pain Symptom Manage 28(4): 396\u2013411.","DOI":"10.1016\/j.jpainsymman.2004.01.014"},{"key":"122412","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.01.014","DOI":"10.1016\/j.jpainsymman.2004.01.014"},{"key":"122413","doi-asserted-by":"crossref","unstructured":"Armstrong, A. W., M. Augustin, J. L. Beaumont and T. P. e. a. Pham (2024). \u201cDeucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.\u201d Dermatol Ther (Heidelb) 14(8): 2235\u20132248.","DOI":"10.1007\/s13555-024-01224-x"},{"key":"122414","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-024-01224-x","DOI":"10.1007\/s13555-024-01224-x"},{"key":"122415","doi-asserted-by":"crossref","unstructured":"Arrese, J. E., L. Dominguez-Soto, M. T. Hojyo-Tomoka, E. Vega-Memije, R. Cortes-Franco, E. Guevara and G. E. Pierard (2001). \u201cEffectors of inflammation in actinic prurigo.\u201d J Am Acad Dermatol 44(6): 957\u2013961.","DOI":"10.1067\/mjd.2001.113477"},{"key":"122416","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2001.113477","DOI":"10.1067\/mjd.2001.113477"},{"key":"122417","doi-asserted-by":"crossref","unstructured":"Ashmore, S. D., C. H. Jones, C. G. Newstead, M. J. Daly and H. Chrystyn (2000). \u201cOndansetron therapy for uremic pruritus in hemodialysis patients.\u201d Am J Kidney Dis 35(5): 827\u2013831.","DOI":"10.1016\/S0272-6386(00)70251-4"},{"key":"122418","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0272-6386(00)70251-4","DOI":"10.1016\/S0272-6386(00)70251-4"},{"key":"122419","doi-asserted-by":"crossref","unstructured":"Ataei, S., L. Kord, A. Larki, F. Yasrebifar, M. Mehrpooya, M. Seyedtabib and M. Hasanzarrini (2019). \u201cComparison of Sertraline with Rifampin in the treatment of Cholestatic Pruritus: A Randomized Clinical Trial.\u201d Rev Recent Clin Trials 14(3): 217\u2013223.","DOI":"10.2174\/1574887114666190328130720"},{"key":"122420","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2174\/1574887114666190328130720","DOI":"10.2174\/1574887114666190328130720"},{"key":"122421","doi-asserted-by":"crossref","unstructured":"Augustin, M., C. Garbe, K. Hagenstr\u00f6m, J. Petersen, M. P. Pereira and S. St\u00e4nder (2021). \u201cPrevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis.\u201d J Eur Acad Dermatol Venereol 35(11): 2270\u20132276.","DOI":"10.1111\/jdv.17485"},{"key":"122422","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17485","DOI":"10.1111\/jdv.17485"},{"key":"122423","doi-asserted-by":"crossref","unstructured":"Augustin, M., J. Lambert, C. Zema and E. H. Z. e. a. Thompson (2020). \u201cEffect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.\u201d JAMA Dermatol 156(12): 1344-1353.","DOI":"10.1001\/jamadermatol.2020.3617"},{"key":"122424","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3617","DOI":"10.1001\/jamadermatol.2020.3617"},{"key":"122425","doi-asserted-by":"crossref","unstructured":"Avgerinou, G., D.-K. Papafragkaki, A. Nasiopoulou, A. Arapaki, A. Katsambas and P. G. Stavropoulos (2012). \u201cEffectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus.\u201d J Eur Acad Dermatol Venereol 26: 762-767.","DOI":"10.1111\/j.1468-3083.2011.04161.x"},{"key":"122426","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04161.x","DOI":"10.1111\/j.1468-3083.2011.04161.x"},{"key":"122427","unstructured":"Badiee Aval, S., Y. Ravanshad, A. Azarfar, H. Mehrad-Majd, S. Torabi and S. Ravanshad (2018). \u201cA Systematic Review and Meta-analysis of Using Acupuncture and Acupressure for Uremic Pruritus.\u201d Iran J Kidney Dis 12(2): 78-83."},{"key":"122428","doi-asserted-by":"crossref","unstructured":"Baldo, A., E. Sammarco, R. Plaitano, V. Martinelli and Monfrecola (2002). \u201cNarrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera.\u201d Br J Dermatol 147(5): 979-981.","DOI":"10.1046\/j.1365-2133.2002.04983.x"},{"key":"122429","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04983.x","DOI":"10.1046\/j.1365-2133.2002.04983.x"},{"key":"122430","doi-asserted-by":"crossref","unstructured":"Baltas, E., Z. Csoma, L. Bodai, F. Ignacz, A. Dobozy and L. Kemeny (2006). \u201cTreatment of atopic dermatitis with the xenon chloride excimer laser.\u201d J Eur Acad Dermatol Venereol 20(6): 657-660.","DOI":"10.1111\/j.1468-3083.2006.01495.x"},{"key":"122431","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01495.x","DOI":"10.1111\/j.1468-3083.2006.01495.x"},{"key":"122432","doi-asserted-by":"crossref","unstructured":"Banerji, D., R. Fox, M. Seleznick and R. Lockey (1988). \u201cControlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis.\u201d J Allergy Clin Immunol 81: 252 (Abstr.).","DOI":"10.1016\/0091-6749(88)90571-4"},{"key":"122433","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0091-6749(88)90571-4","DOI":"10.1016\/0091-6749(88)90571-4"},{"key":"122434","doi-asserted-by":"crossref","unstructured":"Baschong, A., F. Spiess, P. C. Cattin, A. Navarini and S. M. Mueller (2021). \u201cItch reduction using immersive virtual reality-An experimental pilot study.\u201d Dermatol Ther 34(4): e15001.","DOI":"10.1111\/dth.15001"},{"key":"122435","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15001","DOI":"10.1111\/dth.15001"},{"key":"122436","doi-asserted-by":"crossref","unstructured":"Bathe, A., U. Matterne, M. Dewald, T. Grande and E. Weisshaar (2009). \u201cEducational multidisciplinary training programme for patients with chronic pruritus.\u201d Acta Derm Venereol 89(5): 498-501.","DOI":"10.2340\/00015555-0684"},{"key":"122437","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0684","DOI":"10.2340\/00015555-0684"},{"key":"122438","doi-asserted-by":"crossref","unstructured":"Bathe, A., E. Weisshaar and U. Matterne (2013). \u201cChronic pruritus-more than a symptom: a qualitative investigation into patients\u2019 subjective illness perceptions.\u201d J Adv Nurs 69(2): 316-326.","DOI":"10.1111\/j.1365-2648.2012.06009.x"},{"key":"122439","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2648.2012.06009.x","DOI":"10.1111\/j.1365-2648.2012.06009.x"},{"key":"122440","doi-asserted-by":"crossref","unstructured":"Bauer, A., M.-L. Schuttelaar, K. Baranowsk, U. Plohberger, L. S\u00f8rensen and M. Worm (2024). \u201c654 - Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and -2 trials.\u201d BJD 191(Suppl 2).","DOI":"10.1093\/bjd\/ljae266.033"},{"key":"122441","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljae266.033","DOI":"10.1093\/bjd\/ljae266.033"},{"key":"122442","doi-asserted-by":"crossref","unstructured":"Bauer, M., R. Schwameis, T. Scherzer, I. Lang-Zwosta, K. Nishino and M. Zeitlinger (2015). \u201cA double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain.\u201d J Dermatolog Treat 26(4): 367-372.","DOI":"10.3109\/09546634.2014.992384"},{"key":"122443","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/09546634.2014.992384","DOI":"10.3109\/09546634.2014.992384"},{"key":"122444","doi-asserted-by":"crossref","unstructured":"Baumann, U., E. Sturm and F. e. a. Lacaille (2021). \u201cEffects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.\u201d Clin Res Hepatol Gastroenterol 45(5): 101751.","DOI":"10.1016\/j.clinre.2021.101751"},{"key":"122445","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101751","DOI":"10.1016\/j.clinre.2021.101751"},{"key":"122446","doi-asserted-by":"crossref","unstructured":"Bellmann, R., C. Feistritzer, H. Zoller, I. W. Graziadei, H. Schwaighofer, A. Propst, C. J. Wiedermann and M. Joannidis (2004). \u201cTreatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases.\u201d ASAIO J 50(4): 387-391.","DOI":"10.1097\/01.MAT.0000132552.58214.00"},{"key":"122447","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/01.MAT.0000132552.58214.00","DOI":"10.1097\/01.MAT.0000132552.58214.00"},{"key":"122448","doi-asserted-by":"crossref","unstructured":"Bellmann, R., I. W. Graziadei, C. Feistritzer, H. Schwaighofer, F. Stellaard, E. Sturm, C. J. Wiedermann and M. Joannidis (2004). \u201cTreatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis.\u201d Liver Transpl 10(1): 107-114.","DOI":"10.1002\/lt.20001"},{"key":"122449","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/lt.20001","DOI":"10.1002\/lt.20001"},{"key":"122450","doi-asserted-by":"crossref","unstructured":"Belloni Fortina, A. and E. Fontana (2014). \u201cUpdate on antihistamine treatment for chronic urticaria in children.\u201d Curr Treat Options Allergy 1: 287.","DOI":"10.1007\/s40521-014-0023-z"},{"key":"122451","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40521-014-0023-z","DOI":"10.1007\/s40521-014-0023-z"},{"key":"122452","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V. (2005). \u201cThe pruritus of cholestasis.\u201d J Hepatol 43(6): 1078-1088.","DOI":"10.1016\/j.jhep.2005.09.004"},{"key":"122453","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jhep.2005.09.004","DOI":"10.1016\/j.jhep.2005.09.004"},{"key":"122454","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V., D. W. Alling, T. L. Talbot, M. G. Swain, C. Yurdaydin, M. L. Turner, J. M. Schmitt, E. C. Walker and E. A. Jones (1995). \u201cEffects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.\u201d Ann Intern Med 123(3): 161-167.","DOI":"10.7326\/0003-4819-123-3-199508010-00001"},{"key":"122455","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7326\/0003-4819-123-3-199508010-00001","DOI":"10.7326\/0003-4819-123-3-199508010-00001"},{"key":"122456","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V., D. W. Alling, T. L. Talbot, M. C. Wells and E. A. Jones (1999). \u201cOral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.\u201d J Am Acad Dermatol 41(3 Pt 1): 431-434.","DOI":"10.1016\/S0190-9622(99)70117-9"},{"key":"122457","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(99)70117-9","DOI":"10.1016\/S0190-9622(99)70117-9"},{"key":"122458","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V., M. J. Link, M. Keogh, G. Yaroslavsky, R. N. Rosenthal and M. McGee (2001). \u201cPilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease.\u201d Am J Gastroenterol 96(5): 1563-1570.","DOI":"10.1111\/j.1572-0241.2001.03778.x"},{"key":"122459","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1572-0241.2001.03778.x","DOI":"10.1111\/j.1572-0241.2001.03778.x"},{"key":"122460","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V., M. McGee, I. H. Ginsburg and D. Engler (2006). \u201cGabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial.\u201d Hepatology 44(5): 1317-1323.","DOI":"10.1002\/hep.21370"},{"key":"122461","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/hep.21370","DOI":"10.1002\/hep.21370"},{"key":"122462","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V., J. K. Mehlman and E. A. Jones (2000). \u201cPruritus and fatigue in primary biliary cirrhosis.\u201d Baillieres Best Pract Res Clin Gastroenterol 14(4): 643-655.","DOI":"10.1053\/bega.2000.0109"},{"key":"122463","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1053\/bega.2000.0109","DOI":"10.1053\/bega.2000.0109"},{"key":"122464","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V., J. M. Schmitt, T. L. Talbot, D. W. Alling, M. G. Swain, M. L. Turner, J. B. Jenkins and E. A. Jones (1998). \u201cOpen-label trial of oral nalmefene therapy for the pruritus of cholestasis.\u201d Hepatology 27(3): 679-684.","DOI":"10.1002\/hep.510270307"},{"key":"122465","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/hep.510270307","DOI":"10.1002\/hep.510270307"},{"key":"122466","doi-asserted-by":"crossref","unstructured":"Bergasa, N. V., T. L. Talbot, D. W. Alling, J. M. Schmitt, E. C. Walker, B. L. Baker, J. C. Korenman, Y. Park, J. H. Hoofnagle and E. A. Jones (1992). \u201cA controlled trial of naloxone infusions for the pruritus of chronic cholestasis.\u201d Gastroenterology 102(2): 544-549.","DOI":"10.1016\/0016-5085(92)90102-5"},{"key":"122467","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0016-5085(92)90102-5","DOI":"10.1016\/0016-5085(92)90102-5"},{"key":"122468","doi-asserted-by":"crossref","unstructured":"Berger, T. G., M. Shive and G. M. Harper (2013). \u201cPruritus in the older patient: a clinical review.\u201d Jama 310: 2443-2450.","DOI":"10.1001\/jama.2013.282023"},{"key":"122469","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jama.2013.282023","DOI":"10.1001\/jama.2013.282023"},{"key":"122470","doi-asserted-by":"crossref","unstructured":"Berger, T. G. and M. Steinhoff (2011). \u201cPruritus and renal failure.\u201d Semin Cutan Med Surg 30(2): 99-100.","DOI":"10.1016\/j.sder.2011.04.005"},{"key":"122471","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.sder.2011.04.005","DOI":"10.1016\/j.sder.2011.04.005"},{"key":"122472","doi-asserted-by":"crossref","unstructured":"Bergqvist, C., C. Fiani, A. Simantov, C. Lebre, C. Hua, N. Ortonne, P. Wolkenstein and O. Chosidow (2021). \u201cCombined Methotrexate and Alitretinoin for the treatment of difficult-to-treat generalized prurigo nodularis: a case series.\u201d J Eur Acad Dermatol Venereol 35(8): e516-e519.","DOI":"10.1111\/jdv.17262"},{"key":"122473","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17262","DOI":"10.1111\/jdv.17262"},{"key":"122474","unstructured":"Bernhard, J. D. (1994). Itch: Mechanisms and management of pruritus. New York, McGraw-Hill."},{"key":"122475","doi-asserted-by":"crossref","unstructured":"Bernstein, J. E., L. C. Parish, M. Rapaport, M. M. Rosenbaum and H. H. Roenigk, Jr. (1986). \u201cEffects of topically applied capsaicin on moderate and severe psoriasis vulgaris.\u201d J Am Acad Dermatol 15(3): 504-507.","DOI":"10.1016\/S0190-9622(86)70201-6"},{"key":"122476","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(86)70201-6","DOI":"10.1016\/S0190-9622(86)70201-6"},{"key":"122477","doi-asserted-by":"crossref","unstructured":"Berth-Jones, J., I. Pollock, R. M. Heran, S. Lewis-Jones, M. Goodfield, C. E. Griiffiths, R. Gulati, P. McHenry, A. Abdullah, J. Ott, A. Wright, B. Walker, M. T. Stevens and A. M. Edwards (2015). \u201cA randomised, controlled trial of a 4% cutaneous emulsion of sodium cromoglicate in treatment of atopic dermatitis in children.\u201d J Dermatol Treat 26: 291-296.","DOI":"10.3109\/09546634.2014.946380"},{"key":"122478","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/09546634.2014.946380","DOI":"10.3109\/09546634.2014.946380"},{"key":"122479","doi-asserted-by":"crossref","unstructured":"Berth-Jones, J., S. G. Smith and R. A. Graham-Brown (1995). \u201cNodular prurigo responds to cyclosporin.\u201d Br J Dermatol 132(5): 795-799.","DOI":"10.1111\/j.1365-2133.1995.tb00729.x"},{"key":"122480","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb00729.x","DOI":"10.1111\/j.1365-2133.1995.tb00729.x"},{"key":"122481","doi-asserted-by":"crossref","unstructured":"Beuers, U., A. E. Kremer, R. Bolier and R. P. Elferink (2014). \u201cPruritus in cholestasis: facts and fiction.\u201d Hepatology 60(1): 399-407.","DOI":"10.1002\/hep.26909"},{"key":"122482","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/hep.26909","DOI":"10.1002\/hep.26909"},{"key":"122483","doi-asserted-by":"crossref","unstructured":"Bieber, T., E. L. Simpson, J. I. Silverberg, T. Diamant and C. Paul, et al. (2021). \u201cAbrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.\u201d N Engl J Med 384(12): 1101-1112.","DOI":"10.1056\/NEJMoa2019380"},{"key":"122484","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2019380","DOI":"10.1056\/NEJMoa2019380"},{"key":"122485","doi-asserted-by":"crossref","unstructured":"Biondi, M., T. Arcangeli and R. M. Petrucci (2000). \u201cParoxetine in a case of psychogenic pruritus and neurotic excoriations.\u201d Psychother Psychosom 69(3): 165-166.","DOI":"10.1159\/000012386"},{"key":"122486","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000012386","DOI":"10.1159\/000012386"},{"key":"122487","doi-asserted-by":"crossref","unstructured":"Bissonnette, R., R. B. Warren, A. Pinter and T. e. a. Agner (2024). \u201cEfficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.\u201d Lancet 404(10451): 461-473.","DOI":"10.1093\/bjd\/ljae266.032"},{"key":"122488","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(24)01027-4","DOI":"10.1016\/S0140-6736(24)01027-4"},{"key":"122489","doi-asserted-by":"crossref","unstructured":"Blachley, J. D., D. M. Blankenship, A. Menter, T. F. Parker, 3rd and J. P. Knochel (1985). \u201cUremic pruritus: skin divalent ion content and response to ultraviolet phototherapy.\u201d Am J Kidney Dis 5(5): 237-241.","DOI":"10.1016\/S0272-6386(85)80115-3"},{"key":"122490","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0272-6386(85)80115-3","DOI":"10.1016\/S0272-6386(85)80115-3"},{"key":"122491","doi-asserted-by":"crossref","unstructured":"Blauvelt, A., M. de Bruin-Weller, M. Gooderham and J. C. e. a. Cather (2017). \u201cLong-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.\u201d Lancet 389(10086): 2287-2303.","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"122492","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"122493","doi-asserted-by":"crossref","unstructured":"Blauvelt, A., K. Papp, A. Gottlieb, A. Jarell and K. Reich, et al. (2020). \u201cA head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.\u201d Br J Dermatol 182(6): 1348-1358.","DOI":"10.1111\/bjd.18851"},{"key":"122494","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18851","DOI":"10.1111\/bjd.18851"},{"key":"122495","doi-asserted-by":"crossref","unstructured":"Blauvelt, A., H. D. Teixeira and E. L. Simpson (2021). \u201cEfficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis - A Randomized Clinical Trial.\u201d JAMA Dermatol 157(9): 1047-1055.","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"122496","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"122497","doi-asserted-by":"crossref","unstructured":"Bonnel, R. A., L. La Grenade, C. B. Karwoski and J. G. Beitz (2003). \u201cAllergic contact dermatitis from topical doxepin: Food and Drug Administration\u2019s postmarketing surveillance experience.\u201d J Am Acad Dermatol 48(2): 294-296.","DOI":"10.1067\/mjd.2003.46"},{"key":"122498","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2003.46","DOI":"10.1067\/mjd.2003.46"},{"key":"122499","doi-asserted-by":"crossref","unstructured":"Booken, N., M. Heck, J. P. Nicolay, C. D. Klemke, S. Goerdt and J. Utikal (2011). \u201cOral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.\u201d Br J Dermatol 164(3): 665-667.","DOI":"10.1111\/j.1365-2133.2010.10108.x"},{"key":"122500","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10108.x","DOI":"10.1111\/j.1365-2133.2010.10108.x"},{"key":"122501","doi-asserted-by":"crossref","unstructured":"Bornh\u00f6vd, E., W. H. C. Burgdorf and A. Wallenberg (2001). \u201cMacrolactam immunomodulators for topical treatment of inflammatory skin diseases.\u201d J Am Acad Dermatol 45(5): 736-743.","DOI":"10.1067\/mjd.2001.117525"},{"key":"122502","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2001.117525","DOI":"10.1067\/mjd.2001.117525"},{"key":"122503","doi-asserted-by":"crossref","unstructured":"Bosecker, P., S. St\u00e4nder, G. Heuft, L. Dieckmann and G. Schneider (2011). \u201cKonzept und Evaluation einer einst\u00fcndigen psychoedukativen Gruppenintervention f\u00fcr Patienten mit chronischem Pruritus.\u201d Z Psychosom Med Psychother 57(377-386).","DOI":"10.13109\/zptm.2011.57.4.377"},{"key":"122504","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.13109\/zptm.2011.57.4.377","DOI":"10.13109\/zptm.2011.57.4.377"},{"key":"122505","doi-asserted-by":"crossref","unstructured":"Brasileiro, L. E. E., D. P. Barreto and E. A. Nunes (2016). \u201cPsychotropics in different causes of itch: systematic review with controlled studies.\u201d An Bras Dermatol 9(6): 791-798.","DOI":"10.1590\/abd1806-4841.20164878"},{"key":"122506","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1590\/abd1806-4841.20164878","DOI":"10.1590\/abd1806-4841.20164878"},{"key":"122507","doi-asserted-by":"crossref","unstructured":"Brenaut, E., P. Marcorelles, S. Genestet, D. M\u00e9nard and L. Misery (2015). \u201cPruritus: an underrecognized symptom of small-fiber neuropathies.\u201d J Am Acad Dermatol 72(2): 328-332.","DOI":"10.1016\/j.jaad.2014.10.034"},{"key":"122508","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2014.10.034","DOI":"10.1016\/j.jaad.2014.10.034"},{"key":"122509","doi-asserted-by":"crossref","unstructured":"Breneman, D. L., J. S. Cardone, R. F. Blumsack, R. M. Lather, E. A. Searle and V. E. Pollack (1992). \u201cTopical capsaicin for treatment of hemodialysis-related pruritus.\u201d J Am Acad Dermatol 26(1): 91-94.","DOI":"10.1016\/0190-9622(92)70013-6"},{"key":"122510","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0190-9622(92)70013-6","DOI":"10.1016\/0190-9622(92)70013-6"},{"key":"122511","doi-asserted-by":"crossref","unstructured":"Breternitz, M., D. Kowatzki, M. Langenauer, P. Elsner and J. W. Fluhr (2008). \u201cPlacebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation.\u201d Skin Pharmacol Physiol 21(1): 39-45.","DOI":"10.1159\/000111134"},{"key":"122512","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000111134","DOI":"10.1159\/000111134"},{"key":"122513","unstructured":"Britt, H., Y. Pan, G. C. Miller, L. Valenti, J. Charles, S. Knox, J. Henderson, C. Bayram and C. Harrison (2004). \u201cPresentations of \u2018itch\u2019 in Australian general practice.\u201d Aust Fam Physician 33(7): 488."},{"key":"122514","unstructured":"Brunner, W. (1995). \u201c[Pruritus--also a challenge in internal medicine].\u201d Schweiz Med Wochenschr 125(46): 2244-2250."},{"key":"122515","doi-asserted-by":"crossref","unstructured":"Butala, S., L. Castelo-Soccio, R. Seshadri and E. L. e. a. Simpson (2023). \u201cBiologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations.\u201d J Allergy Clin Immunol Pract 11(5): 1361-1373.","DOI":"10.1016\/j.jaip.2023.03.011"},{"key":"122516","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2023.03.011","DOI":"10.1016\/j.jaip.2023.03.011"},{"key":"122517","doi-asserted-by":"crossref","unstructured":"Cacciapuoti, S., L. Potestio, L. Gallo and M. L. e. a. Musumeci (2024). \u201cShort-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience.\u201d Int J Dermatol.","DOI":"10.1111\/ijd.17368"},{"key":"122518","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.17368","DOI":"10.1111\/ijd.17368"},{"key":"122519","doi-asserted-by":"crossref","unstructured":"Cacoub, P., T. Poynard, P. Ghillani, F. Charlotte, M. Olivi, J. C. Piette and P. Opolon (1999). \u201cExtrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.\u201d Arthritis Rheum 42(10): 2204-2212.","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"122520","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"122521","doi-asserted-by":"crossref","unstructured":"Calikoglu, E. and R. Anadolu (2002). \u201cManagement of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin.\u201d Acta Derm Venereol 82(5): 380-382.","DOI":"10.1080\/000155502320624168"},{"key":"122522","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/000155502320624168","DOI":"10.1080\/000155502320624168"},{"key":"122523","unstructured":"Canavero, S., V. Bonicalzi and B. Massa-Micon (1997). \u201cCentral neurogenic pruritus: a literature review.\u201d Acta Neurol Belg 97(4): 244-247."},{"key":"122524","doi-asserted-by":"crossref","unstructured":"Cao, T., H. L. Tey and G. Yosipovitch (2018). \u201cChronic Pruritus in the Geriatric Population.\u201d Dermatol Clin 36(3): 199-211.","DOI":"10.1016\/j.det.2018.02.004"},{"key":"122525","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.det.2018.02.004","DOI":"10.1016\/j.det.2018.02.004"},{"key":"122526","doi-asserted-by":"crossref","unstructured":"Cao, T., A. A. Yong, K. B. Tan and H. L. Tey (2015). \u201cIdiopathic aquagenic pruritus: pathogenesis and effective treatment with atenolol.\u201d Dermatol Ther 28(3): 118-121.","DOI":"10.1111\/dth.12194"},{"key":"122527","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.12194","DOI":"10.1111\/dth.12194"},{"key":"122528","doi-asserted-by":"crossref","unstructured":"Caravati, C. M., Jr., D. R. Richardson, B. T. Wood and E. P. Cawley (1969). \u201cCutaneous manifestations of hyperthyroidism.\u201d South Med J 62(9): 1127-1130.","DOI":"10.1097\/00007611-196909000-00020"},{"key":"122529","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/00007611-196909000-00020","DOI":"10.1097\/00007611-196909000-00020"},{"key":"122530","doi-asserted-by":"crossref","unstructured":"Carlsson, C. P. and J. Wallengren (2010). \u201cTherapeutic and experimental therapeutic studies on acupuncture and itch: review of the literature.\u201d J Eur Acad Dermatol Venereol 24(9): 1013-1016 https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03585.x","DOI":"10.1111\/j.1468-3083.2010.03585.x"},{"key":"122531","doi-asserted-by":"crossref","unstructured":"Cataldi, M., M. Maurer, M. Taglialatela and M. K. Church (2019). \u201cCardiac safety of second-generation H(1) -antihistamines when updosed in chronic spontaneous urticaria.\u201d Clin Exp Allergy 49(12): 1615-1623.","DOI":"10.1111\/cea.13500"},{"key":"122532","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/cea.13500","DOI":"10.1111\/cea.13500"},{"key":"122533","doi-asserted-by":"crossref","unstructured":"Cedeno-Laurent, F., E. M. Singer, M. Wysocka, B. M. Benoit, C. C. Vittorio, E. J. Kim, G. Yosipovitch and A. H. Rook (2015). \u201cImproved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.\u201d Clin Immunol 158(1): 1-7.","DOI":"10.1016\/j.clim.2015.02.014"},{"key":"122534","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clim.2015.02.014","DOI":"10.1016\/j.clim.2015.02.014"},{"key":"122535","doi-asserted-by":"crossref","unstructured":"Cenzer, I., N. Nkansah-Mahaneyn, M. Wehner, M.-M. Chren, T. Berger, K. Covinsky, K. Berger, K. Abuabara and E. Linos (2020). \u201cA Multi Year Cross Sectional Study of US National Prescribing Patterns of First Generation Sedating Antihistamines in Older Adults with Skin Disease.\u201d Br J Dermatol 182(3): 763-769.","DOI":"10.1111\/bjd.18042"},{"key":"122536","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18042","DOI":"10.1111\/bjd.18042"},{"key":"122537","doi-asserted-by":"crossref","unstructured":"Cevikbas, F. and E. A. Lerner (2020). \u201cPhysiology and pathophysiology of itch.\u201d Physiol Rev 100: 945-982.","DOI":"10.1152\/physrev.00017.2019"},{"key":"122538","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1152\/physrev.00017.2019","DOI":"10.1152\/physrev.00017.2019"},{"key":"122539","doi-asserted-by":"crossref","unstructured":"Chan, K. Y., C. W. Li, H. Wong, T. Yip, M. L. Chan, H. W. Cheng and M. K. Sham (2013). \u201cUse of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients.\u201d J Palliat Med 16(8): 966-970.","DOI":"10.1089\/jpm.2012.0504"},{"key":"122540","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1089\/jpm.2012.0504","DOI":"10.1089\/jpm.2012.0504"},{"key":"122541","doi-asserted-by":"crossref","unstructured":"Chan, S., V. Reddy, B. Myers, N. Brownstone, Q. Thibodeaux and J. Koo (2020). \u201cHigh-dose doxepin for the treatment of chronic, intractable scalp pruritus.\u201d JAAD Case Rep 24: 71-73.","DOI":"10.1016\/j.jdcr.2020.12.017"},{"key":"122542","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.017","DOI":"10.1016\/j.jdcr.2020.12.017"},{"key":"122543","doi-asserted-by":"crossref","unstructured":"Chanarin, I. and L. Szur (1975). \u201cLetter: Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine.\u201d Br J Haematol 29(4): 669-670.","DOI":"10.1111\/j.1365-2141.1975.tb02753.x"},{"key":"122544","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2141.1975.tb02753.x","DOI":"10.1111\/j.1365-2141.1975.tb02753.x"},{"key":"122545","doi-asserted-by":"crossref","unstructured":"Che-Yi, C., C. Y. Wen, K. Min-Tsung and H. Chiu-Ching (2005). \u201cAcupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus.\u201d Nephrol Dial Transplant 20(9): 1912-1915.","DOI":"10.1093\/ndt\/gfh955"},{"key":"122546","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/gfh955","DOI":"10.1093\/ndt\/gfh955"},{"key":"122547","doi-asserted-by":"crossref","unstructured":"Chen, Y. C., W. T. Chiu and M. S. Wu (2006). \u201cTherapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus.\u201d Am J Kidney Dis 48(1): 69-76.","DOI":"10.1053\/j.ajkd.2006.03.082"},{"key":"122548","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1053\/j.ajkd.2006.03.082","DOI":"10.1053\/j.ajkd.2006.03.082"},{"key":"122549","doi-asserted-by":"crossref","unstructured":"Chi, C. C., G. Kirtschig, W. Aberer, J. P. Gabbud, J. Lipozen\u010di\u0107, S. K\u00e1rp\u00e1ti, U. F. Haustein, F. Wojnarowska and T. Zuberbier (2017). \u201cUpdated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy.\u201d J Eur Acad Dermatol Venereol 31(5): 761-773.","DOI":"10.1111\/jdv.14101"},{"key":"122550","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14101","DOI":"10.1111\/jdv.14101"},{"key":"122551","doi-asserted-by":"crossref","unstructured":"Chi, C. C., G. Kirtschig, M. Baldo, F. Brackenbury, F. Lewis and F. Wojnarowska (2011). \u201cTopical interventions for genital lichen sclerosus.\u201d Cochrane Database Syst Rev(2): CD008240.","DOI":"10.1002\/14651858.CD008240"},{"key":"122552","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD008240","DOI":"10.1002\/14651858.CD008240"},{"key":"122553","doi-asserted-by":"crossref","unstructured":"Chi, C. C., S. H. Wang, R. Mayon-White and F. Wojnarowska (2013). \u201cPregnancy outcomes after material exposure to topical corticosteroids. A UK population-based cohort study.\u201d JAMA Dermatol 149: 1274-1280.","DOI":"10.1001\/jamadermatol.2013.5768"},{"key":"122554","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2013.5768","DOI":"10.1001\/jamadermatol.2013.5768"},{"key":"122555","doi-asserted-by":"crossref","unstructured":"Chi, C. C., W. H. Wang, F. Wojnarowska, G. Kirtschig, E. Davies and C. Bennett (2015). \u201cSafety of topical corticosteroids in pregnancy.\u201d Cochrane Database Syst Rev (10:): CD007346.","DOI":"10.1002\/14651858.CD007346.pub3"},{"key":"122556","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD007346.pub3","DOI":"10.1002\/14651858.CD007346.pub3"},{"key":"122557","doi-asserted-by":"crossref","unstructured":"Chu, A. W. L., M. M. Wong, D. G. Rayner and G. H. e. a. Guyatt (2023). \u201cSystemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.\u201d J Allergy Clin Immunol 152(6): 1470-1492.","DOI":"10.1016\/j.jaci.2023.08.029"},{"key":"122558","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2023.08.029","DOI":"10.1016\/j.jaci.2023.08.029"},{"key":"122559","doi-asserted-by":"crossref","unstructured":"Chu, D. K., L. Schneider and R. N. e. a. Asiniwasis (2024). \u201cAtopic Dermatitis (Eczema) Guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- And Institute of Medicine-Based Recommendations.\u201d Ann Allergy Asthma Immunol 132(3): 274-312.","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"122560","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.anai.2023.11.009","DOI":"10.1016\/j.anai.2023.11.009"},{"key":"122561","doi-asserted-by":"crossref","unstructured":"Church, M. K., K. Weller, P. Stock and M. Maurer (2011). \u201cChronic spontaneous urticaria in children: itching for insight.\u201d Pediatr Allergy Immunol 22: 1-8.","DOI":"10.1111\/j.1399-3038.2010.01120.x"},{"key":"122562","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1399-3038.2010.01120.x","DOI":"10.1111\/j.1399-3038.2010.01120.x"},{"key":"122563","unstructured":"Cohen, A. D., I. D. Andrews, E. Medvedovsky, R. Peleg and D. A. Vardy (2014). \u201cSimilarities between neuropathic pruritus sites and lichen simplex chronicus sites.\u201d Isr Med Assoc J 16(2): 88-90."},{"key":"122564","doi-asserted-by":"crossref","unstructured":"Cohen, A. D., R. Masalha, E. Medvedovsky and D. A. Vardy (2003). \u201cBrachioradial pruritus: a symptom of neuropathy.\u201d J Am Acad Dermatol 48(6): 825-828.","DOI":"10.1067\/mjd.2003.494"},{"key":"122565","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2003.494","DOI":"10.1067\/mjd.2003.494"},{"key":"122566","doi-asserted-by":"crossref","unstructured":"Corpechot, C., O. Chazouill\u00e8res, A. Rousseau, A. Le Gruyer, F. Habersetzer, P. Mathurin, O. Goria, P. Potier, A. Minello, C. Silvain, A. Abergel, M. Debette-Gratien, D. Larrey, O. Roux, J. P. Bronowicki, J. Boursier, V. de Ledinghen, A. Heurgue-Berlot, E. Nguyen-Khac, F. Zoulim, I. Ollivier-Hourmand, J. P. Zarski, G. Nkontchou, S. Lemoinne, L. Humbert, D. Rainteau, G. Lef\u00e8vre, L. de Chaisemartin, S. Chollet-Martin, F. Gaouar, F. H. Admane, T. Simon and R. Poupon (2018). \u201cA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.\u201d N Engl J Med 378(23): 2171-2181.","DOI":"10.1056\/NEJMoa1714519"},{"key":"122567","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1714519","DOI":"10.1056\/NEJMoa1714519"},{"key":"122568","doi-asserted-by":"crossref","unstructured":"Costanzo, A., M. Llamas-Velasco, G. Fabbrocini and A. e. a. Cuccia (2023). \u201cTildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.\u201d J Eur Acad Dermatol Venereol 37(10): 2004-2015.","DOI":"10.1111\/jdv.19229"},{"key":"122569","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19229","DOI":"10.1111\/jdv.19229"},{"key":"122570","doi-asserted-by":"crossref","unstructured":"Craig-Muller, S. A. and J. S. Reichenberg (2015). \u201cThe Other Itch That Rashes: a Clinical and Therapeutic Approach to Pruritus and Skin Picking Disorders.\u201d Curr Allergy Asthma Rep 15(6): 31.","DOI":"10.1007\/s11882-015-0532-2"},{"key":"122571","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11882-015-0532-2","DOI":"10.1007\/s11882-015-0532-2"},{"key":"122572","doi-asserted-by":"crossref","unstructured":"Curto, L., L. Carnero, D. L\u00f3pez-Aventin, G. Traveria, G. Roura and A. M. Gim\u00e9nez-Arnau (2014). \u201cFast itch relief in an experimental model for methylprednisolone aceponate topical corticosteroid activity, based on allergic contact eczema to nickel sulphate.\u201d J Eur Acad Dermatol Venereol 28(10): 1356-1362.","DOI":"10.1111\/jdv.12292"},{"key":"122573","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12292","DOI":"10.1111\/jdv.12292"},{"key":"122574","doi-asserted-by":"crossref","unstructured":"Cury Martins, J., C. Martins, V. Aoki, A. F. T. Gois, H. A. Ishii and E. M. K. da Silva (2015). \u201cTopical tacrolimus for atopic dermatitis.\u201d Cochrane Database Syst Rev(7): CD009864.","DOI":"10.1002\/14651858.CD009864.pub2"},{"key":"122575","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD009864.pub2","DOI":"10.1002\/14651858.CD009864.pub2"},{"key":"122576","doi-asserted-by":"crossref","unstructured":"D\u2019Onghia, M., J. Ciaffi, L. Calabrese and L. Tognetti, et al. (2024). \u201cFibromyalgia and Skin Disorders: A Systematic Review.\u201d J Clin Med 13(15): 4404.","DOI":"10.3390\/jcm13154404"},{"key":"122577","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm13154404","DOI":"10.3390\/jcm13154404"},{"key":"122578","doi-asserted-by":"crossref","unstructured":"D\u2019Erme, A., F. Zanieri, E. Campolmi, U. Santosuosso, S. Betti, A. Agnoletti, A. Cossidente and T. Lotti (2014). \u201cTherapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study.\u201d J Eur Acad Dermatol Venereol 28: 246-249.","DOI":"10.1111\/j.1468-3083.2012.04690.x"},{"key":"122579","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04690.x","DOI":"10.1111\/j.1468-3083.2012.04690.x"},{"key":"122580","doi-asserted-by":"crossref","unstructured":"Dalgard, F., A. G. Dawn and G. Yosipovitch (2007). \u201cAre itch and chronic pain associated in adults? Results of a large population survey in Norway.\u201d Dermatology 214(4): 305-309.","DOI":"10.1159\/000100881"},{"key":"122581","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000100881","DOI":"10.1159\/000100881"},{"key":"122582","doi-asserted-by":"crossref","unstructured":"Dalgard, F., L. Lien and I. Dalen (2007). \u201cItch in the community: associations with psychosocial factors among adults.\u201d J Eur Acad Dermatol Venereol 21(9): 1215-1219.","DOI":"10.1111\/j.1468-3083.2007.02234.x"},{"key":"122583","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02234.x","DOI":"10.1111\/j.1468-3083.2007.02234.x"},{"key":"122584","doi-asserted-by":"crossref","unstructured":"Dalgard, F., A. Svensson, J. O. Holm and J. Sundby (2004). \u201cSelf-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study.\u201d Br J Dermatol 151(2): 452-457.","DOI":"10.1111\/j.1365-2133.2004.06058.x"},{"key":"122585","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06058.x","DOI":"10.1111\/j.1365-2133.2004.06058.x"},{"key":"122586","doi-asserted-by":"crossref","unstructured":"Dalgard, F. J., A. Svensson, J. A. Halvorsen, U. Gieler, C. Schut, L. Tomas-Aragones, L. Lien, F. Poot, G. B. E. Jemec, L. Misery, C. Szabo, D. Linder, F. Sampogna, S. Spillekom-van Koulil, F. Balieba, J. Szepietowski, A. Lvov, S. E. Marron, I. K. Altunay, A. Y. Finlay, S. S. Salek and J. Kupfer (2020). \u201cItch and Mental Health in Dermatological Patients Across Europe: A Cross Sectional Study in 13 Countries.\u201d J Invest Dermatol 140(3): 568-573.","DOI":"10.1016\/j.jid.2019.05.034"},{"key":"122587","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2019.05.034","DOI":"10.1016\/j.jid.2019.05.034"},{"key":"122588","doi-asserted-by":"crossref","unstructured":"Daly, B. M. and S. Shuster (2000). \u201cAntipruritic action of thalidomide.\u201d Acta Derm Venereol 80(1): 24-25.","DOI":"10.1080\/000155500750012450"},{"key":"122589","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/000155500750012450","DOI":"10.1080\/000155500750012450"},{"key":"122590","doi-asserted-by":"crossref","unstructured":"Darsow, U., A. Wollenberg, D. Simon, A. Taieb, T. Werfel, A. Oranje, C. Gelmetti, A. Svensson, M. Deleuran, A. M. Calza, F. Giusti, J. Lubbe, S. Seidenari and J. Ring (2010). \u201cETFAD\/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis.\u201d J Eur Acad Dermatol Venereol 24(3): 317-328.","DOI":"10.1111\/j.1468-3083.2009.03415.x"},{"key":"122591","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03415.x","DOI":"10.1111\/j.1468-3083.2009.03415.x"},{"key":"122592","doi-asserted-by":"crossref","unstructured":"Daunton, A., C. Bridgett and J. M. R. Goulding (2016). \u201cHabit reversal for refractory atopic dermatitis: a review.\u201d Br J Dermatol 174(657-659).","DOI":"10.1111\/bjd.14176"},{"key":"122593","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.14176","DOI":"10.1111\/bjd.14176"},{"key":"122594","doi-asserted-by":"crossref","unstructured":"Davis, D. M. R., A. M. Drucker and A. e. a. Alikhan (2024). \u201cExecutive Summary: Guidelines of Care for the Management of Atopic Dermatitis in Adults With Phototherapy and Systemic Therapies.\u201d J Am Acad Dermatol 90(2): 342-345.","DOI":"10.1016\/j.jaad.2023.08.103"},{"key":"122595","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2023.08.103","DOI":"10.1016\/j.jaad.2023.08.103"},{"key":"122596","doi-asserted-by":"crossref","unstructured":"Davis, M. P., J. L. Frandsen, D. Walsh, S. Andresen and S. Taylor (2003). \u201cMirtazapine for pruritus.\u201d J Pain Symptom Manage 25(3): 288-291.","DOI":"10.1016\/S0885-3924(02)00645-0"},{"key":"122597","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0885-3924(02)00645-0","DOI":"10.1016\/S0885-3924(02)00645-0"},{"key":"122598","unstructured":"Dawn, A. and G. Yosipovitch (2006). \u201cTreating itch in psoriasis.\u201d Dermatol Nurs 18(3): 227-233."},{"key":"122599","doi-asserted-by":"crossref","unstructured":"De Marchi, S., E. Cecchin, D. Villalta, G. Sepiacci, G. Santini and E. Bartoli (1992). \u201cRelief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia.\u201d N Engl J Med 326(15): 969-974.","DOI":"10.1056\/NEJM199204093261501"},{"key":"122600","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJM199204093261501","DOI":"10.1056\/NEJM199204093261501"},{"key":"122601","doi-asserted-by":"crossref","unstructured":"de Vries, E., R. Bolier, J. Goet, A. Par\u00e9s, J. Verbeek, M. de Vree, J. Drenth, K. van Erpecum, K. van Nieuwkerk, F. van der Heide, N. Mostafavi, J. Helder, C. Ponsioen, O. E. R., H. van Buuren, U. Beuers and N. A. f. t. S. o. t. L.-C. W. Group (2021). \u201cFibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.\u201d Gastroenterology 160(3): 734-743.e736.","DOI":"10.1053\/j.gastro.2020.10.001"},{"key":"122602","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1053\/j.gastro.2020.10.001","DOI":"10.1053\/j.gastro.2020.10.001"},{"key":"122603","doi-asserted-by":"crossref","unstructured":"de Wolf, J. T., D. W. Hendriks, R. C. Egger, M. T. Esselink, M. R. Halie and E. Vellenga (1991). \u201cAlpha-interferon for intractable pruritus in polycythaemia vera.\u201d Lancet 337(8735): 241.","DOI":"10.1016\/0140-6736(91)92206-H"},{"key":"122604","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0140-6736(91)92206-H","DOI":"10.1016\/0140-6736(91)92206-H"},{"key":"122605","doi-asserted-by":"crossref","unstructured":"Decock, S., R. Roelandts, W. V. Steenbergen, W. Laleman, D. Cassiman, C. Verslype, J. Fevery, J. V. Pelt and F. Nevens (2012). \u201cCholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study.\u201d J Hepatol 57(3): 637-641.","DOI":"10.1016\/j.jhep.2012.04.023"},{"key":"122606","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jhep.2012.04.023","DOI":"10.1016\/j.jhep.2012.04.023"},{"key":"122607","doi-asserted-by":"crossref","unstructured":"Demierre, M. F. and J. Taverna (2006). \u201cMirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma.\u201d J Am Acad Dermatol 55(3): 543-544.","DOI":"10.1016\/j.jaad.2006.04.025"},{"key":"122608","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2006.04.025","DOI":"10.1016\/j.jaad.2006.04.025"},{"key":"122609","doi-asserted-by":"crossref","unstructured":"Demirtas, S., C. Houssais, J. Tanniou, L. Misery, E. Brenaut and S. e. a. Demirtas (2020). \u201cEffectiveness of a music intervention on pruritus: an open randomized prospective study.\u201d J Eur Acad Dermatol Venereol 34(6): 1280-1285.","DOI":"10.1111\/jdv.16149"},{"key":"122610","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16149","DOI":"10.1111\/jdv.16149"},{"key":"122611","doi-asserted-by":"crossref","unstructured":"Deng, J., V. Parthasarathy, W. Adawi, Z. Bordeaux, N. Sutaria, A. Gami, M. Taylor, K. K. Lee, M. Marani, I. Brown, A. Kambala, H. L. Cornman, A. Alajmi, T. Pritchard, O. O. Oladipo, Y. R. Semenov and S. G. Kwatra (2022). \u201cRisk of hematological cancer in pruritus patients with undifferentiated pruritus.\u201d JAMA Dermatol 158(7): 791-795.","DOI":"10.1001\/jamadermatol.2022.1562"},{"key":"122612","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.1562","DOI":"10.1001\/jamadermatol.2022.1562"},{"key":"122613","doi-asserted-by":"crossref","unstructured":"Der-Petrossian, M., A. Seeber, H. Honigsmann and A. Tanew (2000). \u201cHalf-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis.\u201d Br J Dermatol 142(1): 39-43.","DOI":"10.1046\/j.1365-2133.2000.03239.x"},{"key":"122614","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03239.x","DOI":"10.1046\/j.1365-2133.2000.03239.x"},{"key":"122615","doi-asserted-by":"crossref","unstructured":"Dermatol, B. J. (2024). \u201cCorrection to: Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u2265 13 years.\u201d Br J Dermatol 191(6): e26-e27.","DOI":"10.1093\/bjd\/ljae338"},{"key":"122616","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljae338","DOI":"10.1093\/bjd\/ljae338"},{"key":"122617","doi-asserted-by":"crossref","unstructured":"Derry, S., A. Sven-Rice, P. Cole, T. Tan and R. Moore (2013). \u201cTopical capsaicin (high concentration) for chronic neuropathic pain in adults.\u201d Cochrane Database Syst Rev 28(2): CD007393.","DOI":"10.1002\/14651858.CD007393.pub3"},{"key":"122618","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD007393.pub3","DOI":"10.1002\/14651858.CD007393.pub3"},{"key":"122619","doi-asserted-by":"crossref","unstructured":"Desai, N. S., G. B. Poindexter, Y. M. Monthrope, S. E. Bendeck, R. A. Swerlick and S. C. Chen (2008). \u201cA pilot quality-of-life instrument for pruritus.\u201d J Am Acad Dermatol 59: 234-244.","DOI":"10.1016\/j.jaad.2008.04.006"},{"key":"122620","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2008.04.006","DOI":"10.1016\/j.jaad.2008.04.006"},{"key":"122621","doi-asserted-by":"crossref","unstructured":"Desai, N. S., G. B. Poindexter, Y. M. Monthrope, S. E. Bendeck, R. A. Swerlick and S. C. Chen (2008). \u201cA pilot quality-of-life instrument for pruritus.\u201d J Am Acad Dermatol 59(2): 234-244.","DOI":"10.1016\/j.jaad.2008.04.006"},{"key":"122622","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2008.04.006","DOI":"10.1016\/j.jaad.2008.04.006"},{"key":"122623","doi-asserted-by":"crossref","unstructured":"Dhand, A. and M. J. Aminoff (2014). \u201cThe neurology of itch.\u201d Brain 137(Pt 2): 313-322.","DOI":"10.1093\/brain\/awt158"},{"key":"122624","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/brain\/awt158","DOI":"10.1093\/brain\/awt158"},{"key":"122625","doi-asserted-by":"crossref","unstructured":"Diehn, F. and A. Tefferi (2001). \u201cPruritus in polycythaemia vera: prevalence, laboratory correlates and management.\u201d Br J Haematol 115(3): 619-621.","DOI":"10.1046\/j.1365-2141.2001.03161.x"},{"key":"122626","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03161.x","DOI":"10.1046\/j.1365-2141.2001.03161.x"},{"key":"122627","doi-asserted-by":"crossref","unstructured":"Domagala, A., J. Szepietowski and A. Reich (2017). \u201cAntihistamines in the treatment of pruritus in psoriasis.\u201d Adv Dermatol Allergol 34(5): 457-463.","DOI":"10.5114\/ada.2017.71112"},{"key":"122628","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5114\/ada.2017.71112","DOI":"10.5114\/ada.2017.71112"},{"key":"122629","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez, O., A. M. Plaza and M. Alvaro (2020). \u201cRelationship Between Atopic Dermatitis and Food Allergy.\u201d Curr Pediatr Rev 16(2): 115-122.","DOI":"10.2174\/1573396315666191111122436"},{"key":"122630","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2174\/1573396315666191111122436","DOI":"10.2174\/1573396315666191111122436"},{"key":"122631","doi-asserted-by":"crossref","unstructured":"Doria, C., L. Mandala, J. Smith, C. H. Vitale, A. Lauro, S. Gruttadauria, I. R. Marino, C. S. Foglieni, M. Magnone and V. L. Scott (2003). \u201cEffect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus.\u201d Liver Transpl 9(4): 437-443.","DOI":"10.1053\/jlts.2003.50055"},{"key":"122632","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1053\/jlts.2003.50055","DOI":"10.1053\/jlts.2003.50055"},{"key":"122633","doi-asserted-by":"crossref","unstructured":"Doyle, C. and R. E. Watchorn (2022). \u201cPersistent pruritus following COVID-19 vaccination.\u201d Ir J Med Sci 192(1): 185-186.","DOI":"10.1007\/s11845-022-02959-2"},{"key":"122634","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11845-022-02959-2","DOI":"10.1007\/s11845-022-02959-2"},{"key":"122635","unstructured":"Draelos, Z. D., L. F. Stein Gold, D. F. Murrell, M. H. Hughes and L. T. Zane (2016). \u201cPost Hoc analysis of the effect of crisaborole topical ointment 2% on atopic dermatitis: Associated pruritus from phase 1 and 2 clinical studies.\u201d J Drugs Dermatol 15(2): 172-176."},{"key":"122636","doi-asserted-by":"crossref","unstructured":"Drake, L. A., J. D. Fallon and A. Sober (1994). \u201cRelief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group.\u201d J Am Acad Dermatol 31(4): 613-616.","DOI":"10.1016\/S0190-9622(94)70225-X"},{"key":"122637","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(94)70225-X","DOI":"10.1016\/S0190-9622(94)70225-X"},{"key":"122638","doi-asserted-by":"crossref","unstructured":"Drake, L. A. and L. E. Millikan (1995). \u201cThe antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group.\u201d Arch Dermatol 131(12): 1403-1408.","DOI":"10.1001\/archderm.1995.01690240065010"},{"key":"122639","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.1995.01690240065010","DOI":"10.1001\/archderm.1995.01690240065010"},{"key":"122640","doi-asserted-by":"crossref","unstructured":"Dugas-Breit, S., P. Schopf, M. Dugas, H. Schiffl, F. Rueff and B. Przybilla (2005). \u201cBaseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus.\u201d J Dtsch Dermatol Ges 3(5): 343-347.","DOI":"10.1111\/j.1610-0387.2005.05706.x"},{"key":"122641","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1610-0387.2005.05706.x","DOI":"10.1111\/j.1610-0387.2005.05706.x"},{"key":"122642","doi-asserted-by":"crossref","unstructured":"D\u00fcll, M. M. and A. E. Kremer (2019). \u201cTreatment of pruritus secondary to liver disease.\u201d Curr Gastroenterol Rep 21(9): 48.","DOI":"10.1007\/s11894-019-0713-6"},{"key":"122643","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11894-019-0713-6","DOI":"10.1007\/s11894-019-0713-6"},{"key":"122644","doi-asserted-by":"crossref","unstructured":"Duque, M. I., S. Thevarajah, Y. H. Chan, A. B. Tuttle, B. I. Freedman and G. Yosipovitch (2006). \u201cUremic pruritus is associated with higher kt\/V and serum calcium concentration.\u201d Clin Nephrol 66(3): 184-191.","DOI":"10.5414\/CNP66184"},{"key":"122645","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5414\/CNP66184","DOI":"10.5414\/CNP66184"},{"key":"122646","doi-asserted-by":"crossref","unstructured":"Duque, M. I., G. Yosipovitch, A. B. Fleischer, Jr., J. Willard and B. I. Freedman (2005). \u201cLack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study.\u201d J Am Acad Dermatol 52(3 Pt 1): 519-521.","DOI":"10.1016\/j.jaad.2004.08.050"},{"key":"122647","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2004.08.050","DOI":"10.1016\/j.jaad.2004.08.050"},{"key":"122648","doi-asserted-by":"crossref","unstructured":"Dvorak, M., A. Watkinson, F. McGlone and R. Rukwied (2003). \u201cHistamine induced responses are attenuated by a cannabinoid receptor agonist in human skin.\u201d Inflamm Res 52(6): 238-245.","DOI":"10.1007\/s00011-003-1162-z"},{"key":"122649","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00011-003-1162-z","DOI":"10.1007\/s00011-003-1162-z"},{"key":"122650","doi-asserted-by":"crossref","unstructured":"EASL (2009). \u201cClinical Practice Guideline: Management of cholestatic liver disease.\u201d J Hepatol 51(2): 237-267.","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"122651","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jhep.2009.04.009","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"122652","doi-asserted-by":"crossref","unstructured":"Easton, P. and P. R. Galbraith (1978). \u201cCimetidine treatment of pruritus in polycythemia vera.\u201d N Engl J Med 299(20): 1134.","DOI":"10.1056\/NEJM197811162992015"},{"key":"122653","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJM197811162992015","DOI":"10.1056\/NEJM197811162992015"},{"key":"122654","doi-asserted-by":"crossref","unstructured":"Ebata, T. (2016). \u201cDrug-Induced Itch Management.\u201d Curr Probl Dermatol 50: 155-163.","DOI":"10.1159\/000446084"},{"key":"122655","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446084","DOI":"10.1159\/000446084"},{"key":"122656","doi-asserted-by":"crossref","unstructured":"Eberlein, B., C. Eicke, H. W. Reinhardt and J. Ring (2008). \u201cAdjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study).\u201d J Eur Acad Dermatol Venereol 22(1): 73-82.","DOI":"10.1111\/j.1468-3083.2007.02351.x"},{"key":"122657","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02351.x","DOI":"10.1111\/j.1468-3083.2007.02351.x"},{"key":"122658","unstructured":"Egli, F., A. Wieczorek, M. Niemoller and K. Rhyner (1988). \u201c[Polycythemia vera: clinical aspects and course in 86 patients].\u201d Schweiz Med Wochenschr 118(52): 1969-1975."},{"key":"122659","doi-asserted-by":"crossref","unstructured":"Ehlers, A., U. Stangier and U. Gieler (1995). \u201cTreatment of atopic dermatitis: A comparison of psychological and dermatological approaches to relapse prevention.\u201d J Consult Clin Psychol 63(4): 624-635.","DOI":"10.1037\/\/0022-006X.63.4.624"},{"key":"122660","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1037\/0022-006X.63.4.624","DOI":"10.1037\/0022-006X.63.4.624"},{"key":"122661","doi-asserted-by":"crossref","unstructured":"Ehrchen, J. and S. Stander (2008). \u201cPregabalin in the treatment of chronic pruritus.\u201d J Am Acad Dermatol 58(2 Suppl): S36-37.","DOI":"10.1016\/j.jaad.2007.07.017"},{"key":"122662","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2007.07.017","DOI":"10.1016\/j.jaad.2007.07.017"},{"key":"122663","unstructured":"Ellis, A. G., C. Flohr and A. M. Drucker (2019). \u201cNetwork meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54."},{"key":"122664","doi-asserted-by":"crossref","unstructured":"Ellis, C. N., B. Berberian, V. I. Sulica, W. A. Dodd, M. T. Jarratt, H. I. Katz, S. Prawer, G. Krueger, I. H. Rex, Jr. and J. E. Wolf (1993). \u201cA double-blind evaluation of topical capsaicin in pruritic psoriasis.\u201d J Am Acad Dermatol 29(3): 438-442.","DOI":"10.1016\/0190-9622(93)70208-B"},{"key":"122665","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0190-9622(93)70208-B","DOI":"10.1016\/0190-9622(93)70208-B"},{"key":"122666","doi-asserted-by":"crossref","unstructured":"Elman, S., L. S. Hynan, V. Gabriel and M. J. Mayo (2010). \u201cThe 5-D itch scale: a new measure of pruritus.\u201d Br J Dermatol 162(3): 587-593.","DOI":"10.1111\/j.1365-2133.2009.09586.x"},{"key":"122667","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09586.x","DOI":"10.1111\/j.1365-2133.2009.09586.x"},{"key":"122668","doi-asserted-by":"crossref","unstructured":"Elmariah, S. B. and E. A. Lerner (2011). \u201cTopical therapies for pruritus.\u201d Semin Cutan Med Surg 30(2): 118-126.","DOI":"10.1016\/j.sder.2011.04.008"},{"key":"122669","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.sder.2011.04.008","DOI":"10.1016\/j.sder.2011.04.008"},{"key":"122670","doi-asserted-by":"crossref","unstructured":"Elsayed, M. M., I. E. Elgohary, H. H. S. Abdelhamid and S. A. Zaki (2023). \u201cThe effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial.\u201d BMC Nephrol 24: 155.","DOI":"10.1186\/s12882-023-03212-3"},{"key":"122671","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12882-023-03212-3","DOI":"10.1186\/s12882-023-03212-3"},{"key":"122672","unstructured":"Engelhardt, H., R. A. Smits, R. Leurs, E. Haaksma and I. J. de Esch (2009). \u201cA new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic.\u201d Curr Opin Drug Discov Devel 12: 628-643."},{"key":"122673","doi-asserted-by":"crossref","unstructured":"Epstein, M. P. and M. M. Kaplan (2004). \u201cA pilot study of etanercept in the treatment of primary sclerosing cholangitis.\u201d Dig Dis Sci 49(1): 1-4.","DOI":"10.1023\/B:DDAS.0000011827.87103.2e"},{"key":"122674","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1023\/B:DDAS.0000011827.87103.2e","DOI":"10.1023\/B:DDAS.0000011827.87103.2e"},{"key":"122675","doi-asserted-by":"crossref","unstructured":"Ersser, S. J., F. Cowdell, S. Latter, E. Gardiner, C. Flohr, A. R. Thompson, K. Jackson, H. Farasat, F. Ware and A. Drury (2014). \u201cPsychological and educational interventions for atopic eczema in children.\u201d Cochrane Database Syst Rev 2014(1): CD004054.","DOI":"10.1002\/14651858.CD004054.pub3"},{"key":"122676","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD004054.pub3","DOI":"10.1002\/14651858.CD004054.pub3"},{"key":"122677","doi-asserted-by":"crossref","unstructured":"Evers, A. W., P. Duller, E. M. de Jong, M. E. Otero, C. M. Verhaak, P. G. van der Valk, P. C. van de Kerkhof and F. W. Kraaimaat (2009). \u201cEffectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis.\u201d Acta Derm Venereol 89(1): 57-63.","DOI":"10.2340\/00015555-0556"},{"key":"122678","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0556","DOI":"10.2340\/00015555-0556"},{"key":"122679","doi-asserted-by":"crossref","unstructured":"Evers, A. W. M., C. Schut, U. Gieler, S. Spillekom-van-Koulil and S. van Beugen (2016). Psychological itch management. Itch - Management in Clinical Practice. J. C. Szepietowski and E. Weisshaar. Basel, Karger. 50: 64-70.","DOI":"10.1159\/000446045"},{"key":"122680","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446045","DOI":"10.1159\/000446045"},{"key":"122681","doi-asserted-by":"crossref","unstructured":"Fang, H.-Y. and C.-H. Lian (2023). \u201cThe effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.\u201d J Dermatol 50(8): 1084-1087.","DOI":"10.1111\/1346-8138.16803"},{"key":"122682","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.16803","DOI":"10.1111\/1346-8138.16803"},{"key":"122683","doi-asserted-by":"crossref","unstructured":"Fardel, M. A., E. Brenaut, D. Guellec, M. Etienne, M. Fouchard, R. Seizeur and L. Misery (2022). \u201cPruritus and brain tumours: A prospective and descriptive study.\u201d Skin Health Dis 3(3): e202.","DOI":"10.1002\/ski2.202"},{"key":"122684","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ski2.202","DOI":"10.1002\/ski2.202"},{"key":"122685","doi-asserted-by":"crossref","unstructured":"Feng, W. W., B. Yuan, F. Y. Shen, W. Y. Fan, D. S. Mei, B. Y. Bao, Q. J. Chen and W. W. e. a. Feng (2020). \u201cEfficacy of uremic pruritus treatment in patients undergoing hemodialysis, a network meta-analysis for randomized clinical trials.\u201d Nephrol Ther 17(1): 30-34.","DOI":"10.1016\/j.nephro.2020.09.006"},{"key":"122686","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.nephro.2020.09.006","DOI":"10.1016\/j.nephro.2020.09.006"},{"key":"122687","doi-asserted-by":"crossref","unstructured":"Ferrandiz, C., J. M. Carrascosa, M. Just, I. Bielsa and M. Ribera (1997). \u201cSequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis.\u201d Dermatology 195(4): 359-361.","DOI":"10.1159\/000245988"},{"key":"122688","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000245988","DOI":"10.1159\/000245988"},{"key":"122689","doi-asserted-by":"crossref","unstructured":"Ferreira, B. R., O. M. Katamanin, M. Jafferany and L. Misery (2024). \u201cPsychodermatology of Chronic Pruritus: An Overview of the Link Between Itch and Distress.\u201d Dermatol Ther (Heidelb) 14(7): 1799-1809.","DOI":"10.1007\/s13555-024-01214-z"},{"key":"122690","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-024-01214-z","DOI":"10.1007\/s13555-024-01214-z"},{"key":"122691","doi-asserted-by":"crossref","unstructured":"Fett, N., K. Haynes, K. J. Robert and D. J. Margolis (2014). \u201cFive-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices.\u201d J Am Acad Dermatol 70: 651-658.","DOI":"10.1016\/j.jaad.2013.11.045"},{"key":"122692","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2013.11.045","DOI":"10.1016\/j.jaad.2013.11.045"},{"key":"122693","doi-asserted-by":"crossref","unstructured":"Finelli, C., L. Gugliotta, B. Gamberi, N. Vianelli, G. Visani and S. Tura (1993). \u201cRelief of intractable pruritus in polycythemia vera with recombinant interferon alfa.\u201d Am J Hematol 43(4): 316-318.","DOI":"10.1002\/ajh.2830430419"},{"key":"122694","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.2830430419","DOI":"10.1002\/ajh.2830430419"},{"key":"122695","doi-asserted-by":"crossref","unstructured":"Fishbane, S., A. Jamal, C. Munera, W. Wen and F. Menzaghi (2020). \u201cA Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.\u201d NEJM 382(3): 222-232.","DOI":"10.1056\/NEJMoa1912770"},{"key":"122696","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1912770","DOI":"10.1056\/NEJMoa1912770"},{"key":"122697","doi-asserted-by":"crossref","unstructured":"Fitzsimons, E. J., J. H. Dagg and E. J. McAllister (1981). \u201cPruritus of polycythaemia vera: a place for pizotifen?\u201d Br Med J (Clin Res Ed) 283(6286): 277.","DOI":"10.1136\/bmj.283.6286.277"},{"key":"122698","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.283.6286.277","DOI":"10.1136\/bmj.283.6286.277"},{"key":"122699","doi-asserted-by":"crossref","unstructured":"Fjellner, B. and O. Hagermark (1979). \u201cPruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement.\u201d Acta Derm Venereol 59(6): 505-512.","DOI":"10.2340\/0001555559505512"},{"key":"122700","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/0001555559505512","DOI":"10.2340\/0001555559505512"},{"key":"122701","doi-asserted-by":"crossref","unstructured":"Fjellner, B. and O. Hagermark (1982). \u201cPotentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine.\u201d Arch Dermatol Res 274(1-2): 29-37.","DOI":"10.1007\/BF00510355"},{"key":"122702","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/BF00510355","DOI":"10.1007\/BF00510355"},{"key":"122703","unstructured":"Fleischer, A. B., Jr. (2000). The clinical management of itching. New York, London, Parthenon Publishing."},{"key":"122704","unstructured":"Fleischer, A. B., Jr. and M. Boguniewicz (2010). \u201cAn approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature.\u201d J Drugs Dermatol 9(5): 488-498."},{"key":"122705","doi-asserted-by":"crossref","unstructured":"Foroutan, N., A. Etminan, N. Nikvarz and M. Shojai Shahrokh Abadi (2017). \u201cComparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial.\u201d Hemodial Int 21(1): 63-71.","DOI":"10.1111\/hdi.12455"},{"key":"122706","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/hdi.12455","DOI":"10.1111\/hdi.12455"},{"key":"122707","doi-asserted-by":"crossref","unstructured":"Fouchard, M., E. Brenaut, S. Genestet, A. S. Ficheux, P. Marcorelles and L. Misery (2023). \u201cObservational case-control study of small-fiber neuropathies, with regards on smoking and vitamin D deficiency and other possible causes.\u201d Front Med (Lausanne) 9: 1051967.","DOI":"10.3389\/fmed.2022.1051967"},{"key":"122708","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2022.1051967","DOI":"10.3389\/fmed.2022.1051967"},{"key":"122709","doi-asserted-by":"crossref","unstructured":"Francos, G. C., Y. C. Kauh, S. D. Gittlen, E. S. Schulman, A. Besarab, S. Goyal and J. F. Burke, Jr. (1991). \u201cElevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus.\u201d Int J Dermatol 30(12): 884-889.","DOI":"10.1111\/j.1365-4362.1991.tb04360.x"},{"key":"122710","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4362.1991.tb04360.x","DOI":"10.1111\/j.1365-4362.1991.tb04360.x"},{"key":"122711","doi-asserted-by":"crossref","unstructured":"Freitas, E., M. Gooderham and T. Torres (2022). \u201cNew Topical Therapies in Development for Atopic Dermatitis.\u201d Drugs 82(8): 843-853.","DOI":"10.1007\/s40265-022-01722-2"},{"key":"122712","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40265-022-01722-2","DOI":"10.1007\/s40265-022-01722-2"},{"key":"122713","doi-asserted-by":"crossref","unstructured":"Frese, T., K. Herrmann and H. Sandholzer (2011). \u201cPruritus as reason for encounter in general practice.\u201d J Clin Med Res 3(5): 223-229.","DOI":"10.4021\/jocmr632w"},{"key":"122714","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4021\/jocmr632w","DOI":"10.4021\/jocmr632w"},{"key":"122715","doi-asserted-by":"crossref","unstructured":"Friedlander, M. S. H. and S. Admani (2021). \u201cAquagenic pruritus in an adolescent effectively managed with \u03b2-alanine supplementation.\u201d Pediatr Dermatol 38(1): 320-321.","DOI":"10.1111\/pde.14440"},{"key":"122716","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.14440","DOI":"10.1111\/pde.14440"},{"key":"122717","doi-asserted-by":"crossref","unstructured":"Fujino, H., M. Tanaka, M. Imamura, K. Morio, A. Ono and T. e. a. Nakahara (2019). \u201cPruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.\u201d BMC gastroenterology 19(1): 169.","DOI":"10.1186\/s12876-019-1092-z"},{"key":"122718","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12876-019-1092-z","DOI":"10.1186\/s12876-019-1092-z"},{"key":"122719","doi-asserted-by":"crossref","unstructured":"Gael, M., T.-. Adam, M. Mariano-Bourin and A.-C. Bursztejn (2022). \u201cEfficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.\u201d J Eur Acad Dermatol Venereol 36(9): 1541-1551.","DOI":"10.1111\/jdv.18221"},{"key":"122720","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18221","DOI":"10.1111\/jdv.18221"},{"key":"122721","unstructured":"Gaig, P., M. Olona, D. Mu\u00f1oz Lejarazu, M. T. Caballero, F. J. Dominguez, S. Echechipia, J. L. Garcia Abujeta, M. A. Gonzalo, R. Lleonart, C. Martinez C\u00f3cera, A. Rodriguez and M. Ferrer (2004). \u201cEpidemiology of urticaria in Spain.\u201d J Investig Allergol Clin Immunol 14: 214-220."},{"key":"122722","doi-asserted-by":"crossref","unstructured":"Gal-Oz, A., O. Rogowski, M. Swartzon and S. Kivity (2010). \u201cEthyl chloride as an antipruritic agent: a double-blind placebo-controlled prospective study.\u201d Dermatology 221(4): 373-377.","DOI":"10.1159\/000321720"},{"key":"122723","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000321720","DOI":"10.1159\/000321720"},{"key":"122724","doi-asserted-by":"crossref","unstructured":"Gambichler, T., J. Hyun, A. Sommer, M. Stucker, P. Altmeyer and A. Kreuter (2006). \u201cA randomised controlled trial on photo(chemo)therapy of subacute prurigo.\u201d Clin Exp Dermatol 31(3): 348-353.","DOI":"10.1111\/j.1365-2230.2006.02081.x"},{"key":"122725","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2230.2006.02081.x","DOI":"10.1111\/j.1365-2230.2006.02081.x"},{"key":"122726","doi-asserted-by":"crossref","unstructured":"Garg, S., J. Zhao, K. Tegtmeyer, P. Shah and P. A. Lio (2021). \u201cUS Prescription trends of antihistamines for atopic dermatitis, 2011-2016.\u201d Pediatr Dermatol 38(1): 324-326.","DOI":"10.1111\/pde.14445"},{"key":"122727","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.14445","DOI":"10.1111\/pde.14445"},{"key":"122728","doi-asserted-by":"crossref","unstructured":"Garritsen, F. M., M. W. Brouwer, J. Limpens and P. I. Spuls (2014). \u201cPhoto(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research.\u201d Br J Dermatol 170(3): 501-513.","DOI":"10.1111\/bjd.12645"},{"key":"122729","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12645","DOI":"10.1111\/bjd.12645"},{"key":"122730","doi-asserted-by":"crossref","unstructured":"Gaspari, A. (2002). \u201cThalidomide neurotoxicity in dermatological patients: the next \u201cSTEP\u201d.\u201d J Invest Dermatol 119(5): 987-988.","DOI":"10.1046\/j.1523-1747.2002.19538.x"},{"key":"122731","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1523-1747.2002.19538.x","DOI":"10.1046\/j.1523-1747.2002.19538.x"},{"key":"122732","doi-asserted-by":"crossref","unstructured":"Ghent, C. N. and S. G. Carruthers (1988). \u201cTreatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial.\u201d Gastroenterology 94(2): 488-493.","DOI":"10.1016\/0016-5085(88)90442-8"},{"key":"122733","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0016-5085(88)90442-8","DOI":"10.1016\/0016-5085(88)90442-8"},{"key":"122734","doi-asserted-by":"crossref","unstructured":"Gholyaf, M., V. Sheikh, F. Yasrebifar, Y. Mohammadi, M. Mirjalili and M. Mehrpooya (2020). \u201cEffect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study.\u201d Int Urol Nephrol 52(6): 1155-1165.","DOI":"10.1007\/s11255-020-02473-3"},{"key":"122735","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11255-020-02473-3","DOI":"10.1007\/s11255-020-02473-3"},{"key":"122736","doi-asserted-by":"crossref","unstructured":"Ghorbani, A. R., A. Feily, A. Khalili and B. Dormanesh (2011). \u201cLack of efficacy of topical calcineurin inhibitor pimecrolimus 1% on pruritus of severely uremic patients: a randomized double-blind study in 60 patients.\u201d Dermatitis 22(3): 167-168.","DOI":"10.2310\/6620.2011.10110"},{"key":"122737","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2310\/6620.2011.10110","DOI":"10.2310\/6620.2011.10110"},{"key":"122738","unstructured":"Ghura, H. S., A. D. Patterson and A. J. Carmichael (1998). \u201cNaltrexone in the treatment of renal itch.\u201d Br J Dermatol 139 (suppl 51): 139."},{"key":"122739","doi-asserted-by":"crossref","unstructured":"Gibson, W., B. M. Wand and N. E. O\u2019Connell (2017). \u201cTranscutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults.\u201d Cochrane Database Syst Rev 14(9): CD011976.","DOI":"10.1002\/14651858.CD011976.pub2"},{"key":"122740","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD011976.pub2","DOI":"10.1002\/14651858.CD011976.pub2"},{"key":"122741","doi-asserted-by":"crossref","unstructured":"Gieler, U., J. Kupfer, V. Niemeier, B. Brosig and U. Stangier (2000). \u201cAtopic eczema prevention programs - a new therapeutic concept for secondary prevention.\u201d Dermatol Psychosom 1: 138-147.","DOI":"10.1159\/000057969"},{"key":"122742","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000057969","DOI":"10.1159\/000057969"},{"key":"122743","doi-asserted-by":"crossref","unstructured":"Gilbert, H. S., R. R. Warner and L. R. Wasserman (1966). \u201cA study of histamine in myeloproliferative disease.\u201d Blood 28(6): 795-806.","DOI":"10.1182\/blood.V28.6.795.795"},{"key":"122744","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood.V28.6.795.795","DOI":"10.1182\/blood.V28.6.795.795"},{"key":"122745","doi-asserted-by":"crossref","unstructured":"Gilchrest, B. A., J. W. Rowe, R. S. Brown, T. I. Steinman and K. A. Arndt (1977). \u201cRelief of uremic pruritus with ultraviolet phototherapy.\u201d N Engl J Med 297(3): 136-138.","DOI":"10.1056\/NEJM197707212970304"},{"key":"122746","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJM197707212970304","DOI":"10.1056\/NEJM197707212970304"},{"key":"122747","doi-asserted-by":"crossref","unstructured":"Gilchrest, B. A., J. W. Rowe, R. S. Brown, T. I. Steinman and K. A. Arndt (1979). \u201cUltraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action.\u201d Ann Intern Med 91(1): 17-21.","DOI":"10.7326\/0003-4819-91-1-17"},{"key":"122748","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7326\/0003-4819-91-1-17","DOI":"10.7326\/0003-4819-91-1-17"},{"key":"122749","unstructured":"Girling, J. C. (2006). Obstetric cholestasis. Guideline no. 43. London, Royal College of Obstetricians and Gynaecologists (RCOG)."},{"key":"122750","doi-asserted-by":"crossref","unstructured":"Gisslinger, H., C. Klade, P. Georgiev, D. Krochmalczyk and L. Gercheva-Kyuchukova, et al. (2020). \u201cRopeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.\u201d Lancet Haematol 7(3): e196-e208.","DOI":"10.2139\/ssrn.3426089"},{"key":"122751","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2139\/ssrn.3426089","DOI":"10.2139\/ssrn.3426089"},{"key":"122752","doi-asserted-by":"crossref","unstructured":"Gokdemir, G. and T. Doruk (2011). \u201cTreatment of generalized pruritus: comparison of narrowband ultraviolet-B with oral cetirizine.\u201d J Eur Acad Dermatol Venereol 25: 1484-1485.","DOI":"10.1111\/j.1468-3083.2010.03948.x"},{"key":"122753","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03948.x","DOI":"10.1111\/j.1468-3083.2010.03948.x"},{"key":"122754","doi-asserted-by":"crossref","unstructured":"Golembesky, A., M. Cooney and R. e. a. Boev (2018). \u201cSafety of Cetirizine in pregnancy.\u201d J Obstet Gynaecol 38(940-945).","DOI":"10.1080\/01443615.2018.1441271"},{"key":"122755","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/01443615.2018.1441271","DOI":"10.1080\/01443615.2018.1441271"},{"key":"122756","doi-asserted-by":"crossref","unstructured":"Gonzalez-Estrada, A. and S. A. Geraci (2016). \u201cAllergy medications during pregnancy.\u201d Am J Med Sci 352(3): 326-331.","DOI":"10.1016\/j.amjms.2016.05.030"},{"key":"122757","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.amjms.2016.05.030","DOI":"10.1016\/j.amjms.2016.05.030"},{"key":"122758","doi-asserted-by":"crossref","unstructured":"Gordon, K. B., P. Foley, J. G. Krueger and A. e. a. Pinter (2021). \u201cBimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.\u201d Lancet 397(10273): 475-486.","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"122759","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"122760","doi-asserted-by":"crossref","unstructured":"Gottlieb, A. B., K. Gordon, S. Hsu, B. Elewski, L. F. Eichenfield, L. Kircik, S. Rastogi, R. Pillai and R. Israel (2018). \u201cImprovement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.\u201d J Eur Acad Dermatol Venereol.","DOI":"10.1111\/jdv.14913"},{"key":"122761","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14913","DOI":"10.1111\/jdv.14913"},{"key":"122762","doi-asserted-by":"crossref","unstructured":"Goulis, J., G. Leandro and A. K. Burroughs (1999). \u201cRandomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis.\u201d Lancet 354(9184): 1053-1060.","DOI":"10.1016\/S0140-6736(98)11293-X"},{"key":"122763","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(98)11293-X","DOI":"10.1016\/S0140-6736(98)11293-X"},{"key":"122764","doi-asserted-by":"crossref","unstructured":"Goutos, I. (2013). \u201cNeuropathic mechanisms in the pathophysiology of burns pruritus: redefining directions for therapy and research.\u201d J Burn Care Res 34(1): 82-93.","DOI":"10.1097\/BCR.0b013e3182644c44"},{"key":"122765","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/BCR.0b013e3182644c44","DOI":"10.1097\/BCR.0b013e3182644c44"},{"key":"122766","doi-asserted-by":"crossref","unstructured":"Grattan, C. E. H. and D. H. Radia (2016). Mastocytosis. Rook\u2019s textbook of dermatology. J. B. C. Griffiths, T. Bleiker, R. Chalmers, & D. Creamer. Chichester, West Sussex; Hoboken, NJ, John Wiley & Sons Inc.","DOI":"10.1002\/9781118441213.rtd0047"},{"key":"122767","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/9781118441213.rtd0047","DOI":"10.1002\/9781118441213.rtd0047"},{"key":"122768","doi-asserted-by":"crossref","unstructured":"Gray, P., J. Kirby, M. T. Smith, P. J. Cabot, B. Williams, J. Doecke and T. Cramond (2011). \u201cPregabalin in severe burn injury pain. A double-blind, randomised placebo-controlled trial.\u201d Pain 152(6): 1279-1288.","DOI":"10.1016\/j.pain.2011.01.055"},{"key":"122769","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.pain.2011.01.055","DOI":"10.1016\/j.pain.2011.01.055"},{"key":"122770","doi-asserted-by":"crossref","unstructured":"Gray, S. L., M. L. Anderson and S. e. a. Dublin (2015). \u201cCumulative use of strong anticholinergics and incident dementia: a prospective cohort study.\u201d JAMA Intern Med 175: 401-407.","DOI":"10.1001\/jamainternmed.2014.7663"},{"key":"122771","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamainternmed.2014.7663","DOI":"10.1001\/jamainternmed.2014.7663"},{"key":"122772","doi-asserted-by":"crossref","unstructured":"Green, B. G. and K. L. Schoen (2007). \u201cThermal and nociceptive sensations from menthol and their suppression by dynamic contact.\u201d Behav Brain Res 176(2): 284-291.","DOI":"10.1016\/j.bbr.2006.10.013"},{"key":"122773","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.bbr.2006.10.013","DOI":"10.1016\/j.bbr.2006.10.013"},{"key":"122774","doi-asserted-by":"crossref","unstructured":"Greenberg, J. H. (1995). \u201cAllergic contact dermatitis from topical doxepin.\u201d Contact Dermatitis 33(4): 281.","DOI":"10.1111\/j.1600-0536.1995.tb00494.x"},{"key":"122775","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1600-0536.1995.tb00494.x","DOI":"10.1111\/j.1600-0536.1995.tb00494.x"},{"key":"122776","doi-asserted-by":"crossref","unstructured":"Griffiths, C. E. M., K. Reich, M. Lebwohl and P. e. a. van de Kerkhof (2015). \u201cComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.\u201d Lancet 386(9993): 541-551.","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"122777","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(15)60125-8","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"122778","doi-asserted-by":"crossref","unstructured":"Grinnell, M., K. N. Price, A. Shah and D. C. Butler (2022). \u201cAntihistamine safety in older adult dermatologic patients.\u201d J Am Acad Dermatol 87(2): 381-386.","DOI":"10.1016\/j.jaad.2021.01.027"},{"key":"122779","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2021.01.027","DOI":"10.1016\/j.jaad.2021.01.027"},{"key":"122780","doi-asserted-by":"crossref","unstructured":"Gu, S., S. Dusza, E. Quigley, H. Haliasos and A. e. a. Markova (2024). \u201cPruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients.\u201d Breast Cancer Res Treat 203(2): 271-280.","DOI":"10.1007\/s10549-023-07143-3"},{"key":"122781","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10549-023-07143-3","DOI":"10.1007\/s10549-023-07143-3"},{"key":"122782","doi-asserted-by":"crossref","unstructured":"Gunal, A. I., G. Ozalp, T. K. Yoldas, S. Y. Gunal, E. Kirciman and H. Celiker (2004). \u201cGabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial.\u201d Nephrol Dial Transplant 19(12): 3137-3139.","DOI":"10.1093\/ndt\/gfh496"},{"key":"122783","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/gfh496","DOI":"10.1093\/ndt\/gfh496"},{"key":"122784","doi-asserted-by":"crossref","unstructured":"Gurnani, P., T. Miloh, J. Chandar, D. A. Landau, F. Hajjar and G. Yosipovitch (2021). \u201cSystemic causes of non-dermatologic chronic pruritus in the pediatric population and their management: An unexplored area.\u201d Pediatr Dermatol 38: 1051-1060.","DOI":"10.1111\/pde.14596"},{"key":"122785","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.14596","DOI":"10.1111\/pde.14596"},{"key":"122786","doi-asserted-by":"crossref","unstructured":"Gutman, A. B., A. M. Kligman, J. Sciacca and W. D. James (2005). \u201cSoak and smear: a standard technique revisited.\u201d Arch Dermatol 141: 1556-1559.","DOI":"10.1001\/archderm.141.12.1556"},{"key":"122787","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.141.12.1556","DOI":"10.1001\/archderm.141.12.1556"},{"key":"122788","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky, E., A. Blauvelt, L. F. Eichenfield, A. S. Paller, A. Armstrong, W., J. Drew, R. Gopalan and E. L. Simpson (2020). \u201cEfficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.\u201d JAMA Dermatol 156(4): 411-420.","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"122789","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"122790","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky, E., E. L. Simpson, K. Reich and K. e. a. Kabashima (2023). \u201cAn anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.\u201d Lancet 401(10372): 204-214.","DOI":"10.1016\/S0140-6736(22)02037-2"},{"key":"122791","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(22)02037-2","DOI":"10.1016\/S0140-6736(22)02037-2"},{"key":"122792","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky, E., H. D. Teixeira, E. L. Simpson, K. A. Papp and A. L. Pangan, et al. (2021). \u201cOnce-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.\u201d Lancet 397(10290): 2151-2168.","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"122793","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"122794","doi-asserted-by":"crossref","unstructured":"G\u00fcnther, M., C. Kobus, C. Perner, S. Sch\u00f6nenberg, and T. Prell. (2025). Chronic Pruritus in Geriatric Patients: Prevalence, Associated Factors, and Itch-related Quality of Life. Acta Derm Venereol. 105: adv42003.","DOI":"10.2340\/actadv.v105.42003"},{"key":"122795","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v105.42003","DOI":"10.2340\/actadv.v105.42003"},{"key":"122796","doi-asserted-by":"crossref","unstructured":"Haber, R., J. Bachour, A. Salloum, T. Maacaron, F. Khoury, L. Habr, A. Ammoury and N. Joubran (2020). \u201cComparison of gabapentin and doxepin in the management of uremic pruritus: A randomized crossover clinical trial.\u201d Dermatol Ther 33(6): e14522.","DOI":"10.1111\/dth.14522"},{"key":"122797","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14522","DOI":"10.1111\/dth.14522"},{"key":"122798","doi-asserted-by":"crossref","unstructured":"Hagino, T., H. Saeki, E. Fujimoto and N. Kanda (2024). \u201cEffectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan.\u201d J Dermatolog Treat 35(1): 2307489.","DOI":"10.1080\/09546634.2024.2307489"},{"key":"122799","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2024.2307489","DOI":"10.1080\/09546634.2024.2307489"},{"key":"122800","doi-asserted-by":"crossref","unstructured":"Halvorsen, J. A. and W. Aaseb\u00f8 (2015). \u201cOral tacrolimus treatment of pruritus in prurigo nodularis.\u201d Acta Derm Venereol 95(7): 866-867.","DOI":"10.2340\/00015555-2107"},{"key":"122801","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2107","DOI":"10.2340\/00015555-2107"},{"key":"122802","doi-asserted-by":"crossref","unstructured":"Halvorsen, J. A., F. Dalgard, M. Thoresen, M. Thoresen, E. Bjertness and L. Lien (2009). \u201cItch and mental distress: a cross-sectional study among late adolescents.\u201d Acta Derm Venereol 89(1): 39-44.","DOI":"10.2340\/00015555-0554"},{"key":"122803","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0554","DOI":"10.2340\/00015555-0554"},{"key":"122804","doi-asserted-by":"crossref","unstructured":"Hamilton, D. V. and D. J. Gould (1985). \u201cGeneralized pruritus as a presentation of idiopathic haemochromatosis.\u201d Br J Dermatol 112(5): 629.","DOI":"10.1111\/j.1365-2133.1985.tb15277.x"},{"key":"122805","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1985.tb15277.x","DOI":"10.1111\/j.1365-2133.1985.tb15277.x"},{"key":"122806","doi-asserted-by":"crossref","unstructured":"Hansen, C., T. A. Desrosiers and K. e. a. Wisniewski (2020). \u201cUse of anthistamine medications during early pregnancy and selected birth defects: the National Birth Defects Prevention Study.\u201d Birth Defects Res 112: 1234-1252.","DOI":"10.1002\/bdr2.1749"},{"key":"122807","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/bdr2.1749","DOI":"10.1002\/bdr2.1749"},{"key":"122808","doi-asserted-by":"crossref","unstructured":"Hartmann, E. M., H. O. Handwerker and C. Forster (2015). \u201cGender differences in itch and pain-related sensations provoked by histamine, cowhage and capsaicin.\u201d Acta Derm Venereol 95: 25-30.","DOI":"10.2340\/00015555-1894"},{"key":"122809","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1894","DOI":"10.2340\/00015555-1894"},{"key":"122810","unstructured":"Hawley, K., P. Lio, T. Nguyen, A. Qureshi, C. Emesiani and M. Meckfessel (2023). \u201cA Novel 3-Step Over-the-Counter Eczema Regimen Improves Eczema Severity, Itch, and Life Quality: Randomized Study.\u201d J Drugs Dermatol 22(10): SF388641s388621-SF388641s388626."},{"key":"122811","doi-asserted-by":"crossref","unstructured":"Hawro, T., J. W. Fluhr, V. Mengeaud, D. Redoul\u00e8s, M. K. Church, M. Maurer and M. Metz (2014). \u201cPolidocanol inhibits cowhage - but not histamine-induced itch in humans.\u201d Exp Dermatol 23(12): 922-923.","DOI":"10.1111\/exd.12555"},{"key":"122812","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.12555","DOI":"10.1111\/exd.12555"},{"key":"122813","doi-asserted-by":"crossref","unstructured":"Hay, R. J., N. E. Johns, H. C. Williams, I. W. Bolliger, R. P. Dellavalle, D. J. Margolis, R. Marks, L. Naldi, M. A. Weinstock, S. K. Wulf, C. J. L. Michaud, C. Murray and M. Naghavi (2014). \u201cThe global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.\u201d J Invest Dermatol 134(6): 1527-1534.","DOI":"10.1038\/jid.2013.446"},{"key":"122814","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2013.446","DOI":"10.1038\/jid.2013.446"},{"key":"122815","doi-asserted-by":"crossref","unstructured":"Hayani, K., M. Weiss and E. Weisshaar (2016). \u201cClinical Findings and Provision of Care in Haemodialysis Patients with Chronic Itch: New Results from the German Epidemiological Haemodialysis Itch Study.\u201d Acta Derm Venereol 96(3): 361-366.","DOI":"10.2340\/00015555-2280"},{"key":"122816","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2280","DOI":"10.2340\/00015555-2280"},{"key":"122817","doi-asserted-by":"crossref","unstructured":"Haydek, C. G., E. Love, N. K. Mollanazar, R. Valdes Rodriguez, H. Lee, G. Yosipovitch, M. D. Tharp, J. M. Hanifin, K.-H. Chen and C. S. C. (2017). \u201cValidation and Banding of the ItchyQuant: A Self-Report Itch Severity Scale.\u201d J Invest Dermatol 137(1): 57-61.","DOI":"10.1016\/j.jid.2016.06.633"},{"key":"122818","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2016.06.633","DOI":"10.1016\/j.jid.2016.06.633"},{"key":"122819","doi-asserted-by":"crossref","unstructured":"He, A., S. R. Feldman and A. B. Fleischer (2018). \u201cAn assessment of the use of antihistamines in atopic dermatitis.\u201d J Amer Acad Dermatol 79(1): 92-96.","DOI":"10.1016\/j.jaad.2017.12.077"},{"key":"122820","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.12.077","DOI":"10.1016\/j.jaad.2017.12.077"},{"key":"122821","doi-asserted-by":"crossref","unstructured":"He, M., L. Wu, D. Huang, V. Yau and S. Yu (2020). \u201cPruritus in neuromyelitis optica spectrum disorders and multiple sclerosis.\u201d J Clin Neurosci 79(108-112).","DOI":"10.1016\/j.jocn.2020.07.022"},{"key":"122822","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jocn.2020.07.022","DOI":"10.1016\/j.jocn.2020.07.022"},{"key":"122823","doi-asserted-by":"crossref","unstructured":"He, Q., X. Xie, Q. Chen and W. e. a. Li (2024). \u201cJanus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.\u201d Front Immunol 15: 1342810.","DOI":"10.3389\/fimmu.2024.1342810"},{"key":"122824","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2024.1342810","DOI":"10.3389\/fimmu.2024.1342810"},{"key":"122825","doi-asserted-by":"crossref","unstructured":"He, Y., S. Ji and Q. Yu (2021). \u201cEffectiveness of baricitinib in prurigo-type atopic dermatitis: A case report.\u201d Dermatol Ther 34(2): e14878.","DOI":"10.1111\/dth.14878"},{"key":"122826","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14878","DOI":"10.1111\/dth.14878"},{"key":"122827","doi-asserted-by":"crossref","unstructured":"Hearn, R. M., A. C. Kerr, K. F. Rahim, J. Ferguson and R. S. Dawe (2008). \u201cIncidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.\u201d Br J Dermatol 159(4): 931-935.","DOI":"10.1111\/j.1365-2133.2008.08776.x"},{"key":"122828","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08776.x","DOI":"10.1111\/j.1365-2133.2008.08776.x"},{"key":"122829","doi-asserted-by":"crossref","unstructured":"Hedman-Lagerl\u00f6f, E., J. Fust, E. Axelsson, M. Bonnert, M. Lalouni, O. Molander, P. Agrell, A. Bergman, N. Lindefors and M. Bradley (2021). \u201cInternet-Delivered Cognitive Behavior Therapy for Atopic Dermatitis: A Randomized Clinical Trial.\u201d JAMA Dermatol 157(7): 796-804.","DOI":"10.1001\/jamadermatol.2021.1450"},{"key":"122830","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.1450","DOI":"10.1001\/jamadermatol.2021.1450"},{"key":"122831","doi-asserted-by":"crossref","unstructured":"Heinlin, J., G. Isbary, W. Stolz, F. Zeman, M. Landthaler, G. Morfill, T. Shimizu, J. L. Zimmermann and S. Karrer (2013). \u201cA randomized two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus.\u201d J Eur Acad Dermatol Venereol 27(3): 324-331.","DOI":"10.1111\/j.1468-3083.2011.04395.x"},{"key":"122832","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04395.x","DOI":"10.1111\/j.1468-3083.2011.04395.x"},{"key":"122833","unstructured":"Heisig, M., J. Salomon and J. C. Szepietowski (2012). \u201cChronic pruritus in an elderly patient with dementia successfully treated with paroxetine.\u201d Przegl Dermatol 99: 620-624."},{"key":"122834","doi-asserted-by":"crossref","unstructured":"Heratizadeh, A., T. Werfel, A. Wollenberg, S. Abraham, S. Plank-Habibi and C. e. a. Schnopp (2017). \u201cEffects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial.\u201d J Allergy Clin Immunol Pract 140(845-853).","DOI":"10.1016\/j.jaci.2017.01.029"},{"key":"122835","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2017.01.029","DOI":"10.1016\/j.jaci.2017.01.029"},{"key":"122836","doi-asserted-by":"crossref","unstructured":"Hettrick, H. H., K. O\u2019Brien, H. Laznick, J. Sanchez, D. Gorga, W. Nagler and R. Yurt (2004). \u201cEffect of transcutaneous electrical nerve stimulation for the management of burn pruritus: a pilot study.\u201d J Burn Care Rehabil 25(3): 236-240.","DOI":"10.1097\/01.BCR.0000124745.22170.86"},{"key":"122837","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/01.BCR.0000124745.22170.86","DOI":"10.1097\/01.BCR.0000124745.22170.86"},{"key":"122838","doi-asserted-by":"crossref","unstructured":"Hide, M., T. Suzuki, A. Tanaka and H. Aoki (2019). \u201cEfficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.\u201d Allergol Int 68(1): 59-67.","DOI":"10.1016\/j.alit.2018.06.002"},{"key":"122839","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.alit.2018.06.002","DOI":"10.1016\/j.alit.2018.06.002"},{"key":"122840","doi-asserted-by":"crossref","unstructured":"Hide, M., T. Suzuki, A. Tanaka and H. Aoki (2019). \u201cLong-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.\u201d J Dermatol Sci 94(3): 339-345.","DOI":"10.1016\/j.jdermsci.2019.05.008"},{"key":"122841","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2019.05.008","DOI":"10.1016\/j.jdermsci.2019.05.008"},{"key":"122842","doi-asserted-by":"crossref","unstructured":"Hirschfield, G. M., C. L. Bowlus, M. J. Mayo and A. E. e. a. Kremer (2024). \u201cA phase 3 trial of seladelpar in primary biliary cholangitis.\u201d N Engl J Med 390(9): 783-794.","DOI":"10.1056\/NEJMoa2312100"},{"key":"122843","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2312100","DOI":"10.1056\/NEJMoa2312100"},{"key":"122844","doi-asserted-by":"crossref","unstructured":"Hirschfield, G. M., M. L. Shiffman, A. Gulamhusein and K. V. e. a. Kowdley (2023). \u201cSeladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.\u201d Hepatology 78(2): 397-415.","DOI":"10.1097\/HEP.0000000000000395"},{"key":"122845","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/HEP.0000000000000395","DOI":"10.1097\/HEP.0000000000000395"},{"key":"122846","doi-asserted-by":"crossref","unstructured":"Hoare, C., A. Li Wan Po and H. Williams (2000). \u201cSystematic review of treatments for atopic eczema.\u201d Health Technol Assess 4(37): 1-191.","DOI":"10.3310\/hta4370"},{"key":"122847","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3310\/hta4370","DOI":"10.3310\/hta4370"},{"key":"122848","doi-asserted-by":"crossref","unstructured":"Ho\u0142drowicz, A. M. and A. Wo\u017aniacka (2024). \u201cThe Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis.\u201d J Clin Med 13(6): 1754.","DOI":"10.3390\/jcm13061754"},{"key":"122849","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm13061754","DOI":"10.3390\/jcm13061754"},{"key":"122850","doi-asserted-by":"crossref","unstructured":"Holme, S. A. and A. V. Anstey (2001). \u201cAquagenic pruritus responding to intermittent photochemotherapy.\u201d Clin Exp Dermatol 26(1): 40-41.","DOI":"10.1046\/j.1365-2230.2001.00757.x"},{"key":"122851","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2230.2001.00757.x","DOI":"10.1046\/j.1365-2230.2001.00757.x"},{"key":"122852","unstructured":"Holmes, R. C. (1988). \u201cPolymorphic eruption in pregnancy.\u201d Sem Dermatol 8: 18-22."},{"key":"122853","doi-asserted-by":"crossref","unstructured":"Hong, J., J. Buddenkotte, T. G. Berger and M. Steinhoff (2011). \u201cManagement of itch in atopic dermatitis.\u201d Semin Cutan Med Surg 30(2): 71-86.","DOI":"10.1016\/j.sder.2011.05.002"},{"key":"122854","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.sder.2011.05.002","DOI":"10.1016\/j.sder.2011.05.002"},{"key":"122855","doi-asserted-by":"crossref","unstructured":"Hoogenberg, K., R. A. Tupker, L. H. van Essen, A. J. Smit and C. G. Kallenberg (1992). \u201cSuccessful treatment of ulcerating livedo reticularis with infusions of prostacyclin.\u201d Br J Dermatol 127(1): 64-66.","DOI":"10.1111\/j.1365-2133.1992.tb14834.x"},{"key":"122856","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1992.tb14834.x","DOI":"10.1111\/j.1365-2133.1992.tb14834.x"},{"key":"122857","doi-asserted-by":"crossref","unstructured":"Horimukai, K., K. Morita, M. Narita, M. Kondo, H. Kitazawa, M. Nozaki and Y. e. a. Shigematsu (2014). \u201cApplication of moisturizer to neonates prevents development of atopic dermatitis.\u201d J Allergy Clin Immunol 134(4): 824-830.e826.","DOI":"10.1016\/j.jaci.2014.07.060"},{"key":"122858","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2014.07.060","DOI":"10.1016\/j.jaci.2014.07.060"},{"key":"122859","doi-asserted-by":"crossref","unstructured":"Hsu, M. M. and C. C. Yang (2003). \u201cUraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy.\u201d Br J Dermatol 149(4): 888-889.","DOI":"10.1046\/j.1365-2133.2003.05590.x"},{"key":"122860","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05590.x","DOI":"10.1046\/j.1365-2133.2003.05590.x"},{"key":"122861","doi-asserted-by":"crossref","unstructured":"Hu, M., J. Scheffel, S. Frischbutter, C. Steinert, U. Reidel, M. Spindler, K. Przyby\u0142owicz, M. Hawro, M. Maurer, M. Metz and T. Hawro (2024). \u201cCharacterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.\u201d Clin Exp Med 24(1): 171.","DOI":"10.1007\/s10238-024-01407-y"},{"key":"122862","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10238-024-01407-y","DOI":"10.1007\/s10238-024-01407-y"},{"key":"122863","doi-asserted-by":"crossref","unstructured":"Huang, D., J. Lu and F. Tan (2024). \u201cImprovement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.\u201d Dermatitis 35(1): 77-83.","DOI":"10.1089\/derm.2023.0132"},{"key":"122864","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1089\/derm.2023.0132","DOI":"10.1089\/derm.2023.0132"},{"key":"122865","doi-asserted-by":"crossref","unstructured":"Ingrasci, G., L. Tornes, A. Brown, S. Delgado, J. Hernandez and Q. V. Yap (2023). \u201cChronic pruritus in multiple sclerosis and clinical correlates.\u201d J Eur Acad Dermatol Venereol 37(1): 154-159.","DOI":"10.1111\/jdv.18561"},{"key":"122866","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18561","DOI":"10.1111\/jdv.18561"},{"key":"122867","doi-asserted-by":"crossref","unstructured":"Ingrassia, J. P., M. H. Maqsood, J. M. Gelfand and B. N. e. a. Weber (2024). \u201cCardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.\u201d JAMA Dermatol 160(1): 28-36.","DOI":"10.1001\/jamadermatol.2023.4090"},{"key":"122868","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.4090","DOI":"10.1001\/jamadermatol.2023.4090"},{"key":"122869","doi-asserted-by":"crossref","unstructured":"Ireland, P. A., N. Jansson, S. K. R. Spencer, J. Braden and D. Sebaratnam (2024). \u201cShort-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.\u201d JAMA Dermatol 160(3): 281-289.","DOI":"10.1001\/jamadermatol.2023.5509"},{"key":"122870","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.5509","DOI":"10.1001\/jamadermatol.2023.5509"},{"key":"122871","doi-asserted-by":"crossref","unstructured":"Ishida, J. H., C. E. McCulloch, M. A. Steinman, B. A. Grimes and K. L. Johansen (2018). \u201cGabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.\u201d J Am Soc Nephrol 29(7): 1970-1979.","DOI":"10.1681\/ASN.2018010096"},{"key":"122872","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1681\/ASN.2018010096","DOI":"10.1681\/ASN.2018010096"},{"key":"122873","doi-asserted-by":"crossref","unstructured":"Jabbour, S. A. (2003). \u201cCutaneous manifestations of endocrine disorders: a guide for dermatologists.\u201d Am J Clin Dermatol 4(5): 315-331.","DOI":"10.2165\/00128071-200304050-00003"},{"key":"122874","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00128071-200304050-00003","DOI":"10.2165\/00128071-200304050-00003"},{"key":"122875","unstructured":"Jahn, S., G. von Kobyletzki, S. Behrens, A. R\u00f6chling, P. Altmeyer and M. Kerscher (1997). \u201cErfolgreiche Behandlung des aquagenen Pruritus mit PUVA-Bad-Photochemotherapie.\u201d Z Hautkr 72: 821-824."},{"key":"122876","doi-asserted-by":"crossref","unstructured":"Jain, V., A. Gim\u00e9nez-Arnau, K. Hayama and A. e. a. Reich (2024). \u201cRemibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.\u201d J Allergy Clin Immunol 153(2): 479-486.e474.","DOI":"10.1016\/j.jaci.2023.10.007"},{"key":"122877","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2023.10.007","DOI":"10.1016\/j.jaci.2023.10.007"},{"key":"122878","doi-asserted-by":"crossref","unstructured":"Jaworek, A., K. Szafraniec, M. Jaworek, \u0141. Matusiak, A. Wojas-Pelc and J. C. Szepietowski (2020). \u201cItch Relief in Atopic Dermatitis: Comparison of Narrowband Ultraviolet B Radiation and Cyclosporine Treatment.\u201d Acta Derm Venereol 100(17): adv00291.","DOI":"10.2340\/00015555-3652"},{"key":"122879","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3652","DOI":"10.2340\/00015555-3652"},{"key":"122880","doi-asserted-by":"crossref","unstructured":"Jeanmougin, M., J. D. Rain and Y. Najean (1996). \u201cEfficacy of photochemotherapy on severe pruritus in polycythemia vera.\u201d Ann Hematol 73(2): 91-93.","DOI":"10.1007\/s002770050207"},{"key":"122881","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s002770050207","DOI":"10.1007\/s002770050207"},{"key":"122882","doi-asserted-by":"crossref","unstructured":"Jia, H.-X. and Y.-L. He (2020). \u201cEfficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.\u201d Am J Ther 27(5): e455-e467.","DOI":"10.1097\/MJT.0000000000000912"},{"key":"122883","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MJT.0000000000000912","DOI":"10.1097\/MJT.0000000000000912"},{"key":"122884","doi-asserted-by":"crossref","unstructured":"Johannesdottir, S. A., B. K. Farkas, G. R. Vinding, L. Pedersen, A. Lamberg, H. T. Sorensen and A. B. Olesen (2014). \u201cCancer incidence among patients with a hospital diagnosis of pruritus: a nationwide Danish cohort study.\u201d Br J Dermatol 171(4): 839-846.","DOI":"10.1111\/bjd.13157"},{"key":"122885","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.13157","DOI":"10.1111\/bjd.13157"},{"key":"122886","unstructured":"Johnke, H. and H. Zachariae (1993). \u201cThaildomide treatment of prurigo nodularis.\u201d Ugeskr Laeger 155(38): 3028-3030."},{"key":"122887","doi-asserted-by":"crossref","unstructured":"Ju, T., A. Vander Does and G. Yosipovitch (2022). \u201cScalp dysesthesia: a neuropathic phenomenon.\u201d J Eur Acad Dermatol Venereol 36(6): 790-796.","DOI":"10.1111\/jdv.17985"},{"key":"122888","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17985","DOI":"10.1111\/jdv.17985"},{"key":"122889","doi-asserted-by":"crossref","unstructured":"Kabashima, K., T. Matsumura, H. Komazaki and M. Kawashima (2020). \u201cTrial of Nemolizumab and Topical Agents for Atopic Dermatitis With Pruritus.\u201d N Engl J Med 38(2): 141-150.","DOI":"10.1056\/NEJMoa1917006"},{"key":"122890","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1917006","DOI":"10.1056\/NEJMoa1917006"},{"key":"122891","doi-asserted-by":"crossref","unstructured":"Kalb, R. E., J. Bagel, N. J. Korman, M. G. Lebwohl, M. Young, E. J. Horn, A. S. Van Vorhees and N. P. Foundation (2009). \u201cTreatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation.\u201d J Am Acad Derm 60(1): 120-124.","DOI":"10.1016\/j.jaad.2008.06.041"},{"key":"122892","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2008.06.041","DOI":"10.1016\/j.jaad.2008.06.041"},{"key":"122893","doi-asserted-by":"crossref","unstructured":"Kamata, Y., M. Tominaga and K. Takamori (2016). \u201cItch in Atopic Dermatitis Management.\u201d Curr Probl Dermatol 50: 86-93.","DOI":"10.1159\/000446048"},{"key":"122894","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446048","DOI":"10.1159\/000446048"},{"key":"122895","doi-asserted-by":"crossref","unstructured":"Kanavy, H., J. Bahner and N. J. Korman (2012). \u201cTreatment of refractory prurigo nodularis with lenalidomide.\u201d Arch Dermatol 148(7): 794-796.","DOI":"10.1001\/archdermatol.2011.2918"},{"key":"122896","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archdermatol.2011.2918","DOI":"10.1001\/archdermatol.2011.2918"},{"key":"122897","unstructured":"Kanitakis, J. (2006). \u201cBrachioradial pruritus: report of a new case responding to gabapentin.\u201d Eur J Dermatol 16(3): 311-312."},{"key":"122898","doi-asserted-by":"crossref","unstructured":"Kaplan, A. P. (1984). \u201cDrug-induced skin disease.\u201d J Allergy Clin Immunol 74(4 Pt 2): 573-579.","DOI":"10.1016\/0091-6749(84)90109-X"},{"key":"122899","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0091-6749(84)90109-X","DOI":"10.1016\/0091-6749(84)90109-X"},{"key":"122900","doi-asserted-by":"crossref","unstructured":"Kaptanoglu, A. F. and T. Oskay (2003). \u201cUltraviolet B treatment for pruritus in Hodgkin\u2019s lymphoma.\u201d J Eur Acad Dermatol Venereol 17(4): 489-490.","DOI":"10.1046\/j.1468-3083.2003.00614_15.x"},{"key":"122901","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1468-3083.2003.00614_15.x","DOI":"10.1046\/j.1468-3083.2003.00614_15.x"},{"key":"122902","doi-asserted-by":"crossref","unstructured":"Karaosmano\u011flu, N., P. O. Cetinkaya, \u0130. Y\u00fcksel, I. Bilen and C. M\u00fclko\u011flu (2024). \u201cInvestigating the relationship between chronic pruritus and fibromyalgia: an evaluation of 200 patients.\u201d Arch Dermatol Res 316(8): 545.","DOI":"10.1007\/s00403-024-03291-8"},{"key":"122903","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00403-024-03291-8","DOI":"10.1007\/s00403-024-03291-8"},{"key":"122904","doi-asserted-by":"crossref","unstructured":"Karppinen, A., H. Brummer-Korvenkontio, T. Reunala and I. Izquierdo (2012). \u201cRupatadine 10 mg in the treatment of immediate mosquito-bite allergy.\u201d J Eur Acad Dermatol Venereol 26: 919-922.","DOI":"10.1111\/j.1468-3083.2012.04543.x"},{"key":"122905","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04543.x","DOI":"10.1111\/j.1468-3083.2012.04543.x"},{"key":"122906","doi-asserted-by":"crossref","unstructured":"Kaur, R. and V. R. Sinha (2018). \u201cAntidepressants as antipruritic agents: A review.\u201d Eur Neuropsychopharmacol 28(3): 341-352.","DOI":"10.1016\/j.euroneuro.2018.01.007"},{"key":"122907","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.01.007","DOI":"10.1016\/j.euroneuro.2018.01.007"},{"key":"122908","doi-asserted-by":"crossref","unstructured":"Kaur, S., I. S. Jabbal and A. K. Bhasin (2022). \u201cOmalizumab as a treatment option for antihistamine-refractory aquagenic urticaria.\u201d BMJ Case Rep 15(7): e251057.","DOI":"10.1136\/bcr-2022-251057"},{"key":"122909","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bcr-2022-251057","DOI":"10.1136\/bcr-2022-251057"},{"key":"122910","doi-asserted-by":"crossref","unstructured":"Kaushik, S. B., F. B. Cerci, J. Miracle, A. Pokharel, S. C. Chen, Y. H. Chan, A. Wilkin and G. Yosipovitch (2014). \u201cChronic pruritus in HIV-positive patients in the southeastern United States: its prevalence and effect on quality of life.\u201d J Am Acad Dermatol 70(4): 659-664.","DOI":"10.1016\/j.jaad.2013.12.015"},{"key":"122911","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2013.12.015","DOI":"10.1016\/j.jaad.2013.12.015"},{"key":"122912","doi-asserted-by":"crossref","unstructured":"Keaney, T. C., T. Bhutani, P. Sivanesan, G. D. Bandow, S. B. Weinstein, L. C. Cheung, F. Malick and J. Koo (2012). \u201cOpen-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis.\u201d J Am Acad Dermatol 67(4): 636-641.","DOI":"10.1016\/j.jaad.2011.10.033"},{"key":"122913","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2011.10.033","DOI":"10.1016\/j.jaad.2011.10.033"},{"key":"122914","doi-asserted-by":"crossref","unstructured":"Kee, Y. K., H. J. Jeon, J. Oh and D. H. Shin (2024). \u201cVitamin D and narrowband ultraviolet B phototherapy for chronic kidney disease-associated pruritus.\u201d Kidney Res Clin Pract 43(2): 177-185.","DOI":"10.23876\/j.krcp.22.153"},{"key":"122915","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.23876\/j.krcp.22.153","DOI":"10.23876\/j.krcp.22.153"},{"key":"122916","doi-asserted-by":"crossref","unstructured":"Kemperman, P. M. J. H., N. C. C. Vulink, C. Smit, J. W. Hovius and M. A. de Rie (2024). \u201cReview of literature and clinical practice experience for the therapeutic management of Morgellons disease.\u201d J Eur Acad Dermatol Venereol 38(7): 1300-1304.","DOI":"10.1111\/jdv.19831"},{"key":"122917","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19831","DOI":"10.1111\/jdv.19831"},{"key":"122918","doi-asserted-by":"crossref","unstructured":"Keshari, S., A. D. Sipayung, C.-C. Hsieh, L.-J. Su, Y.-R. Chiang, H.-C. Chang, Y. W.-C., T.-H. Chuang, C.-L. Chen and C.-M. Huang (2019). \u201cIL-6\/p-BTK\/p-ERK signaling mediates calcium phosphate-induced pruritus.\u201d FASEB J 33: 12036-12046.","DOI":"10.1096\/fj.201900016RR"},{"key":"122919","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1096\/fj.201900016RR","DOI":"10.1096\/fj.201900016RR"},{"key":"122920","unstructured":"Khan, N. J., Wahaj, S. Haider, H. Gilani and N. Iqbal, et al. (2022). \u201cComparing The Efficacy And Safety Of Pregabalin Vs Gabapentin In Uremic Pruritus In Patients Of Chronic Kidney Injury Undergoing Haemodialysis.\u201d J Ayub Med Coll Abbottabad 34(3): 524-527."},{"key":"122921","doi-asserted-by":"crossref","unstructured":"Khanna, R., E. Boozalis, M. Belzberg, J. G. Zampella and S. G. Kwatra (2019). \u201cMirtazapine for the Treatment of Chronic Pruritus.\u201d Medicines (Basel) 6(3): 73.","DOI":"10.3390\/medicines6030073"},{"key":"122922","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/medicines6030073","DOI":"10.3390\/medicines6030073"},{"key":"122923","doi-asserted-by":"crossref","unstructured":"Kibsgaard, L., B. Bay, M. Deleuran and C. Vestergaard (2015). \u201cA retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre.\u201d Acta Derm Venereol 95(3): 307-311.","DOI":"10.2340\/00015555-1925"},{"key":"122924","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1925","DOI":"10.2340\/00015555-1925"},{"key":"122925","doi-asserted-by":"crossref","unstructured":"Kilic, A., U. Gul and S. Soylu (2007). \u201cSkin findings in internal malignant diseases.\u201d Int. J Dermatol 46: 1055-1060.","DOI":"10.1111\/j.1365-4632.2007.03288.x"},{"key":"122926","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03288.x","DOI":"10.1111\/j.1365-4632.2007.03288.x"},{"key":"122927","doi-asserted-by":"crossref","unstructured":"Kim, B. S., R. Bissonnette, K. Nograles, C. Munera and N. Shah (2023). \u201cPhase 2 Trial of Difelikefalin in Notalgia Paresthetica.\u201d N Engl J Med 388(6): 511-517.","DOI":"10.1056\/NEJMoa2210699"},{"key":"122928","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2210699","DOI":"10.1056\/NEJMoa2210699"},{"key":"122929","doi-asserted-by":"crossref","unstructured":"Kim, H. J., M. Zeidi, D. Bonciani, S. M. Pena, J. Tiao, S. Sahu and V. P. Werth (2018). \u201cItch in dermatomyositis: the role of increased skin interleukin-31.\u201d Br J Dermatol 179(3): 669-678.","DOI":"10.1111\/bjd.16498"},{"key":"122930","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16498","DOI":"10.1111\/bjd.16498"},{"key":"122931","doi-asserted-by":"crossref","unstructured":"Kim, Y. J., D. J. Lim, M. Y. Lee, W. J. Lee, S. E. Chang and C. H. Won (2021). \u201cProspective, comparative clinical pilot study of cold atmospheric plasma device in the treatment of atopic dermatitis.\u201d Sci Rep 11: 14461.","DOI":"10.1038\/s41598-021-93941-y"},{"key":"122932","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41598-021-93941-y","DOI":"10.1038\/s41598-021-93941-y"},{"key":"122933","doi-asserted-by":"crossref","unstructured":"Kimball, A. B., T. Luger, A. Gottlieb, L. Puig, R. Kaufmann, R. Burge, C. Y. Lin and G. Yosipovitch (2018). \u201cLong-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.\u201d Acta Derm Venereol 98(98-102).","DOI":"10.2340\/00015555-2801"},{"key":"122934","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2801","DOI":"10.2340\/00015555-2801"},{"key":"122935","doi-asserted-by":"crossref","unstructured":"Kimmel, M., D. M. Alscher, R. Dunst, N. Braun, C. Machleidt, T. Kiefer, C. Stulten, H. van der Kuip, C. Pauli-Magnus, U. Raub, U. Kuhlmann and T. Mettang (2006). \u201cThe role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients.\u201d Nephrol Dial Transplant 21(3): 749-755.","DOI":"10.1093\/ndt\/gfi204"},{"key":"122936","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/gfi204","DOI":"10.1093\/ndt\/gfi204"},{"key":"122937","doi-asserted-by":"crossref","unstructured":"Kirby, B. and S. Rogers (1997). \u201cTreatment of PUVA itch with capsaicin.\u201d Br J Dermatol 137(1): 152.","DOI":"10.1111\/j.1365-2133.1997.tb03723.x"},{"key":"122938","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1997.tb03723.x","DOI":"10.1111\/j.1365-2133.1997.tb03723.x"},{"key":"122939","doi-asserted-by":"crossref","unstructured":"Kishimoto, S., N. Watanabe, Y. Yamamoto, T. Imai, R. Aida, C. Germer, R. Tamagawa-Mineoka, R. Shimizu, S. Hickman, Y. Nakayama, T. Etoh, E. Sahker, M. B. Carnie and T. A. Furukawa (2023). \u201cEfficacy of Integrated Online Mindfulness and Self-compassion Training for Adults With Atopic Dermatitis: A Randomized Clinical Trial.\u201d JAMA Dermatol 159(6): 628-636.","DOI":"10.1001\/jamadermatol.2023.0975"},{"key":"122940","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.0975","DOI":"10.1001\/jamadermatol.2023.0975"},{"key":"122941","doi-asserted-by":"crossref","unstructured":"Kleinman, E., J. Laborada, L. Metterle and L. F. Eichenfield (2022). \u201cWhat\u2019s New in Topicals for Atopic Dermatitis?\u201d Am J Clin Dermatol 23(5): 595-603.","DOI":"10.1007\/s40257-022-00712-0"},{"key":"122942","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-022-00712-0","DOI":"10.1007\/s40257-022-00712-0"},{"key":"122943","doi-asserted-by":"crossref","unstructured":"Klejtman, T., M. Beylot-Barry, P. Joly, M. A. Richard, S. Debarbieux, L. Misery, P. Wolkenstein, O. Chosidow and S. Ingen-Housz-Oro (2018). \u201cTreatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases.\u201d.J Eur Acad Dermatol Venereol 32(3): 437-440.","DOI":"10.1111\/jdv.14646"},{"key":"122944","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14646","DOI":"10.1111\/jdv.14646"},{"key":"122945","doi-asserted-by":"crossref","unstructured":"Knolle, E., M. Zadrazil, G. G. Kovacs, S. Medwed, G. Scharbert and M. Schemper (2013). \u201cComparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study.\u201d Pain 154(12): 2729-2236.","DOI":"10.1016\/j.pain.2013.08.001"},{"key":"122946","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.pain.2013.08.001","DOI":"10.1016\/j.pain.2013.08.001"},{"key":"122947","doi-asserted-by":"crossref","unstructured":"Ko, M. J., J. Y. Yang, H. Y. Wu, F. C. Hu, S. I. Chen, P. J. Tsai, S. H. Jee and H. C. Chiu (2011). \u201cNarrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial.\u201d Br J Dermatol 165(3): 633-639.","DOI":"10.1111\/j.1365-2133.2011.10448.x"},{"key":"122948","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10448.x","DOI":"10.1111\/j.1365-2133.2011.10448.x"},{"key":"122949","doi-asserted-by":"crossref","unstructured":"Koh, M. J. and W. S. Chong (2009). \u201cAquagenic pruritus responding to combined ultraviolet A\/narrowband ultraviolet B therapy.\u201d Photodermatol Photoimmunol Photomed 25(3): 169-170.","DOI":"10.1111\/j.1600-0781.2009.00429.x"},{"key":"122950","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1600-0781.2009.00429.x","DOI":"10.1111\/j.1600-0781.2009.00429.x"},{"key":"122951","doi-asserted-by":"crossref","unstructured":"Kong, H. E., S. Francois, S. Smith, G. Lee, B. Bradley, K.-H. Chen, L. P. Lawley, M. Spraker, J. S. Roberts and S. C. Chen (2021). \u201cTools to study the severity of itch in 8-to 17 year old children : Validation of TweenItchyQOL and ItchyQuant.\u201d Pediatr Dermatol 38: 1118-1126.","DOI":"10.1111\/pde.14662"},{"key":"122952","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.14662","DOI":"10.1111\/pde.14662"},{"key":"122953","doi-asserted-by":"crossref","unstructured":"Kong, X., Y. Kong, F. Zhang, T. Wang and J. Yan (2016). \u201cEvaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).\u201d Medicine (Baltimore) 95(40): e494.","DOI":"10.1097\/MD.0000000000004949"},{"key":"122954","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MD.0000000000004949","DOI":"10.1097\/MD.0000000000004949"},{"key":"122955","doi-asserted-by":"crossref","unstructured":"Kopecky, E. A., S. Jacobson, M. B. Bch, P. Hubley, L. Palozzi, H. M. Clarke and G. Koren (2001). \u201cSafety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study.\u201d J Burn Care Rehabil 22(3): 235-242.","DOI":"10.1097\/00004630-200105000-00010"},{"key":"122956","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/00004630-200105000-00010","DOI":"10.1097\/00004630-200105000-00010"},{"key":"122957","doi-asserted-by":"crossref","unstructured":"Koschmieder, S., S. Isfort, D. Wolf, F. H. Heidel and A. Hochhaus, et al. (2023). \u201cEfficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.\u201d Ann Hematol 102(2): 349-358.","DOI":"10.1007\/s00277-022-05080-7"},{"key":"122958","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00277-022-05080-7","DOI":"10.1007\/s00277-022-05080-7"},{"key":"122959","doi-asserted-by":"crossref","unstructured":"Koumaki, D., S. Gregoriou, G. Evangelou and K. Krasagakis (2023). \u201cPruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis.\u201d J Clin Med 12(6): 2091.","DOI":"10.3390\/jcm12062091"},{"key":"122960","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm12062091","DOI":"10.3390\/jcm12062091"},{"key":"122961","doi-asserted-by":"crossref","unstructured":"Kouwenhoven, T. A., P. C. M. van de Kerkhof and M. Kamsteeg (2017). \u201cUse of oral antidepressants in patients with chronic pruritus: A systematic review.\u201d J Am Acad Dermatol 77(6): 1068-1073.e1067.","DOI":"10.1016\/j.jaad.2017.08.025"},{"key":"122962","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.08.025","DOI":"10.1016\/j.jaad.2017.08.025"},{"key":"122963","doi-asserted-by":"crossref","unstructured":"Kouwenhoven, T. A., M. E. van Muijen and v. d. K. P. C. M. et. al. (2024). \u201cEffectiveness of Systemic Treatments on Pruritus Associated With Atopic Dermatitis: A Systematic Review in Pediatric Patients.\u201d Pediatr Dermatol 41(1): 34-40.","DOI":"10.1111\/pde.15468"},{"key":"122964","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.15468","DOI":"10.1111\/pde.15468"},{"key":"122965","doi-asserted-by":"crossref","unstructured":"Krajnik, M. and Z. Zylicz (2001). \u201cPruritus in advanced internal diseases. Pathogenesis and treatment.\u201d Neth J Med 58(1): 27-40.","DOI":"10.1016\/S0300-2977(00)00084-X"},{"key":"122966","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0300-2977(00)00084-X","DOI":"10.1016\/S0300-2977(00)00084-X"},{"key":"122967","doi-asserted-by":"crossref","unstructured":"Kraut, R. Y. (2017). \u201cTreatment of pruritus in a palliative care patient with low-dose paroxetine: a case report.\u201d J Med Case Rep 11(1): 280.","DOI":"10.1186\/s13256-017-1437-6"},{"key":"122968","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13256-017-1437-6","DOI":"10.1186\/s13256-017-1437-6"},{"key":"122969","doi-asserted-by":"crossref","unstructured":"Kremer, A. E., R. Bolier, R. van Dijk, R. P. Oude Elferink and U. Beuers (2014). \u201cAdvances in pathogenesis and management of pruritus in cholestasis.\u201d Dig Dis 32(5): 637-645.","DOI":"10.1159\/000360518"},{"key":"122970","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000360518","DOI":"10.1159\/000360518"},{"key":"122971","doi-asserted-by":"crossref","unstructured":"Kremer, A. E., R. V. Dijk, P. Leckie, F. G. Schaap, E. M. Kuiper, T. Mettang, K. S. Reiners, U. Raap, H. R. Buuren, K. J. Erpecum, N. A. Davies, C. Rust, A. Engert, R. Jalan, R. P. Elferink and U. Beuers (2012). \u201cSerum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions.\u201d Hepatology.","DOI":"10.1002\/hep.25748"},{"key":"122972","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/hep.25748","DOI":"10.1002\/hep.25748"},{"key":"122973","doi-asserted-by":"crossref","unstructured":"Kremer, A. E., M. J. Mayo, G. M. Hirschfield and C. e. a. Levy (2024). \u201cSeladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.\u201d Hepatology 80(1): 27-37.","DOI":"10.1097\/HEP.0000000000000728"},{"key":"122974","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/HEP.0000000000000728","DOI":"10.1097\/HEP.0000000000000728"},{"key":"122975","doi-asserted-by":"crossref","unstructured":"Kremer, A. E., B. Namer, R. Bolier, M. J. Fischer, R. P. Oude Elferink and U. Beuers (2015). \u201cPathogenesis and management of pruritus in PBC and PSC.\u201d Dig Dis 33(Suppl 2): 164-175.","DOI":"10.1159\/000440829"},{"key":"122976","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000440829","DOI":"10.1159\/000440829"},{"key":"122977","doi-asserted-by":"crossref","unstructured":"Kuhn, A., K. Gensch, M. Haust, S. W. Schneider, G. Bonsmann, N. Gaebelein-Wissing, P. Lehmann, A. Wons, P. Reitmeir, V. Ruland, T. A. Luger and T. Ruzicka (2011). \u201cEfficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial.\u201d J Am Acad Dermatol 65(1): 54-64, 64 e51-52.","DOI":"10.1016\/j.jaad.2010.03.037"},{"key":"122978","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2010.03.037","DOI":"10.1016\/j.jaad.2010.03.037"},{"key":"122979","doi-asserted-by":"crossref","unstructured":"Kumada, H., H. Miyakawa, T. Muramatsu, N. Ando, T. Oh, K. Takamori and H. Nakamoto (2016). \u201cEfficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial.\u201d Hepatol Res.","DOI":"10.1111\/hepr.12830"},{"key":"122980","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/hepr.12830","DOI":"10.1111\/hepr.12830"},{"key":"122981","doi-asserted-by":"crossref","unstructured":"Kumagai, H., T. Ebata, K. Takamori, K. Miyasato, T. Muramatsu, H. Nakamoto, M. Kurihara, T. Yanagita and H. Suzuki (2012). \u201cEfficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients.\u201d Am J Nephrol 36(2): 175-183.","DOI":"10.1159\/000341268"},{"key":"122982","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000341268","DOI":"10.1159\/000341268"},{"key":"122983","doi-asserted-by":"crossref","unstructured":"Kumagai, H., T. Ebata, K. Takamori, T. Muramatsu, H. Nakamoto and H. Suzuki (2010). \u201cEffect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.\u201d Nephrol Dial Transplant 25(4): 1251-1257.","DOI":"10.1093\/ndt\/gfp588"},{"key":"122984","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/gfp588","DOI":"10.1093\/ndt\/gfp588"},{"key":"122985","doi-asserted-by":"crossref","unstructured":"Kupsa, R., A. Gruber-Wackernagel, A. Hofer, F. Quehenberger, P. Wolf and F. J. Legat (2023). \u201cNarrowband-ultraviolet B vs Broadband-ultraviolet B in Treatment of Chronic Pruritus: A Randomized, Single-blinded, Non-inferiority Study.\u201d Acta Derm Venereol 103: adv9403.","DOI":"10.2340\/actadv.v103.9403"},{"key":"122986","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v103.9403","DOI":"10.2340\/actadv.v103.9403"},{"key":"122987","doi-asserted-by":"crossref","unstructured":"Kursewicz, C., E. Fowler, J. Rosen, D. Castillo, Y. H. Chan, L. Nattkemper and G. Yosipovitch (2020). \u201cSex differences in the perception of itch and quality of life in patients with chronic pruritus in the United States.\u201d Itch 5(3): p e41.","DOI":"10.1097\/itx.0000000000000041"},{"key":"122988","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/itx.0000000000000041","DOI":"10.1097\/itx.0000000000000041"},{"key":"122989","doi-asserted-by":"crossref","unstructured":"Kuypers, D. R., K. Claes, P. Evenepoel, B. Maes and Y. Vanrenterghem (2004). \u201cA prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy.\u201d Nephrol Dial Transplant 19(7): 1895-1901.","DOI":"10.1093\/ndt\/gfh202"},{"key":"122990","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/gfh202","DOI":"10.1093\/ndt\/gfh202"},{"key":"122991","doi-asserted-by":"crossref","unstructured":"Kwatra, S. G., Z. A. Bordeaux, V. Parthasarathy and A. L. e. a. Kollhoff (2024). \u201cEfficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin. A Nonrandomized Controlled Trial.\u201d JAMA Dermatol 160(7): 717-724.","DOI":"10.1001\/jamadermatol.2024.1464"},{"key":"122992","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.1464","DOI":"10.1001\/jamadermatol.2024.1464"},{"key":"122993","doi-asserted-by":"crossref","unstructured":"Kwatra, S. G., S. Stander, J. D. Bernhard, E. Weisshaar and G. Yosipovitch (2013). \u201cBrachioradial pruritus: a trigger for generalization of itch.\u201d J Am Acad Dermatol 68(5): 870-873.","DOI":"10.1016\/j.jaad.2012.11.026"},{"key":"122994","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2012.11.026","DOI":"10.1016\/j.jaad.2012.11.026"},{"key":"122995","doi-asserted-by":"crossref","unstructured":"Kwatra, S. G., G. Yosipovitch, F. J. Legat and A. e. a. Reich (2023). \u201cPhase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.\u201d N Engl J Med 389(17): 1579-1589.","DOI":"10.1056\/NEJMoa2301333"},{"key":"122996","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2301333","DOI":"10.1056\/NEJMoa2301333"},{"key":"122997","doi-asserted-by":"crossref","unstructured":"Kwatra, S. G., G. Yosipovitch, S. St\u00e4nder and I. e. a. Guillemin (2024). \u201cResponder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.\u201d J Eur Acad Dermatol Venereol 38(10): 1965-1972.","DOI":"10.1111\/jdv.20099"},{"key":"122998","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.20099","DOI":"10.1111\/jdv.20099"},{"key":"122999","doi-asserted-by":"crossref","unstructured":"Labib, A., L. A. Nattkemper, A. Vander Does, T. Ju, S. Cacciapuoti, M. Vastarella, G. Fabbrocini and G. Yosipovitch (2022). \u201cLB1043 COVID-19-associated pruritus is non-histaminergic mediated.\u201d J Invest Dermatol 142(8): B38.","DOI":"10.1016\/j.jid.2022.05.1081"},{"key":"123000","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2022.05.1081","DOI":"10.1016\/j.jid.2022.05.1081"},{"key":"123001","unstructured":"Labib, A., J. Rosen and G. Yosipovitch (2022). Skin Manifestations of Diabetes Mellitus. Endotext [Internet]. K. R. Feingold, B. Anawalt and M. R. e. a. Blackman. South Dartmouth (MA), MDText.com, Inc."},{"key":"123002","doi-asserted-by":"crossref","unstructured":"Lam, M., J. W. Zhu, M. Tadrous and A. M. Drucker (2021). \u201cAssociation Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.\u201d JAMA Dermatol 157(5): 549-558.","DOI":"10.1001\/jamadermatol.2021.0345"},{"key":"123003","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.0345","DOI":"10.1001\/jamadermatol.2021.0345"},{"key":"123004","doi-asserted-by":"crossref","unstructured":"Langley, R. G., B. E. Elewski, M. Lebwohl and K. e. a. Reich (2014). \u201cSecukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials.\u201d N Engl J Med 371(4): 326-338.","DOI":"10.1056\/NEJMoa1314258"},{"key":"123005","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1314258","DOI":"10.1056\/NEJMoa1314258"},{"key":"123006","doi-asserted-by":"crossref","unstructured":"Laniosz, V., D. A. Wetter and D. A. Godar (2014). \u201cDermatologic manifestations of fibromyalgia.\u201d Clin Rheumatol 33(7): 1009-1013.","DOI":"10.1007\/s10067-014-2488-3"},{"key":"123007","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10067-014-2488-3","DOI":"10.1007\/s10067-014-2488-3"},{"key":"123008","doi-asserted-by":"crossref","unstructured":"Larson, V. A., O. Tang, S. St\u00e4nder, S. Kang and S. G. Kwatra (2018). \u201cAssociation between itch and cancer in 16,925 patients with pruritus: Experience at a tertiary care center.\u201d J Am Acad Dermatol 80(4): 931-937.","DOI":"10.1016\/j.jaad.2018.08.044"},{"key":"123009","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.08.044","DOI":"10.1016\/j.jaad.2018.08.044"},{"key":"123010","doi-asserted-by":"crossref","unstructured":"Lavda, A. C., T. L. Webb and A. R. Thompson (2012). \u201cA meta-analysis of the effectiveness of psychological interventions for adults with skin conditions.\u201d Br J Dermatol 167(970-979).","DOI":"10.1111\/j.1365-2133.2012.11183.x"},{"key":"123011","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11183.x","DOI":"10.1111\/j.1365-2133.2012.11183.x"},{"key":"123012","doi-asserted-by":"crossref","unstructured":"Lavery, M. J., C. Stull, M. O. Kinney and G. Yosipovitch (2016). \u201cNocturnal Pruritus: The Battle for a Peaceful Night\u2019s Sleep.\u201d Int J Mol Sci 17: 425.","DOI":"10.3390\/ijms17030425"},{"key":"123013","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms17030425","DOI":"10.3390\/ijms17030425"},{"key":"123014","doi-asserted-by":"crossref","unstructured":"Lawson, V., M. S. Lewis-Jones, A. Y. Finlay, P. Reid and R. G. Owens (1998). \u201cThe family impact of childhood atopic dermatitis : the dermatitis family impact questionnaire.\u201d Br J Dermatol 138: 107-113.","DOI":"10.1046\/j.1365-2133.1998.02034.x"},{"key":"123015","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.1998.02034.x","DOI":"10.1046\/j.1365-2133.1998.02034.x"},{"key":"123016","doi-asserted-by":"crossref","unstructured":"Layton, A. M. and J. A. Cotterill (1991). \u201cNotalgia paraesthetica--report of three cases and their treatment.\u201d Clin Exp Dermatol 16(3): 197-198.","DOI":"10.1111\/j.1365-2230.1991.tb00345.x"},{"key":"123017","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2230.1991.tb00345.x","DOI":"10.1111\/j.1365-2230.1991.tb00345.x"},{"key":"123018","doi-asserted-by":"crossref","unstructured":"Lebwohl, M., R. B. Warren, H. Sofen and S. e. a. Imafuku (2024). \u201cDeucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.\u201d Br J Dermatol 190(5): 668-679.","DOI":"10.1093\/bjd\/ljae014"},{"key":"123019","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljae014","DOI":"10.1093\/bjd\/ljae014"},{"key":"123020","doi-asserted-by":"crossref","unstructured":"Lebwohl, M. G., L. H. Kircik, A. Y. Moore and L. e. a. Stein Gold (2022). \u201cEffect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.\u201d JAMA 328(11): 1073-1084.","DOI":"10.1001\/jama.2022.15632"},{"key":"123021","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jama.2022.15632","DOI":"10.1001\/jama.2022.15632"},{"key":"123022","doi-asserted-by":"crossref","unstructured":"Lebwohl, M. G., K. A. Papp, L. Stein Gold and M. J. e. a. Gooderham (2020). \u201cTrial of Roflumilast Cream for Chronic Plaque Psoriasis.\u201d N Engl J Med 383(3): 229-239.","DOI":"10.1056\/NEJMoa2000073"},{"key":"123023","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2000073","DOI":"10.1056\/NEJMoa2000073"},{"key":"123024","doi-asserted-by":"crossref","unstructured":"Lebwohl, M. G., L. Stein Gold, B. Strober and K. A. e. a. Papp (2021). \u201cPhase 3 Trials of Tapinarof Cream for Plaque Psoriasis.\u201d N Engl J Med 385(24): 2219-2229.","DOI":"10.1056\/NEJMoa2103629"},{"key":"123025","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2103629","DOI":"10.1056\/NEJMoa2103629"},{"key":"123026","doi-asserted-by":"crossref","unstructured":"Lee, E., J. Koo and T. G. Berger (2005). \u201cUVB phototherapy and skin cancer risk: a review of the literature.\u201d Int J Dermatol 44(5): 355-360.","DOI":"10.1111\/j.1365-4632.2004.02186.x"},{"key":"123027","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02186.x","DOI":"10.1111\/j.1365-4632.2004.02186.x"},{"key":"123028","doi-asserted-by":"crossref","unstructured":"Lee, F. J., B. S. Frankum and C. H. Katelaris (2012). \u201cPoor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series.\u201d Australas J Dermatol 53(4): 295-297.","DOI":"10.1111\/j.1440-0960.2011.00789.x"},{"key":"123029","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1440-0960.2011.00789.x","DOI":"10.1111\/j.1440-0960.2011.00789.x"},{"key":"123030","doi-asserted-by":"crossref","unstructured":"Lee, J. J., S. D. Girouard, V. M. Carlberg and A. Mostaghimi (2016). \u201cEffective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse.\u201d BMJ Support Palliat Care 2016(1): 119-121.","DOI":"10.1136\/bmjspcare-2014-000790"},{"key":"123031","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjspcare-2014-000790","DOI":"10.1136\/bmjspcare-2014-000790"},{"key":"123032","doi-asserted-by":"crossref","unstructured":"Lee, J. J., C. Morillo-Hernandez, V. Agarwal, C. J. Standaert and J. C. r. English (2023). \u201cCervical spine imaging and treatment outcomes in scalp dysesthesia: A retrospective cohort study.\u201d J Am Acad Dermatol 88(3): 655-656.","DOI":"10.1016\/j.jaad.2020.08.010"},{"key":"123033","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.08.010","DOI":"10.1016\/j.jaad.2020.08.010"},{"key":"123034","doi-asserted-by":"crossref","unstructured":"Lee, S. S., G. Yosipovitch, Y. H. Chan and C. L. Goh (2004). \u201cPruritus, pain, and small nerve fiber function in keloids: a controlled study.\u201d J Am Acad Dermatol 51(6): 1002-1006.","DOI":"10.1016\/j.jaad.2004.07.054"},{"key":"123035","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2004.07.054","DOI":"10.1016\/j.jaad.2004.07.054"},{"key":"123036","doi-asserted-by":"crossref","unstructured":"Legat, F. J. (2018). \u201cThe Antipruritic Effect of Phototherapy.\u201d Front Med (Lausanne) 5: 333.","DOI":"10.3389\/fmed.2018.00333"},{"key":"123037","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2018.00333","DOI":"10.3389\/fmed.2018.00333"},{"key":"123038","doi-asserted-by":"crossref","unstructured":"Legat, F. J. (2019). \u201cIs there still a role for UV therapy in itch treatment?\u201d Exp Dermatol 28(12): 1432-1438.","DOI":"10.1111\/exd.14011"},{"key":"123039","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.14011","DOI":"10.1111\/exd.14011"},{"key":"123040","doi-asserted-by":"crossref","unstructured":"Legroux-Crespel, E., J. Cl\u00e8des and L. Misery (2004). \u201cA comparative study on the effects of naltrexone and loratadine on uremic pruritus.\u201d Dermatology 208(4): 326-330.","DOI":"10.1159\/000077841"},{"key":"123041","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000077841","DOI":"10.1159\/000077841"},{"key":"123042","doi-asserted-by":"crossref","unstructured":"Lepping, P., M. Huber and R. W. Freudenmann (2015). \u201cHow to approach delusional infestation.\u201d BMJ 350: h1328.","DOI":"10.1136\/bmj.h1328"},{"key":"123043","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.h1328","DOI":"10.1136\/bmj.h1328"},{"key":"123044","doi-asserted-by":"crossref","unstructured":"Leslie, T. A. (2013). \u201cItch.\u201d Medicine 41(7): 367-371.","DOI":"10.1016\/j.mpmed.2013.04.004"},{"key":"123045","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.mpmed.2013.04.004","DOI":"10.1016\/j.mpmed.2013.04.004"},{"key":"123046","doi-asserted-by":"crossref","unstructured":"Leslie, T. A. (2013). \u201cItch.\u201d Medicine 41: 367-371.","DOI":"10.1016\/j.mpmed.2013.04.004"},{"key":"123047","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.mpmed.2013.04.004","DOI":"10.1016\/j.mpmed.2013.04.004"},{"key":"123048","doi-asserted-by":"crossref","unstructured":"Leslie, T. A. (2015). Antihistamines. Abingdon, Taylor and Francis Group.","DOI":"10.1201\/b18491-8"},{"key":"123049","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1201\/b18491-8","DOI":"10.1201\/b18491-8"},{"key":"123050","doi-asserted-by":"crossref","unstructured":"Leslie, T. A. (2016). \u201cItch management in the elderly.\u201d Curr Prob Dermatol 50: 192-201.","DOI":"10.1159\/000446094"},{"key":"123051","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446094","DOI":"10.1159\/000446094"},{"key":"123052","doi-asserted-by":"crossref","unstructured":"Leslie, T. A. (2016). \u201cItch Management in the Elderly.\u201d Curr Probl Dermatol 50: 192-201.","DOI":"10.1159\/000446094"},{"key":"123053","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446094","DOI":"10.1159\/000446094"},{"key":"123054","unstructured":"Leslie, T. A. and C. H. Grattan (2017). Antihistamines, sodium cromoglicate, and leukotriene receptor antagonists. Handbook of Dermatology Treatment. M. Arden-Jones, P. Hampton and R. A. Vleugels. London, JP Medical Ltd: 64-67 (in press)."},{"key":"123055","doi-asserted-by":"crossref","unstructured":"Leslie, T. A., M. W. Greaves and G. Yosipovitch (2015). \u201cCurrent topical and systemic therapies for itch.\u201d Handb Exp Pharmacol 226: 337-356.","DOI":"10.1007\/978-3-662-44605-8_18"},{"key":"123056","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/978-3-662-44605-8_18","DOI":"10.1007\/978-3-662-44605-8_18"},{"key":"123057","doi-asserted-by":"crossref","unstructured":"Lewis-Jones, M. S. and A. Y. Finlay (1995). \u201cThe Children\u2019s Dermatology Life Quality Index ( CDLQI): initial validation and practical use.\u201d Br J Dermatol 132: 942-949.","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"123058","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1995.tb16953.x","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"123059","doi-asserted-by":"crossref","unstructured":"Lewis-Jones, S. (2001). \u201cAtopic dermatitis in childhood.\u201d Hosp Med 62: 136-143.","DOI":"10.12968\/hosp.2001.62.3.1531"},{"key":"123060","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.12968\/hosp.2001.62.3.1531","DOI":"10.12968\/hosp.2001.62.3.1531"},{"key":"123061","doi-asserted-by":"crossref","unstructured":"Liao, V., H. L. Cornman, E. Ma and S. G. Kwatra (2024). \u201cPrurigo nodularis: new insights into pathogenesis and novel therapeutics.\u201d Br J Dermatol 190(6): 798-810.","DOI":"10.1093\/bjd\/ljae052"},{"key":"123062","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljae052","DOI":"10.1093\/bjd\/ljae052"},{"key":"123063","doi-asserted-by":"crossref","unstructured":"Lim, H. W., S. Vallurupalli, T. Meola and N. A. Soter (1997). \u201cUVB phototherapy is an effective treatment for pruritus in patients infected with HIV.\u201d J Am Acad Dermatol 37(3 Pt 1): 414-417.","DOI":"10.1016\/S0190-9622(97)70142-7"},{"key":"123064","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(97)70142-7","DOI":"10.1016\/S0190-9622(97)70142-7"},{"key":"123065","doi-asserted-by":"crossref","unstructured":"Lim, V. M., E. L. Maranda, V. Patel, B. J. Simmons and J. J. Jimenez (2016). \u201cA review of the efficacy of Thalidomide and Lenalidomide in the treatment of refractory prurigo nodularis.\u201d Dermatol Ther 6: 397-411.","DOI":"10.1007\/s13555-016-0122-9"},{"key":"123066","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-016-0122-9","DOI":"10.1007\/s13555-016-0122-9"},{"key":"123067","doi-asserted-by":"crossref","unstructured":"Lim, Y. L., Y. H. Chan, G. Yosipovitch and M. W. Greaves (2008). \u201cPruritus is a common and significant symptom of acne.\u201d J Eur Acad Dermatol Venereol 22(11): 1332-1336.","DOI":"10.1111\/j.1468-3083.2008.02828.x"},{"key":"123068","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02828.x","DOI":"10.1111\/j.1468-3083.2008.02828.x"},{"key":"123069","doi-asserted-by":"crossref","unstructured":"Lindelof, B., B. Sigurgeirsson, E. Tegner, O. Larko, A. Johannesson, B. Berne, B. Ljunggren, T. Andersson, L. Molin, E. Nylander-Lundqvist and L. Emtestam (1999). \u201cPUVA and cancer risk: the Swedish follow-up study.\u201d Br J Dermatol 141(1): 108-112.","DOI":"10.1046\/j.1365-2133.1999.02928.x"},{"key":"123070","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02928.x","DOI":"10.1046\/j.1365-2133.1999.02928.x"},{"key":"123071","doi-asserted-by":"crossref","unstructured":"Lindh, J. D. and M. Bradley (2015). \u201cClinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review.\u201d Am J Clin Dermatol 16(5): 341-359.","DOI":"10.1007\/s40257-015-0146-4"},{"key":"123072","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-015-0146-4","DOI":"10.1007\/s40257-015-0146-4"},{"key":"123073","doi-asserted-by":"crossref","unstructured":"Lisante, T. A., C. Nu\u00f1ez and P. Zhang (2017). \u201cEfficacy and safety of an over-the-counter 1% colloidal oatmeal cream in the management of mild to moderate atopic dermatitis in children: a double-blind, randomized, active-controlled study.\u201d J Dermatolog Treat 28(7): 659-667.","DOI":"10.1080\/09546634.2017.1303569"},{"key":"123074","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2017.1303569","DOI":"10.1080\/09546634.2017.1303569"},{"key":"123075","doi-asserted-by":"crossref","unstructured":"Liu, T., Y. Chu, Y. Wang and X. e. a. Zhong (2023). \u201cSuccessful treatment of prurigo nodularis with tofacitinib: The experience from a single center.\u201d Int J Dermatol 62(5): e293-e295.","DOI":"10.1111\/ijd.16568"},{"key":"123076","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.16568","DOI":"10.1111\/ijd.16568"},{"key":"123077","doi-asserted-by":"crossref","unstructured":"Liu, T., R. Gao, L. Li, B. Wu and F. Wu (2023). \u201cAnalysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.\u201d Int J Dermatol 45(6): 1483-1491.","DOI":"10.1007\/s11096-023-01634-5"},{"key":"123078","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11096-023-01634-5","DOI":"10.1007\/s11096-023-01634-5"},{"key":"123079","doi-asserted-by":"crossref","unstructured":"Lod\u00e9n, M. (2012). \u201cEffect of moisturizers on epidermal barrier function.\u201d Clin Dermatol 30(3): 286-296.","DOI":"10.1016\/j.clindermatol.2011.08.015"},{"key":"123080","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.08.015","DOI":"10.1016\/j.clindermatol.2011.08.015"},{"key":"123081","doi-asserted-by":"crossref","unstructured":"Lode\u0301n, M. (2003). \u201cRole of topical emollients and moisturizers in the treatment of dry skin barrier disorders.\u201d Am J Clin Dermatol 4(11): 771-788.","DOI":"10.2165\/00128071-200304110-00005"},{"key":"123082","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00128071-200304110-00005","DOI":"10.2165\/00128071-200304110-00005"},{"key":"123083","doi-asserted-by":"crossref","unstructured":"Long, D., R. A. Long, M. P. Grillo and G. Marshman (2006). \u201cDevelopment of a psychological treatment service for pruritic skin conditions.\u201d Australas J Dermatol 47(237-241).","DOI":"10.1111\/j.1440-0960.2006.00288.x"},{"key":"123084","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1440-0960.2006.00288.x","DOI":"10.1111\/j.1440-0960.2006.00288.x"},{"key":"123085","doi-asserted-by":"crossref","unstructured":"L\u00f6nndahl, L., M. Holst, M. Bradley, H. Killasli, J. Heilborn, M. A. Hall, E. Theodorsson, J. Holmberg and K. Nordlind (2018). \u201cSubstance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis.\u201d Acta Derm Venereol 98(3): 324-328.","DOI":"10.2340\/00015555-2852"},{"key":"123086","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2852","DOI":"10.2340\/00015555-2852"},{"key":"123087","doi-asserted-by":"crossref","unstructured":"Lopes, J., M. Teixeira and A. Moreira (2020). \u201cHypnosis for the treatment of chronic refractory pruritus.\u201d Int J Dermatol 59(300-301).","DOI":"10.1111\/ijd.14908"},{"key":"123088","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.14908","DOI":"10.1111\/ijd.14908"},{"key":"123089","doi-asserted-by":"crossref","unstructured":"Lotti, T., P. Teofoli and D. Tsampau (1994). \u201cTreatment of aquagenic pruritus with topical capsaicin cream.\u201d J Am Acad Dermatol 30(2 Pt 1): 232-235.","DOI":"10.1016\/S0190-9622(94)70022-2"},{"key":"123090","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(94)70022-2","DOI":"10.1016\/S0190-9622(94)70022-2"},{"key":"123091","doi-asserted-by":"crossref","unstructured":"Lowney, A. C., M. A. McAleer, S. Kelly and R. J. McQuillan (2014). \u201cThalidomide therapy for pruritus in the palliative setting - a distinct subset of patients in whom the benefit may outweigh the risk.\u201d Pain Symptom Manag 48: e3-e5.","DOI":"10.1016\/j.jpainsymman.2014.06.001"},{"key":"123092","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2014.06.001","DOI":"10.1016\/j.jpainsymman.2014.06.001"},{"key":"123093","doi-asserted-by":"crossref","unstructured":"Lu, P.-H., C.-H. Chung, H.-E. Chuo, I.-H. Lin and P.-H. Lu (2022). \u201cEfficacy of acupoint stimulation as a treatment for uremic pruritus: A systematic review and meta-analysis.\u201d Front Med 9: 1036072.","DOI":"10.3389\/fmed.2022.1036072"},{"key":"123094","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2022.1036072","DOI":"10.3389\/fmed.2022.1036072"},{"key":"123095","doi-asserted-by":"crossref","unstructured":"Luger, T., M. Boguniewicz, W. Carr, M. Cork, M. Deleuran, L. Eichenfield, P. Eigenmann, R. F\u00f6lster-Holst, C. Gelmetti, H. Gollnick, E. Hamelmann, A. A. Hebert, A. Muraro, A. P. Oranje, A. S. Paller, C. Paul, L. Puig, J. Ring, E. Siegfried, J. M. Spergel, G. Stingl, A. Taieb, A. Torrelo, T. Werfel and U. Wahn (2015). \u201cPimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.\u201d Pediatr Allergy Immunol 26(4): 306-315.","DOI":"10.1111\/pai.12331"},{"key":"123096","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pai.12331","DOI":"10.1111\/pai.12331"},{"key":"123097","doi-asserted-by":"crossref","unstructured":"Luger, T., A. S. Paller, A. D. Irvine, R. Sidbury, L. F. Eichenfield, T. Werfel and T. Bieber (2021). \u201cTopical therapy of atopic dermatitis with a focus on pimecrolimus.\u201d J Eur Acad Dermatol Venereol 35(7): 1505-1518.","DOI":"10.1111\/jdv.17272"},{"key":"123098","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17272","DOI":"10.1111\/jdv.17272"},{"key":"123099","doi-asserted-by":"crossref","unstructured":"Lynde, C. W., G. Sussman, P. L. Dion, L. Guenther, J. H\u00e9bert, J. Rao, T. V. Leek and S. Waserman (2020). \u201cMultidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine.\u201d J Drugs Dermatol 19(2): 145-154.","DOI":"10.36849\/JDD.2020.4835"},{"key":"123100","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.36849\/JDD.2020.4835","DOI":"10.36849\/JDD.2020.4835"},{"key":"123101","doi-asserted-by":"crossref","unstructured":"Lysy, J., M. Sistiery-Ittah, Y. Israelit, A. Shmueli, N. Strauss-Liviatan, V. Mindrul, D. Keret and E. Goldin (2003). \u201cTopical capsaicin--a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study.\u201d Gut 52(9): 1323-1326.","DOI":"10.1136\/gut.52.9.1323"},{"key":"123102","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/gut.52.9.1323","DOI":"10.1136\/gut.52.9.1323"},{"key":"123103","doi-asserted-by":"crossref","unstructured":"Macpherson, L. J., S. W. Hwang, T. Miyamoto, A. E. Dubin, A. Patapoutian and G. M. Story (2006). \u201cMore than cool: promiscuous relationships of menthol and other sensory compounds.\u201d Mol Cell Neurosci 32(4): 335-343.","DOI":"10.1016\/j.mcn.2006.05.005"},{"key":"123104","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.mcn.2006.05.005","DOI":"10.1016\/j.mcn.2006.05.005"},{"key":"123105","doi-asserted-by":"crossref","unstructured":"Magerl, M., E. Borzova, A. Gimenez-Arnau, C. E. Grattan, F. Lawlor, P. Mathelier-Fusade, M. Metz, A. Mlynek, M. Maurer and Eaaci\/Ga2Len\/Edf\/Unev (2009). \u201cThe definition and diagnostic testing of physical and cholinergic urticarias--EAACI\/GA2LEN\/EDF\/UNEV consensus panel recommendations.\u201d Allergy 64(12): 1715-1721.","DOI":"10.1111\/j.1398-9995.2009.02177.x"},{"key":"123106","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02177.x","DOI":"10.1111\/j.1398-9995.2009.02177.x"},{"key":"123107","doi-asserted-by":"crossref","unstructured":"Magerl, W., R. A. Westerman, B. Mohner and H. O. Handwerker (1990). \u201cProperties of transdermal histamine iontophoresis: differential effects of season, gender, and body region.\u201d J Invest Dermatol 94: 347-352.","DOI":"10.1111\/1523-1747.ep12874474"},{"key":"123108","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1523-1747.ep12874474","DOI":"10.1111\/1523-1747.ep12874474"},{"key":"123109","doi-asserted-by":"crossref","unstructured":"Magnolo, N., T. Jaenicke, A. Tsianakas, W. Czech, D. Tha\u00e7i, A. Pinter, D. Kerob, S. Salah and T. A. Luger (2023). \u201cComparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial.\u201d J Eur Acad Dermatol Venereol Suppl 5: 18-26.","DOI":"10.1111\/jdv.18949"},{"key":"123110","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18949","DOI":"10.1111\/jdv.18949"},{"key":"123111","doi-asserted-by":"crossref","unstructured":"Mahil, S. K., M. C. Ezejimofor, L. S. Exton and L. e. a. Manounah (2020). \u201cComparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.\u201d Br J Dermatol 183(4): 638-649.","DOI":"10.1111\/bjd.19325"},{"key":"123112","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19325","DOI":"10.1111\/bjd.19325"},{"key":"123113","unstructured":"Mahmudpour, M., J. Roozbeh, G. A. Raiss Jalali, M. Pakfetrat, S. Ezzat Zadegan and M. M. Sagheb (2017). \u201cTherapeutic effect of montelukastfor treatment of uremic pruritus in hemodialysis patients.\u201d Iran J Kidney Dis 11(1): 50-55."},{"key":"123114","doi-asserted-by":"crossref","unstructured":"Majeski, C. J., J. A. Johnson, S. N. Davison and G. J. Lauzon (2007). \u201cItch Severity Scale: a self-report instrument for the measurement of pruritus severity.\u201d Br J Dermatol 156(4): 667-673.","DOI":"10.1111\/j.1365-2133.2006.07736.x"},{"key":"123115","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07736.x","DOI":"10.1111\/j.1365-2133.2006.07736.x"},{"key":"123116","doi-asserted-by":"crossref","unstructured":"Majoie, I. M., J. M. Oldhoff, H. van Weelden, M. Laaper-Ertmann, M. T. Bousema, V. Sigurdsson, E. F. Knol, C. A. Bruijnzeel-Koomen and M. S. de Bruin-Weller (2009). \u201cNarrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis.\u201d J Am Acad Dermatol 60(1): 77-84.","DOI":"10.1016\/j.jaad.2008.08.048"},{"key":"123117","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2008.08.048","DOI":"10.1016\/j.jaad.2008.08.048"},{"key":"123118","doi-asserted-by":"crossref","unstructured":"Malekzad, F., M. Arbabi, N. Mohtasham, P. Toosi, M. Jaberian, M. Mohajer, M. R. Mohammadi, M. R. Roodsari and S. Nasiri (2009). \u201cEfficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.\u201d J Eur Acad Dermatol Venereol 23(8): 948-950.","DOI":"10.1111\/j.1468-3083.2009.03129.x"},{"key":"123119","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03129.x","DOI":"10.1111\/j.1468-3083.2009.03129.x"},{"key":"123120","doi-asserted-by":"crossref","unstructured":"Maley, A. and R. A. Swerlick (2015). \u201cAzathioprine treatment of intractable pruritus: A retrospective review.\u201d J Am Acad Dermatol 73(3): 439-443.","DOI":"10.1016\/j.jaad.2015.05.025"},{"key":"123121","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2015.05.025","DOI":"10.1016\/j.jaad.2015.05.025"},{"key":"123122","doi-asserted-by":"crossref","unstructured":"Mannix, S., E. Edson-Heredia, A. Paller, S., G. Yosipovitch, R. Burge and L. P. D.-. Kleinman (2021). \u201cThe experience of itch in children with psoriasis: A qualitative exploration of the itch Numeric Rating Scale.\u201d Pediatr Dermatol 38: 405-412.","DOI":"10.1111\/pde.14403"},{"key":"123123","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pde.14403","DOI":"10.1111\/pde.14403"},{"key":"123124","doi-asserted-by":"crossref","unstructured":"Martinez-Escribano, J. A., E. Quecedo, J. De la Cuadra, J. Frias, P. Sanchez-Pedreno and A. Aliaga (1997). \u201cTreatment of aquagenic urticaria with PUVA and astemizole.\u201d J Am Acad Dermatol 36(1): 118-119.","DOI":"10.1016\/S0190-9622(97)70344-X"},{"key":"123125","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(97)70344-X","DOI":"10.1016\/S0190-9622(97)70344-X"},{"key":"123126","doi-asserted-by":"crossref","unstructured":"Martora, F., A. Villani, G. Fabbrocini and T. Battista (2022). \u201cCOVID-19 and cutaneous manifestations: A review of the published literature.\u201d J Cosmet Dermatol 22(1): 4-10.","DOI":"10.1111\/jocd.15477"},{"key":"123127","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jocd.15477","DOI":"10.1111\/jocd.15477"},{"key":"123128","doi-asserted-by":"crossref","unstructured":"Mathur, V. S., J. Kumar, P. W. Crawford, H. Hait, T. Sciascia and T. S. Investigators (2017). \u201cA Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.\u201d Am J Nephrol 46(6): 450-458.","DOI":"10.1159\/000484573"},{"key":"123129","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000484573","DOI":"10.1159\/000484573"},{"key":"123130","doi-asserted-by":"crossref","unstructured":"Maticic, M., M. Poljak, T. Lunder, K. Rener-Sitar and L. Stojanovic (2008). \u201cLichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area.\u201d J Eur Acad Dermatol Venereol 22(7): 779-788.","DOI":"10.1111\/j.1468-3083.2008.02676.x"},{"key":"123131","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02676.x","DOI":"10.1111\/j.1468-3083.2008.02676.x"},{"key":"123132","doi-asserted-by":"crossref","unstructured":"Matsuda, K. M., D. Sharma, A. R. Schonfeld and S. G. Kwatra (2016). \u201cGabapentin and pregabalin for the treatment of chronic pruritus.\u201d J Am Acad Dermatol 75(3): 619-625.","DOI":"10.1016\/j.jaad.2016.02.1237"},{"key":"123133","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1237","DOI":"10.1016\/j.jaad.2016.02.1237"},{"key":"123134","unstructured":"Matsuura, J., A. Kimura, T. Kasai, T. Yoshida, M. Nakagawa and T. Mizuno (2015). \u201cA case of neuromyelitis optica with relapse symptoms from paroxysmal pruritus.\u201d Brain Nerve 67(8): 1057-1060."},{"key":"123135","doi-asserted-by":"crossref","unstructured":"Matterne, U., C. J. Apfelbacher, A. Loerbroks, T. Schwarzer, M. Buttner, R. Ofenloch, T. L. Diepgen and E. Weisshaar (2011). \u201cPrevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study.\u201d Acta Derm Venereol 91(6): 674-679.","DOI":"10.2340\/00015555-1159"},{"key":"123136","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1159","DOI":"10.2340\/00015555-1159"},{"key":"123137","doi-asserted-by":"crossref","unstructured":"Matterne, U., C. J. Apfelbacher, L. Vogelgsang, A. Loerbroks and E. Weisshaar (2013). \u201cIncidence and determinants of chronic pruritus: a population-based cohort study.\u201d Acta Derm Venereol 93(5): 532-537.","DOI":"10.2340\/00015555-1572"},{"key":"123138","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1572","DOI":"10.2340\/00015555-1572"},{"key":"123139","doi-asserted-by":"crossref","unstructured":"Matterne, U., M. M. B\u00f6hmer, E. Weisshaar, A. Jupiter, B. Carter and C. J. Apfelbacher (2019). \u201cOral H1 antihistamines as \u2018add-on\u2019 therapy to topical treatment for eczema.\u201d Cochrane Database Syst Rev 1: Cd012167.","DOI":"10.1002\/14651858.CD012167.pub2"},{"key":"123140","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD012167.pub2","DOI":"10.1002\/14651858.CD012167.pub2"},{"key":"123141","doi-asserted-by":"crossref","unstructured":"Maurer, M., W. Berger, A. Gim\u00e9nez-Arnau and K. e. a. Hayama (2022). \u201cRemibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.\u201d J Allergy Clin Immunol 150(6): 1498-1506.e1492.","DOI":"10.1016\/j.jaci.2022.08.027"},{"key":"123142","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2022.08.027","DOI":"10.1016\/j.jaci.2022.08.027"},{"key":"123143","doi-asserted-by":"crossref","unstructured":"Maurer, M., T. B. Casale, S. S. Saini and M. e. a. Ben-Shoshan (2024). \u201cDupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.\u201d J Allergy Clin Immunol 154(1): 184-194.","DOI":"10.1016\/j.jaci.2024.01.028"},{"key":"123144","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028","DOI":"10.1016\/j.jaci.2024.01.028"},{"key":"123145","doi-asserted-by":"crossref","unstructured":"Maurer, M., L. F. Ensina, A. M. Gimenez-Arnau and G. e. a. Sussman (2024). \u201cEfficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.\u201d Lancet 403(10422): 147-159.","DOI":"10.1016\/S0140-6736(23)01684-7"},{"key":"123146","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7","DOI":"10.1016\/S0140-6736(23)01684-7"},{"key":"123147","doi-asserted-by":"crossref","unstructured":"Maurer, M., A. M. Gim\u00e9nez-Arnau, G. Sussman, M. Metz, D. R. Baker, A. Bauer, J. A. Bernstein, R. Brehler, C. Y. Chu, W. H. Chung, I. Danilycheva, C. Grattan, J. H\u00e9bert, C. Katelaris, M. Makris, R. Meshkova, S. Savic, R. Sinclair, K. Sitz, P. Staubach, B. Wedi, J. L\u00f6ffler, A. Barve, K. Kobayashi, E. Hua, T. Severin and R. Janocha (2019). \u201cLigelizumab for Chronic Spontaneous Urticaria.\u201d N Engl J Med 381(14): 1321-1332.","DOI":"10.1056\/NEJMoa1900408"},{"key":"123148","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1900408","DOI":"10.1056\/NEJMoa1900408"},{"key":"123149","doi-asserted-by":"crossref","unstructured":"Maurer, M., K. Ros\u00e9n, H.-J. Hsieh and S. e. a. Saini (2013). \u201cOmalizumab for the treatment of chronic idiopathic or spontaneous urticaria.\u201d N Engl J Med 368(10): 924-935.","DOI":"10.1056\/NEJMoa1215372"},{"key":"123150","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1215372","DOI":"10.1056\/NEJMoa1215372"},{"key":"123151","doi-asserted-by":"crossref","unstructured":"Maurer, M., K. Ros\u00e9n, H. J. Hsieh, S. Saini, C. Grattan, A. Gimen\u00e9z-Arnau, S. Agarwal, R. Doyle, J. Canvin, A. Kaplan and T. Casaleet (2013). \u201cOmalizumab for the treatment of chronic idiopathic or spontaneous urticaria.\u201d N Engl J Med 368: 924-935.","DOI":"10.1056\/NEJMoa1215372"},{"key":"123152","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1215372","DOI":"10.1056\/NEJMoa1215372"},{"key":"123153","doi-asserted-by":"crossref","unstructured":"Maurer, T., A. Poncelet and T. Berger (2004). \u201cThalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.\u201d Arch Dermatol 140(7): 845-849.","DOI":"10.1001\/archderm.140.7.845"},{"key":"123154","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.140.7.845","DOI":"10.1001\/archderm.140.7.845"},{"key":"123155","doi-asserted-by":"crossref","unstructured":"Mayo, M. J., I. Handem, S. Saldana, H. Jacobe, Y. Getachew and A. J. Rush (2007). \u201cSertraline as a first-line treatment for cholestatic pruritus.\u201d Hepatology 45(3): 666-674.","DOI":"10.1002\/hep.21553"},{"key":"123156","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/hep.21553","DOI":"10.1002\/hep.21553"},{"key":"123157","doi-asserted-by":"crossref","unstructured":"Mayo, M. J., P. J. Pockros, D. Jones, C. L. Bowlus, C. Levy and I. e. a. Patanwala (2019). \u201cA Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.\u201d Hepatol Commun 3(3): 365\u2011381.","DOI":"10.1002\/hep4.1305"},{"key":"123158","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/hep4.1305","DOI":"10.1002\/hep4.1305"},{"key":"123159","doi-asserted-by":"crossref","unstructured":"Mazeh, D., Y. Melamed, A. Cholostoy, V. Aharonovitzch, A. Weizman and G. Yosipovitch (2008). \u201cItching in the psychiatric ward.\u201d Acta dermato-venereologica 88(2): 128-131.","DOI":"10.2340\/00015555-0406"},{"key":"123160","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0406","DOI":"10.2340\/00015555-0406"},{"key":"123161","doi-asserted-by":"crossref","unstructured":"Mazza, M., G. Guerriero, G. Marano, L. Janiri, P. Bria and S. Mazza (2013). \u201cTreatment of prurigo nodularis with pregabalin.\u201d J Clin Pharm Ther 38(1): 16-18.","DOI":"10.1111\/jcpt.12005"},{"key":"123162","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jcpt.12005","DOI":"10.1111\/jcpt.12005"},{"key":"123163","doi-asserted-by":"crossref","unstructured":"Mazzatenta, C., G. Peonia and P. Martini (2004). \u201cPruritus induced by interruption of paroxetine therapy.\u201d Br J Dermatol 150(4): 787.","DOI":"10.1111\/j.0007-0963.2004.05882.x"},{"key":"123164","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.0007-0963.2004.05882.x","DOI":"10.1111\/j.0007-0963.2004.05882.x"},{"key":"123165","unstructured":"McCormick, A., D. Fleming and J. Charlton (1995). Morbidity Statistics from General Practice. Fourth national study 1991-1992. London, Her Majestic\u2019s Stationery Office."},{"key":"123166","doi-asserted-by":"crossref","unstructured":"McCormick, P. A., F. Scott, O. Epstein, A. K. Burroughs, P. J. Scheuer and N. McIntyre (1994). \u201cThalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study.\u201d J Hepatol 21(4): 496-499.","DOI":"10.1016\/S0168-8278(94)80092-8"},{"key":"123167","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0168-8278(94)80092-8","DOI":"10.1016\/S0168-8278(94)80092-8"},{"key":"123168","doi-asserted-by":"crossref","unstructured":"McGovern, C., T. Quasim, K. Puxty, M. Shaw, W. Ng, C. Gilhooly, N. Arkoulis, M. Basler, A. Macfarlane and L. Paton (2021). \u201cNeuropathic agents in the management of pruritus in burn injuries: a systematic review and meta-analysis.\u201d Trauma Surg Acute Care Open 6(1): e000810.","DOI":"10.1136\/tsaco-2021-000810"},{"key":"123169","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/tsaco-2021-000810","DOI":"10.1136\/tsaco-2021-000810"},{"key":"123170","doi-asserted-by":"crossref","unstructured":"Mehrkash, M., S.-J. Golestaneh, Y. Madihi, F. Paknazar, M. Hadian, M. Akbari and B. Abtahi-Naeini (2021). \u201cPruritus features in children with end-stage renal disease underwent dialysis: A Cross-Sectional Study.\u201d Int J Pediatr 9970321.","DOI":"10.1155\/2021\/9970321"},{"key":"123171","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2021\/9970321","DOI":"10.1155\/2021\/9970321"},{"key":"123172","doi-asserted-by":"crossref","unstructured":"Mehrpooya, M., M. Gholyaf, F. Yasrebifar, Y. Mohammadi and V. Sheikh (2020). \u201cEvaluation of Efficacy of Mirtazapine on Pruritus and Serum Histamine and Serotonin Levels in Patients Undergoing Hemodialysis: A Before-After Pilot Clinical Trial.\u201d Int J Nephrol Renovasc Dis 13: 129-138.","DOI":"10.2147\/IJNRD.S246393"},{"key":"123173","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/IJNRD.S246393","DOI":"10.2147\/IJNRD.S246393"},{"key":"123174","doi-asserted-by":"crossref","unstructured":"Menage, H. D., P. G. Norris, J. L. Hawk and M. W. Graves (1993). \u201cThe efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus.\u201d Br J Dermatol 129(2): 163-165.","DOI":"10.1111\/j.1365-2133.1993.tb03520.x"},{"key":"123175","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1993.tb03520.x","DOI":"10.1111\/j.1365-2133.1993.tb03520.x"},{"key":"123176","doi-asserted-by":"crossref","unstructured":"Mendham, J. E. (2004). \u201cGabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study.\u201d Burns 30(8): 851-853.","DOI":"10.1016\/j.burns.2004.05.009"},{"key":"123177","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.burns.2004.05.009","DOI":"10.1016\/j.burns.2004.05.009"},{"key":"123178","doi-asserted-by":"crossref","unstructured":"Menter, A., B. E. Strober and D. H. e. a. Kaplan (2019). \u201cJoint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis With Biologics.\u201d J Am Acad Dermatol 80(4): 1029-1072.","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"123179","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"123180","doi-asserted-by":"crossref","unstructured":"Merkel, T., A. Navarini and S. Mueller (2024). \u201cThe impact of phototherapy on itch intensity and itch-related quality of life amongst different skin diseases, skin phototypes and genders - A prospective study with 102 patients.\u201d Photodermatol Photoimmunol Photomed 40(1): e12948.","DOI":"10.1111\/phpp.12948"},{"key":"123181","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/phpp.12948","DOI":"10.1111\/phpp.12948"},{"key":"123182","doi-asserted-by":"crossref","unstructured":"Merkel, T. A., A. Navarini and S. Mueller (2021). \u201cDifferences in phototherapy among skin diseases and genders in real-life conditions-A retrospective analysis of the cumulative doses, numbers of sessions, side effects and costs in 561 patients.\u201d Photodermatol Photoimmunol Photomed 37(5): 464-473.","DOI":"10.1111\/phpp.12683"},{"key":"123183","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/phpp.12683","DOI":"10.1111\/phpp.12683"},{"key":"123184","doi-asserted-by":"crossref","unstructured":"Mettang, T. (2016). \u201cUremic itch management.\u201d Curr Prob Dermatol 50: 133-141.","DOI":"10.1159\/000446056"},{"key":"123185","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446056","DOI":"10.1159\/000446056"},{"key":"123186","doi-asserted-by":"crossref","unstructured":"Mettang, T., C. Pauli-Magnus and D. M. Alscher (2002). \u201cUraemic pruritus--new perspectives and insights from recent trials.\u201d Nephrol Dial Transplant 17(9): 1558-1563.","DOI":"10.1093\/ndt\/17.9.1558"},{"key":"123187","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/17.9.1558","DOI":"10.1093\/ndt\/17.9.1558"},{"key":"123188","doi-asserted-by":"crossref","unstructured":"Metz, M., G. Sussman, R. Gagnon and P. e. a. Staubach (2021). \u201cFenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.\u201d Nat Med 27(11): 1961-1969.","DOI":"10.1038\/s41591-021-01537-w"},{"key":"123189","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41591-021-01537-w","DOI":"10.1038\/s41591-021-01537-w"},{"key":"123190","doi-asserted-by":"crossref","unstructured":"Metz, M., U. Wahn, U. Gieler, P. Stock, J. Schmitt and U. Blume-Peytavi (2013). \u201cChronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and paediatricians.\u201d Pediatr Allergy Immunol 24(6): 527-539.","DOI":"10.1111\/pai.12115"},{"key":"123191","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pai.12115","DOI":"10.1111\/pai.12115"},{"key":"123192","doi-asserted-by":"crossref","unstructured":"Metze, D., S. Reimann, Z. Szepfalusi, B. Bohle, D. Kraft and T. A. Luger (1997). \u201cPersistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves.\u201d Br J Dermatol 136(4): 553-559.","DOI":"10.1111\/j.1365-2133.1997.tb02140.x"},{"key":"123193","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.1997.d01-1234.x","DOI":"10.1046\/j.1365-2133.1997.d01-1234.x"},{"key":"123194","doi-asserted-by":"crossref","unstructured":"Millington, G. W. M., A. Collins and C. R. e. a. Lovell (2018). \u201cBritish Association of Dermatologists\u2019 guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis.\u201d BJD 178: 34-60.","DOI":"10.1111\/bjd.16186"},{"key":"123195","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16186","DOI":"10.1111\/bjd.16186"},{"key":"123196","doi-asserted-by":"crossref","unstructured":"Min, T. K. and S. S. Saini (2024). \u201cThe future of targeted therapy in chronic spontaneous urticaria.\u201d Ann Allergy Asthma Immunol 133(4): 367-373.","DOI":"10.1016\/j.anai.2024.05.020"},{"key":"123197","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.anai.2024.05.020","DOI":"10.1016\/j.anai.2024.05.020"},{"key":"123198","doi-asserted-by":"crossref","unstructured":"Miron, Y., P. E. Miller, C. Hughes, T. Indersmitten, E. A. Lerner and F. Cevikbas (2022). \u201cMechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb.\u201d J Allergy Clin Immunol 150(3): 690-700.","DOI":"10.1016\/j.jaci.2022.01.028"},{"key":"123199","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2022.01.028","DOI":"10.1016\/j.jaci.2022.01.028"},{"key":"123200","doi-asserted-by":"crossref","unstructured":"Mirzoyev, S. A. and M. D. Davis (2013). \u201cBrachioradial pruritus: Mayo Clinic experience over the past decade.\u201d Br J Dermatol 169(5): 1007-1015.","DOI":"10.1111\/bjd.12483"},{"key":"123201","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12483","DOI":"10.1111\/bjd.12483"},{"key":"123202","doi-asserted-by":"crossref","unstructured":"Misery, L. (2005). \u201cGabapentin in dermatology.\u201d Dermatology 211(2): 79-80.","DOI":"10.1159\/000086432"},{"key":"123203","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000086432","DOI":"10.1159\/000086432"},{"key":"123204","doi-asserted-by":"crossref","unstructured":"Misery, L. (2016). Neuropathic pruritus secondary to brain and spinal cord tumors\u201d in Misery, L., St\u00e4nder S. (eds): Pruritus. 2nd ed. London, Springer-Verlag: 215-218.","DOI":"10.1007\/978-3-319-33142-3_28"},{"key":"123205","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/978-3-319-33142-3_28","DOI":"10.1007\/978-3-319-33142-3_28"},{"key":"123206","doi-asserted-by":"crossref","unstructured":"Misery, L., S. Alexandre, S. Dutray, M. Chastaing, S. G. Consoli, H. Audra, D. Bauer, S. Bertolus, V. Callot, F. Cardinaud, E. Corrin, N. Feton-Danou, R. Malet, S. Touboul and S. M. Consoli (2007). \u201cFunctional itch disorder or psychogenic pruritus: suggested diagnosis criteria from the French psychodermatology group.\u201d Acta Derm Venereol 87(4): 341-344.","DOI":"10.2340\/00015555-0266"},{"key":"123207","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0266","DOI":"10.2340\/00015555-0266"},{"key":"123208","doi-asserted-by":"crossref","unstructured":"Misery, L., C. Bodere, S. Genestet, F. Zagnoli and P. Marcorelles (2014). \u201cSmall-fibre neuropathies and skin: news and perspectives for dermatologists.\u201d Eur J Dermatol 24(2): 147-153.","DOI":"10.1684\/ejd.2013.2189"},{"key":"123209","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1684\/ejd.2013.2189","DOI":"10.1684\/ejd.2013.2189"},{"key":"123210","doi-asserted-by":"crossref","unstructured":"Misery, L., E. Brenaut, R. Le Garrec, C. Abasq, S. Genestet, P. Marcorelles and F. Zagnoli (2014). \u201cNeuropathic pruritus.\u201d Nat Rev Neurol 10(7): 408-416.","DOI":"10.1038\/nrneurol.2014.99"},{"key":"123211","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrneurol.2014.99","DOI":"10.1038\/nrneurol.2014.99"},{"key":"123212","doi-asserted-by":"crossref","unstructured":"Misery, L., N. Erfan, E. Castela, E. Brenaut, M. Lant\u00e9ri-Minet, J. P. Lacour and T. Passeron (2015). \u201cSuccessful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up.\u201d Acta Derm Venereol 95(7): 864-865.","DOI":"10.2340\/00015555-2085"},{"key":"123213","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2085","DOI":"10.2340\/00015555-2085"},{"key":"123214","doi-asserted-by":"crossref","unstructured":"Misery, L., S. Genestet and F. Zagnoli (2022). \u201cNeuromyelitis Optica and Skin.\u201d Dermatology 238(5): 823-828.","DOI":"10.1159\/000522168"},{"key":"123215","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000522168","DOI":"10.1159\/000522168"},{"key":"123216","doi-asserted-by":"crossref","unstructured":"Misery, L., A. Santerre, A. Batardi\u00e8re, N. Hornez, A. S. Nedelec, F. Le Ca\u00ebr, P. Bourgeois, F. Huet and G. Neufang (2018). \u201cReal-life study of anti-itching effects of a cream containing menthoxypropanediol, a TRPM8 agonist, in atopic dermatitis patients.\u201d J Eur Acad Dermatol Venereol.","DOI":"10.1111\/jdv.15199"},{"key":"123217","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15199","DOI":"10.1111\/jdv.15199"},{"key":"123218","doi-asserted-by":"crossref","unstructured":"Mittal, A., A. Srivastava, M. Balai and A. K. Khare (2016). \u201cA study of postherpetic pruritus.\u201d Indian Dermatol Online J 7(4): 343-344.","DOI":"10.4103\/2229-5178.185479"},{"key":"123219","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/2229-5178.185479","DOI":"10.4103\/2229-5178.185479"},{"key":"123220","doi-asserted-by":"crossref","unstructured":"Miyamoto, T., H. Nojima, T. Shinkado, T. Nakahashi and Y. Kuraishi (2002). \u201cItch-associated response induced by experimental dry skin in mice.\u201d Jpn J Pharmacol 88: 285-292.","DOI":"10.1254\/jjp.88.285"},{"key":"123221","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1254\/jjp.88.285","DOI":"10.1254\/jjp.88.285"},{"key":"123222","doi-asserted-by":"crossref","unstructured":"Mohammad Ali, B. M., D. S. Hegab and H. M. El Saadany (2015). \u201cUse of transcutaneous electrical nerve stimulation for chronic pruritus.\u201d Dermatol Ther 28(4): 210-215.","DOI":"10.1111\/dth.12242"},{"key":"123223","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.12242","DOI":"10.1111\/dth.12242"},{"key":"123224","doi-asserted-by":"crossref","unstructured":"Mollanazar, N. K., P. K. Smith and G. Yosipovitch (2015). \u201cMediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?\u201d Clin Rev Allergy Immunol 51: 263-292.","DOI":"10.1007\/s12016-015-8488-5"},{"key":"123225","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12016-015-8488-5","DOI":"10.1007\/s12016-015-8488-5"},{"key":"123226","doi-asserted-by":"crossref","unstructured":"Monroe, E. W. (1989). \u201cEfficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis.\u201d J Am Acad Dermatol 21(1): 135-136.","DOI":"10.1016\/S0190-9622(89)80353-6"},{"key":"123227","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(89)80353-6","DOI":"10.1016\/S0190-9622(89)80353-6"},{"key":"123228","doi-asserted-by":"crossref","unstructured":"Montero, J. L., J. C. Pozo, P. Barrera, E. Fraga, G. Costan, J. L. Dominguez, J. Muntane, A. Rodriguez-Ariza, M. Pleguezuelo, S. Rufian, P. Lopez-Cillero and M. de la Mata (2006). \u201cTreatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS).\u201d Transplant Proc 38(8): 2511-2513.","DOI":"10.1016\/j.transproceed.2006.08.052"},{"key":"123229","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.transproceed.2006.08.052","DOI":"10.1016\/j.transproceed.2006.08.052"},{"key":"123230","doi-asserted-by":"crossref","unstructured":"Moon, I. J., M. R. Yun, H. K. Yoon, K. H. Lee, S. Y. Choi, W. J. Lee, S. E. Chang and C. H. Won (2021). \u201cTreatment of atopic dermatitis using non-thermal atmospheric plasma in an animal model.\u201d Sci Rep 11(1): 16091.","DOI":"10.1038\/s41598-021-95471-z"},{"key":"123231","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41598-021-95471-z","DOI":"10.1038\/s41598-021-95471-z"},{"key":"123232","doi-asserted-by":"crossref","unstructured":"Morgado-Carrasco, D., J. Riera-Monroig, H. Feola and P. Aguilera (2020). \u201cTreatment of 2 Patients With Aquagenic Pruritus With UVA\/Narrow Band UVB Combined Therapy Once a Year.\u201d Actas Dermosifiliogr 111(10): 889-892.","DOI":"10.1016\/j.adengl.2019.02.027"},{"key":"123233","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ad.2019.02.026","DOI":"10.1016\/j.ad.2019.02.026"},{"key":"123234","doi-asserted-by":"crossref","unstructured":"Mueller, S. M., H. R. Carruthers, A. A. Navarini, M. Goldust, S. Gysin and P. H. Itin (2020). \u201cPruritic and antipruritic colors: An exploratory pilot study.\u201d Dermatol Ther 33(3): e13447.","DOI":"10.1111\/dth.13447"},{"key":"123235","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13447","DOI":"10.1111\/dth.13447"},{"key":"123236","doi-asserted-by":"crossref","unstructured":"Mueller, S. M., F. Mueller, J. Reinhardt, P. Itin and A. e. a. Navarini (2019). \u201cAssessment of the impact of sex in intensity, skin flares and central processing of histaminergic itch-A pilot study.\u201d Exp Dermatol 28(12): 1493-1500.","DOI":"10.1111\/exd.14021"},{"key":"123237","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.14021","DOI":"10.1111\/exd.14021"},{"key":"123238","doi-asserted-by":"crossref","unstructured":"Mueller, S. M., A. A. Navarini, M. Goldust, B. O., C. E. M. Griffiths and C. E. Kleyn (2020). \u201cLevocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.\u201d Dermatol Ther 33(1): e13166.","DOI":"10.1111\/dth.13166"},{"key":"123239","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13166","DOI":"10.1111\/dth.13166"},{"key":"123240","doi-asserted-by":"crossref","unstructured":"M\u00fclko\u011flu, C. and B. Nac\u0131r (2020). \u201cNotalgia paresthetica: clinical features, radiological evaluation, and a novel therapeutic option.\u201d BMC Neurol 20(1): 191.","DOI":"10.1186\/s12883-020-01773-6"},{"key":"123241","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12883-020-01773-6","DOI":"10.1186\/s12883-020-01773-6"},{"key":"123242","doi-asserted-by":"crossref","unstructured":"Muller, C., S. Pongratz, J. Pidlich, E. Penner, A. Kaider, M. Schemper, M. Raderer, W. Scheithauer and P. Ferenci (1998). \u201cTreatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.\u201d Eur J Gastroenterol Hepatol 10(10): 865-870.","DOI":"10.1097\/00042737-199810000-00010"},{"key":"123243","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/00042737-199810000-00010","DOI":"10.1097\/00042737-199810000-00010"},{"key":"123244","doi-asserted-by":"crossref","unstructured":"Muller, E. W., J. T. de Wolf, R. Egger, P. W. Wijermans, P. C. Huijgens, M. R. Halie and E. Vellenga (1995). \u201cLong-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera.\u201d Br J Haematol 89(2): 313-318.","DOI":"10.1111\/j.1365-2141.1995.tb03306.x"},{"key":"123245","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2141.1995.tb03306.x","DOI":"10.1111\/j.1365-2141.1995.tb03306.x"},{"key":"123246","doi-asserted-by":"crossref","unstructured":"M\u00fcller, S., L. Maintz and T. Bieber (2024). \u201cTreatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs.\u201d Allergy 79(6): 1501-1515.","DOI":"10.1111\/all.16009"},{"key":"123247","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.16009","DOI":"10.1111\/all.16009"},{"key":"123248","doi-asserted-by":"crossref","unstructured":"M\u00fcller, S., C. Zeidler and S. St\u00e4nder (2024). \u201cChronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.\u201d Am J Clin Dermatol 25(1): 15-33.","DOI":"10.1007\/s40257-023-00818-z"},{"key":"123249","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-023-00818-z","DOI":"10.1007\/s40257-023-00818-z"},{"key":"123250","doi-asserted-by":"crossref","unstructured":"Mullhaupt, B., G. A. Kullak-Ublick, P. M. Ambuhl, R. Stocker and E. L. Renner (2003). \u201cSuccessful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus.\u201d Hepatol Res 25(4): 442-446.","DOI":"10.1016\/S1386-6346(02)00310-8"},{"key":"123251","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1386-6346(02)00310-8","DOI":"10.1016\/S1386-6346(02)00310-8"},{"key":"123252","doi-asserted-by":"crossref","unstructured":"Mullol, J., J. Bousquet, C. Bachert, G. W. Canonica, A. Gim\u00e9nez-Arnau, M. L. Kowalski, F. E. R. Simons, M. Maurer, D. Ryan and G. Scadding (2015). \u201cUpdate on rupatadine in the management of allergic disorders.\u201d Allergy 70: 1-24.","DOI":"10.1111\/all.12531"},{"key":"123253","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.12531","DOI":"10.1111\/all.12531"},{"key":"123254","doi-asserted-by":"crossref","unstructured":"Murase, J. E., M. M. Heller and D. C. Butler (2014). \u201cSafety of dermatological medications in pregnancy and lactation: Part I. Pregnancy.\u201d J Am Acad Dermatol 70: 401-414.","DOI":"10.1016\/j.jaad.2013.09.010"},{"key":"123255","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2013.09.010","DOI":"10.1016\/j.jaad.2013.09.010"},{"key":"123256","doi-asserted-by":"crossref","unstructured":"Murphy, B., M. Duffin and J. Tolland (2018). \u201cAquagenic pruritus successfully treated with omalizumab.\u201d Clin Exp Dermatol 43(7): 858-859.","DOI":"10.1111\/ced.13415"},{"key":"123257","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.13415","DOI":"10.1111\/ced.13415"},{"key":"123258","doi-asserted-by":"crossref","unstructured":"Murphy, M., D. Reaich, P. Pai, P. Finn and A. J. Carmichael (2003). \u201cA randomized, placebo-controlled, double-blind trial of ondansetron in renal itch.\u201d Br J Dermatol 148(2): 314-317.","DOI":"10.1046\/j.1365-2133.2003.05172.x"},{"key":"123259","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05172.x","DOI":"10.1046\/j.1365-2133.2003.05172.x"},{"key":"123260","unstructured":"Naini, A. E., A. A. Harandi, S. Khanbabapour, S. Shadidi, S. Seirafivan and M. Mosheni (2007). \u201cGabapentin: a promising drug for the treatment of uremic pruritus.\u201d Saudi J Kidney Dis Transpl 18(3): 378-381."},{"key":"123261","doi-asserted-by":"crossref","unstructured":"Nakagawa, H., O. Nemoto, A. Igarashi, H. Saeki, H. Kaino and T. Nagata (2020). \u201cDelgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.\u201d J Am Acad Dermatol 82(4): 823-831.","DOI":"10.1016\/j.jaad.2019.12.015"},{"key":"123262","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.12.015","DOI":"10.1016\/j.jaad.2019.12.015"},{"key":"123263","unstructured":"Narita, I., Y. Tsubakihara, T. Uchiyama, O. S. and N. Oya, et al. (2022). Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial 5(5): e2210339."},{"key":"123264","unstructured":"Nasrollahi A., M. A., Ghanei E. et al. (2007). \u201cMontelukast for Treatment of Refractory Pruritus in Patients on Hemodialysis.\u201d Iran J Kidney Dis 1: 73-77."},{"key":"123265","doi-asserted-by":"crossref","unstructured":"Nast, A., C. Smith, P. I. Spuls and G. e. a. Avila Valle (2020). \u201cEuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.\u201d J Eur Acad Dermatol Venereol 34(11): 2461-2498.","DOI":"10.1111\/jdv.16915"},{"key":"123266","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16915","DOI":"10.1111\/jdv.16915"},{"key":"123267","doi-asserted-by":"crossref","unstructured":"Nattkemper, L. A., M. E. Martinez-Escala, A. B. Gelman, E. M. Singer, A. H. Rook, J. Guitart and G. Yosipovitch (2016). \u201c Cutaneous T-Cell Lymphoma and Pruritus: the Expression of IL-31 and its Receptors in the Skin.\u201d Acta Derm Venereol.","DOI":"10.2340\/00015555-2417"},{"key":"123268","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2417","DOI":"10.2340\/00015555-2417"},{"key":"123269","doi-asserted-by":"crossref","unstructured":"Neilly, J. B., A. Martin, N. Simpson and A. C. MacCuish (1986). \u201cPruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control.\u201d Diabetes Care 9(3): 273-275.","DOI":"10.2337\/diacare.9.3.273"},{"key":"123270","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2337\/diacare.9.3.273","DOI":"10.2337\/diacare.9.3.273"},{"key":"123271","doi-asserted-by":"crossref","unstructured":"Nestler, J. E. (1983). \u201cHemochromatosis and pruritus.\u201d Ann Intern Med 98(6): 1026.","DOI":"10.7326\/0003-4819-98-6-1026_1"},{"key":"123272","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.7326\/0003-4819-98-6-1026_1","DOI":"10.7326\/0003-4819-98-6-1026_1"},{"key":"123273","doi-asserted-by":"crossref","unstructured":"Neuberger, J. (2003). \u201cLiver Transplantation for Cholestatic Liver Disease.\u201d Curr Treat Options Gastroenterol 6(2): 113-121.","DOI":"10.1007\/s11938-003-0012-y"},{"key":"123274","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11938-003-0012-y","DOI":"10.1007\/s11938-003-0012-y"},{"key":"123275","doi-asserted-by":"crossref","unstructured":"Nevols, J., L. Watkins and R. Lewis (2023). \u201cA phase IV, randomised, double-blind, controlled, parallel group trial to evaluate the effectiveness and safety of Balneum Plus versus emollient in the treatment of chronic kidney disease-associated pruritus in haemodialysis patients.\u201d Clin Kidney J 16(8): 1307-1315.","DOI":"10.1093\/ckj\/sfad066"},{"key":"123276","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ckj\/sfad066","DOI":"10.1093\/ckj\/sfad066"},{"key":"123277","doi-asserted-by":"crossref","unstructured":"Nieto, A., M. Nieto and \u00c1. Maz\u00f3n (2021). \u201cThe clinical evidence of second-generation H1-antihistamines in the treatment of allergic rhinitis and urticaria in children over 2 years with a special focus on rupatadine.\u201d Expert Opin Pharmacother 22(4): 511-519.","DOI":"10.1080\/14656566.2020.1830970"},{"key":"123278","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14656566.2020.1830970","DOI":"10.1080\/14656566.2020.1830970"},{"key":"123279","doi-asserted-by":"crossref","unstructured":"Nilsson, H. J., A. Levinsson and J. Schouenborg (1997). \u201cCutaneous field stimulation (CFS): a new powerful method to combat itch.\u201d Pain 71(1): 49-55.","DOI":"10.1016\/S0304-3959(97)03339-3"},{"key":"123280","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0304-3959(97)03339-3","DOI":"10.1016\/S0304-3959(97)03339-3"},{"key":"123281","doi-asserted-by":"crossref","unstructured":"Nilsson, H. J., E. Psouni, R. Carstam and J. Schouenborg (2004). \u201cProfound inhibition of chronic itch induced by stimulation of thin cutaneous nerve fibres.\u201d J Eur Acad Dermatol Venereol 18(1): 37-43.","DOI":"10.1111\/j.1468-3083.2004.00724.x"},{"key":"123282","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2004.00724.x","DOI":"10.1111\/j.1468-3083.2004.00724.x"},{"key":"123283","doi-asserted-by":"crossref","unstructured":"Nor\u00e9n, P., L. Hagstr\u00f6mer, M. Alimohammadi and L. Melin (2018). \u201cThe positive effects of habit reversal treatment of scratching in children with atopic dermatitis: a randomized controlled study.\u201d Br J Dermatol 178: 665-673.","DOI":"10.1111\/bjd.16009"},{"key":"123284","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16009","DOI":"10.1111\/bjd.16009"},{"key":"123285","doi-asserted-by":"crossref","unstructured":"Norman, T., J. Guenther, N. Vecerek, B. L. Adler, A. Crew and S. Worswick (2023). \u201cPsychiatric comorbidities on an inpatient dermatology consultation service: A cross-sectional analysis.\u201d Skin Health Dis 3(5): e266.","DOI":"10.1002\/ski2.266"},{"key":"123286","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ski2.266","DOI":"10.1002\/ski2.266"},{"key":"123287","doi-asserted-by":"crossref","unstructured":"Nosbaum, A., C. Pecquet, O. Bayrou, E. Amsler, J. F. Nicolas, F. B\u00e9rard and C. Franc\u00e8s (2011). \u201cTreatment with propranolol of 6 patients with idiopathic aquagenic pruritus.\u201d J Allergy Clin Immunol 128(5): 1113.","DOI":"10.1016\/j.jaci.2011.05.001"},{"key":"123288","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2011.05.001","DOI":"10.1016\/j.jaci.2011.05.001"},{"key":"123289","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue, M. and M. D. Tharp (2005). \u201cAntihistamines and their role as antipruritics.\u201d Dermatol Ther 18(4): 333-340.","DOI":"10.1111\/j.1529-8019.2005.00034.x"},{"key":"123290","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1529-8019.2005.00034.x","DOI":"10.1111\/j.1529-8019.2005.00034.x"},{"key":"123291","unstructured":"O\u2019Donohue, J. W., C. Haigh and R. Williams (1997). \u201cOndansetron in the treatment of cholestasis: a randomised controlled trial.\u201d Gastroenterology 112: A1349."},{"key":"123292","doi-asserted-by":"crossref","unstructured":"Oaklander, A. (2012). \u201cCommon neuropathic itch syndromes.\u201d Acta Derm Venereol 92(2): 118-125.","DOI":"10.2340\/00015555-1318"},{"key":"123293","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1318","DOI":"10.2340\/00015555-1318"},{"key":"123294","doi-asserted-by":"crossref","unstructured":"Oaklander, A. L. (2011). \u201cNeuropathic itch.\u201d Semin Cutan Med Surg 30(2): 87-92.","DOI":"10.1016\/j.sder.2011.04.006"},{"key":"123295","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.sder.2011.04.006","DOI":"10.1016\/j.sder.2011.04.006"},{"key":"123296","doi-asserted-by":"crossref","unstructured":"Ofenloch, R., K. Grochulska, T. Mettang and E. Weisshaar (2022). \u201cThe incidence of chronic itch in hemodialysis patients and factors associated.\u201d Br J Dermatol.","DOI":"10.1111\/bjd.21024"},{"key":"123297","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.21024","DOI":"10.1111\/bjd.21024"},{"key":"123298","doi-asserted-by":"crossref","unstructured":"Ofenloch, R., K. Grochulska, T. Mettang and E. Weisshaar. The incidence of chronic itch in hemodialysis patients and factors associated. Br J Dermatol. 2022 Jun;186(6):1052-1054.","DOI":"10.1111\/bjd.21024"},{"key":"123299","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.21024","DOI":"10.1111\/bjd.21024"},{"key":"123300","doi-asserted-by":"crossref","unstructured":"Ohanyan, T., N. Schoepke, S. Eirefelt, G. Hoey, W. Koopmann, T. Hawro, M. Maurer and M. Metz (2018). \u201cRole of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant.\u201d Acta Derm Venereol 98(1): 26-31.","DOI":"10.2340\/00015555-2780"},{"key":"123301","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2780","DOI":"10.2340\/00015555-2780"},{"key":"123302","doi-asserted-by":"crossref","unstructured":"Ozkan, S., Y. Ceylan, O. V. Ozkan and S. R. Yildirim (2015). \u201cReview of a challenging clinical issue: Intrahepatic cholestasis of pregnancy.\u201d World J Gastroenterol 2(237): 7134-7141.","DOI":"10.3748\/wjg.v21.i23.7134"},{"key":"123303","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3748\/wjg.v21.i23.7134","DOI":"10.3748\/wjg.v21.i23.7134"},{"key":"123304","doi-asserted-by":"crossref","unstructured":"Pacan, P., M. Grzesiak, A. Reich and J. C. Szepietowski (2009). \u201cIs pruritus in depression a rare phenomenon?\u201d Acta Derm Venereol 89: 109-110.","DOI":"10.2340\/00015555-0576"},{"key":"123305","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0576","DOI":"10.2340\/00015555-0576"},{"key":"123306","doi-asserted-by":"crossref","unstructured":"Pakfetrat, M., L. Malekmakan, N. Hashemi and T. Tadayon (2018). \u201cSertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran.\u201d Hemodial Int 22(1): 103-109.","DOI":"10.1111\/hdi.12540"},{"key":"123307","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/hdi.12540","DOI":"10.1111\/hdi.12540"},{"key":"123308","doi-asserted-by":"crossref","unstructured":"Paller, A. S., E. L. Simpson, E. C. Siegfried and M. J. e. a. Cork (2022). \u201cDupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.\u201d Lancet 400(10356): 908-919.","DOI":"10.1016\/S0140-6736(22)01539-2"},{"key":"123309","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2","DOI":"10.1016\/S0140-6736(22)01539-2"},{"key":"123310","doi-asserted-by":"crossref","unstructured":"Paller, A. S., W. L. Tom, M. G. Lebwohl and R. L. e. a. Blumenthal (2016). \u201cEfficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.\u201d J Am Acad Dermatol 75(3): 494-503.","DOI":"10.1016\/j.jaad.2016.05.046"},{"key":"123311","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.05.046","DOI":"10.1016\/j.jaad.2016.05.046"},{"key":"123312","doi-asserted-by":"crossref","unstructured":"Palmer, R. B., K. M. Reynolds, W. Banner, G. R. Bond, R. E. Kauffman, I. M. Paul, J. L. Green and R. C. Dart (2020). \u201cAdverse events associated with diphenhydramine in children.\u201d Clin Toxicol (Phila) 58(2): 99-106.","DOI":"10.1080\/15563650.2019.1609683"},{"key":"123313","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/15563650.2019.1609683","DOI":"10.1080\/15563650.2019.1609683"},{"key":"123314","doi-asserted-by":"crossref","unstructured":"Palungwachira, P., K. Vilaisri, K. Musikatavorn and J. Wongpiyabovorn (2021). \u201cA randomized controlled trial of adding intravenous corticosteroids to H1 antihistamines in patients with acute urticaria.\u201d J.Am J Emerg Med 42: 197-197.","DOI":"10.1016\/j.ajem.2020.02.025"},{"key":"123315","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ajem.2020.02.025","DOI":"10.1016\/j.ajem.2020.02.025"},{"key":"123316","doi-asserted-by":"crossref","unstructured":"Papadopoulos, N. G. and T. Zuberbier (2019). \u201cThe safety and tolerability profile of bilastine for chronic urticaria in children.\u201d Clin Transl Allergy 23(9): 55.","DOI":"10.1186\/s13601-019-0294-3"},{"key":"123317","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13601-019-0294-3","DOI":"10.1186\/s13601-019-0294-3"},{"key":"123318","doi-asserted-by":"crossref","unstructured":"Papageorgiou, C., E. Lazaridou, K. Lallas, K. Papaioannou, V. Nikolaou, V. Mateeva, K. Efthymiadis, C. Koukoutzeli and K. e. a. Loga (2023). \u201cA retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management.\u201d Photodermatol Photoimmunol Photomed 39(5): 506-511.","DOI":"10.1111\/phpp.12892"},{"key":"123319","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/phpp.12892","DOI":"10.1111\/phpp.12892"},{"key":"123320","doi-asserted-by":"crossref","unstructured":"Papp, K., K. Reich, C. L. Leonardi, L. Kircik, S. Chimenti, R. G. Langley, C. Hu, R. M. Stevens, R. M. Day, K. B. Gordon, N. J. Korman and C. E. Griffiths (2015). \u201cApremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).\u201d J Am Acad Dermatol 73(1): 37-49.","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"123321","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"123322","doi-asserted-by":"crossref","unstructured":"Papp, K., J. C. Szepietowski, L. Kircik and D. e. a. Toth (2021). \u201cEfficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.\u201d J Am Acad Dermatol 85(4): 863-872.","DOI":"10.1016\/j.jaad.2021.04.085"},{"key":"123323","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085","DOI":"10.1016\/j.jaad.2021.04.085"},{"key":"123324","doi-asserted-by":"crossref","unstructured":"Papp, K., J. C. Szepietowski, L. Kircik and D. e. a. Toth (2023). \u201cLong-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.\u201d J Am Acad Dermatol 88(5): 1008-1016.","DOI":"10.1016\/j.jaad.2022.09.060"},{"key":"123325","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2022.09.060","DOI":"10.1016\/j.jaad.2022.09.060"},{"key":"123326","doi-asserted-by":"crossref","unstructured":"Papp, K. A., A. Papp, B. Dahmer and C. S. Clark (2011). \u201cSingle-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.\u201d J Am Acad Dermatol.","DOI":"10.1016\/j.jaad.2011.02.032"},{"key":"123327","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2011.02.032","DOI":"10.1016\/j.jaad.2011.02.032"},{"key":"123328","doi-asserted-by":"crossref","unstructured":"Passamonti, F., M. Griesshammer, F. Palandri, M. Egyed, G. Benevolo, T. Devos and J. e. a. Callum (2017). \u201cRuxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.\u201d Lancet Oncol 18(1): 88-99.","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"123329","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(16)30558-7","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"123330","unstructured":"Patel, T. and G. Yosipovitch (2010). \u201cThe management of chronic pruritus in the elderly.\u201d Skin Therapy Lett 15(8): 5-9."},{"key":"123331","doi-asserted-by":"crossref","unstructured":"Paul, C., J. Cather, M. Gooderham, Y. Poulin, U. Mrowietz, C. Ferrandiz, J. Crowley, C. Hu, R. M. Stevens, K. Shah, R. M. Day, G. Girolomoni and A. B. Gottlieb (2015). \u201cEfficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).\u201d Br J Dermatol 173(6): 1387-1399.","DOI":"10.1111\/bjd.14164"},{"key":"123332","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.14164","DOI":"10.1111\/bjd.14164"},{"key":"123333","doi-asserted-by":"crossref","unstructured":"Paul, E. and R. H. Bodeker (1986). \u201cTreatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients.\u201d Eur J Clin Pharmacol 31(3): 277-280.","DOI":"10.1007\/BF00981123"},{"key":"123334","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/BF00981123","DOI":"10.1007\/BF00981123"},{"key":"123335","doi-asserted-by":"crossref","unstructured":"Pauli-Magnus, C., S. Klumpp, D. M. Alscher, U. Kuhlmann and T. Mettang (2000). \u201cShort-term efficacy of tacrolimus ointment in severe uremic pruritus.\u201d Perit Dial Int 20(6): 802-803.","DOI":"10.1177\/089686080002000641"},{"key":"123336","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/089686080002000641","DOI":"10.1177\/089686080002000641"},{"key":"123337","doi-asserted-by":"crossref","unstructured":"Pauli-Magnus, C., G. Mikus, D. M. Alscher, T. Kirschner, W. Nagel, N. Gugeler, T. Risler, E. D. Berger, U. Kuhlmann and T. Mettang (2000). \u201cNaltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.\u201d J Am Soc Nephrol 11(3): 514-519.","DOI":"10.1681\/ASN.V113514"},{"key":"123338","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1681\/ASN.V113514","DOI":"10.1681\/ASN.V113514"},{"key":"123339","doi-asserted-by":"crossref","unstructured":"Paus, R., M. Schmelz, T. Biro and M. Steinhoff (2006). \u201cFrontiers in pruritus research: scratching the brain for more effective itch therapy.\u201d J Clin Invest 116(5): 1174-1186.","DOI":"10.1172\/JCI28553"},{"key":"123340","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1172\/JCI28553","DOI":"10.1172\/JCI28553"},{"key":"123341","doi-asserted-by":"crossref","unstructured":"Pavlovsky, M., S. Baum, D. Shpiro, L. Pavlovsky and F. Pavlotsky (2011). \u201cNarrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis?\u201d J Eur Acad Dermatol Venereol 25(6): 727-729.","DOI":"10.1111\/j.1468-3083.2010.03832.x"},{"key":"123342","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03832.x","DOI":"10.1111\/j.1468-3083.2010.03832.x"},{"key":"123343","doi-asserted-by":"crossref","unstructured":"Pazyar, N., R. Yaghoobi, A. Kazerouni and A. Feily (2012). \u201cOatmeal in dermatology: a brief review.\u201d Indian J Dermatol Venereol Leprol 78: 142-145.","DOI":"10.4103\/0378-6323.93629"},{"key":"123344","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/0378-6323.93629","DOI":"10.4103\/0378-6323.93629"},{"key":"123345","doi-asserted-by":"crossref","unstructured":"Pedersen, C. B., C. A. McHorney, L. S. Larsen, K. W. Lophaven, A. H. Moeller and M. Reaney (2016). \u201cReliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris.\u201d Journal of Dermatological Treatment 28(3): 213-220.","DOI":"10.1080\/09546634.2016.1215405"},{"key":"123346","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2016.1215405","DOI":"10.1080\/09546634.2016.1215405"},{"key":"123347","doi-asserted-by":"crossref","unstructured":"Peer, G., S. Kivity, O. Agami, E. Fireman, D. Silverberg, M. Blum and A. laina (1996). \u201cRandomised crossover trial of naltrexone in uraemic pruritus.\u201d Lancet 348(9041): 1552-1554.","DOI":"10.1016\/S0140-6736(96)04176-1"},{"key":"123348","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(96)04176-1","DOI":"10.1016\/S0140-6736(96)04176-1"},{"key":"123349","doi-asserted-by":"crossref","unstructured":"Peng, C., C. Li, Y. Zhou and Q. e. a. Wang (2022). \u201cTofacitinib for Prurigo Nodularis: A Case Report.\u201d Clin Cosmet Investig Dermatol 15: 503-506.","DOI":"10.2147\/CCID.S354025"},{"key":"123350","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CCID.S354025","DOI":"10.2147\/CCID.S354025"},{"key":"123351","doi-asserted-by":"crossref","unstructured":"Pereira, M., A. Farcas, C. Zeidler and S. St\u00e4nder (2021). \u201cChronic Pruritus of Unknown Origin: Clinical Profile and Disease Related Burden.\u201d Acta Derm Venereol 101: adv00550.","DOI":"10.2340\/00015555-3892"},{"key":"123352","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3892","DOI":"10.2340\/00015555-3892"},{"key":"123353","doi-asserted-by":"crossref","unstructured":"Pereira, M. P., L. Derichs, G. Meyer Zu H\u00f6rste, K. Agelopoulos and S. St\u00e4nder (2020). \u201cGeneralized chronic itch induced by small-fibre neuropathy: clinical profile and proposed diagnostic criteria.\u201d JEADV 34: 1795-1802.","DOI":"10.1111\/jdv.16151"},{"key":"123354","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16151","DOI":"10.1111\/jdv.16151"},{"key":"123355","doi-asserted-by":"crossref","unstructured":"Pereira, M. P., A. E. Kremer, T. Mettang and S. St\u00e4nder (2016). \u201cChronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment.\u201d Am J Clin Dermatol 17(4): 337-348.","DOI":"10.1007\/s40257-016-0198-0"},{"key":"123356","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-016-0198-0","DOI":"10.1007\/s40257-016-0198-0"},{"key":"123357","doi-asserted-by":"crossref","unstructured":"Pereira, M. P. and S. St\u00e4nder (2017). \u201cAssessment of severity and burden of pruritus.\u201d Allergol Int 66(1): 3-7.","DOI":"10.1016\/j.alit.2016.08.009"},{"key":"123358","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.alit.2016.08.009","DOI":"10.1016\/j.alit.2016.08.009"},{"key":"123359","doi-asserted-by":"crossref","unstructured":"Pereira, M. P. and S. St\u00e4nder (2019). \u201cMeasurement tools for chronic pruritus: assessment of the symptom and the associated burden: a review.\u201d Itch 4(4): e29.","DOI":"10.1097\/itx.0000000000000029"},{"key":"123360","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/itx.0000000000000029","DOI":"10.1097\/itx.0000000000000029"},{"key":"123361","doi-asserted-by":"crossref","unstructured":"Pereira, M. P., S. Steinke, C. Zeidler, C. Forner, C. Riepe, M. Augustin, S. Bobko, F. Dalgard, J. Elberling, S. Garcovich, U. Gieler, M. Gon\u00e7alo, J. A. Halvorsen, T. Leslie, M. Metz, A. Reich, E. \u015eavk, G. Schneider, E. Serra-Baldrich, H. St\u00e4nder, M. Streit, J. Wallengren, K. Weller, A. Wollenberg, P. Bruland, I. Soto-Rey, M. Storck, M. Dugas, E. Weisshaar, J. C. Szepietowski, F. J. Legat, S. St\u00e4nder and E. T. F. P. g. members (2018). \u201cEuropean academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.\u201d J Eur Acad Dermatol Venereol 32(7): 1059-1065.","DOI":"10.1111\/jdv.14570"},{"key":"123362","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14570","DOI":"10.1111\/jdv.14570"},{"key":"123363","doi-asserted-by":"crossref","unstructured":"Pereira, M. P., C. Zeidler and S. St\u00e4nder (2022). \u201cImprovement of chronic nodular prurigo with baricitinib.\u201d J Eur Acad Dermatol Venereol 36(6): e486-e488.","DOI":"10.1111\/jdv.17991"},{"key":"123364","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17991","DOI":"10.1111\/jdv.17991"},{"key":"123365","doi-asserted-by":"crossref","unstructured":"Pereira, P. J. S. and E. A. Lerner (2014). \u201cInterneurons Scratch an Itch.\u201d Neuron 82(3): 503-505.","DOI":"10.1016\/j.neuron.2014.04.026"},{"key":"123366","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.neuron.2014.04.026","DOI":"10.1016\/j.neuron.2014.04.026"},{"key":"123367","doi-asserted-by":"crossref","unstructured":"Pezzolo, E., A. Gambardella, M. Guanti and T. e. a. Bianchelli (2023). \u201cTralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.\u201d J Am Acad Dermatol 89(2): 430-432.","DOI":"10.1016\/j.jaad.2023.04.056"},{"key":"123368","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.056","DOI":"10.1016\/j.jaad.2023.04.056"},{"key":"123369","doi-asserted-by":"crossref","unstructured":"Pfab, F., J. Huss-Marp, A. Gatti, J. Fuqin, G. I. Athanasiadis, D. Irnich, U. Raap, W. Schober, H. Behrendt, J. Ring and U. Darsow (2010). \u201cInfluence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial.\u201d Allergy 65(7): 903-910.","DOI":"10.1111\/j.1398-9995.2009.02284.x"},{"key":"123370","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02284.x","DOI":"10.1111\/j.1398-9995.2009.02284.x"},{"key":"123371","doi-asserted-by":"crossref","unstructured":"Pfab, F., P. C. Schalock, V. Napadow, G. I. Athanasiadis, J. Huss-Marp and J. Ring (2014). \u201cAcupuncture for allergic disease therapy--the current state of evidence.\u201d Expert Rev Clin Immunol 10: 831-841.","DOI":"10.1586\/1744666X.2014.924855"},{"key":"123372","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1586\/1744666X.2014.924855","DOI":"10.1586\/1744666X.2014.924855"},{"key":"123373","doi-asserted-by":"crossref","unstructured":"Pfab, F., M. Valet, T. Sprenger, J. Huss-Marp, G. I. Athanasiadis, H. J. Baurecht, A. Konstantinow, C. Zimmer, H. Behrendt, J. Ring, T. R. Tolle and U. Darsow (2010). \u201cTemperature modulated histamine-itch in lesional and nonlesional skin in atopic eczema - a combined psychophysical and neuroimaging study.\u201d Allergy 65(1): 84-94.","DOI":"10.1111\/j.1398-9995.2009.02163.x"},{"key":"123374","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02163.x","DOI":"10.1111\/j.1398-9995.2009.02163.x"},{"key":"123375","doi-asserted-by":"crossref","unstructured":"Phan, N. Q., J. D. Bernhard, T. A. Luger and S. Stander (2012). \u201cSystemic kappa opioid receptor (KOR) agonists in the treatment of chronic pruritus: a review.\u201d Acta Derm Venereol 2012 Sep;92(5):555-60.","DOI":"10.2340\/00015555-1353"},{"key":"123376","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1353","DOI":"10.2340\/00015555-1353"},{"key":"123377","doi-asserted-by":"crossref","unstructured":"Phan, N. Q., J. D. Bernhard, T. A. Luger and S. St\u00e4nder (2010). \u201cAntipruritic treatment with systemic \u03bc-opioid receptor antagonists: a review.\u201d J Am Acad Dermatol 63(4): 680-688.","DOI":"10.1016\/j.jaad.2009.08.052"},{"key":"123378","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2009.08.052","DOI":"10.1016\/j.jaad.2009.08.052"},{"key":"123379","doi-asserted-by":"crossref","unstructured":"Phan, N. Q., C. Blome, F. Fritz, J. Gerss, A. Reich, T. Ebata, M. Augustin, J. C. Szepietowski and S. Stander (2012). \u201cAssessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus.\u201d Acta Derm Venereol 92(5): 502-507.","DOI":"10.2340\/00015555-1246"},{"key":"123380","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1246","DOI":"10.2340\/00015555-1246"},{"key":"123381","doi-asserted-by":"crossref","unstructured":"Phan, N. Q., T. Lotts, A. Antal, J. D. Bernhard and S. Stander (2012). \u201cSystemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review.\u201d Acta Derm Venereol.","DOI":"10.2340\/00015555-1353"},{"key":"123382","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1353","DOI":"10.2340\/00015555-1353"},{"key":"123383","doi-asserted-by":"crossref","unstructured":"Phan, N. Q., D. Siepmann, I. Gralow and S. Stander (2010). \u201cAdjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia.\u201d J Dtsch Dermatol Ges 8(2): 88-91.","DOI":"10.1111\/j.1610-0387.2009.07213.x"},{"key":"123384","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1610-0387.2009.07213.x","DOI":"10.1111\/j.1610-0387.2009.07213.x"},{"key":"123385","doi-asserted-by":"crossref","unstructured":"Phinyo, P., P. Koompawichit, S. Nochaiwong, N. Tovanabutra, S. Chiewchanvit and M. Chuamanochan (2021). \u201cComparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis.\u201d.J Allergy Clin Immunol Pract 9(2): 956-970.e957.","DOI":"10.1016\/j.jaip.2020.08.055"},{"key":"123386","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaip.2020.08.055","DOI":"10.1016\/j.jaip.2020.08.055"},{"key":"123387","doi-asserted-by":"crossref","unstructured":"Polat, G., B. Erni, A. Navarini, A. Kind and S. M. Mueller (2021). \u201cThree patients with chronic vulvar pruritus successfully treated with cold atmospheric pressure plasma.\u201d J Dtsch Dermatol Ges 19(9): 1346-1349.","DOI":"10.1111\/ddg.14541"},{"key":"123388","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14541","DOI":"10.1111\/ddg.14541"},{"key":"123389","doi-asserted-by":"crossref","unstructured":"Polat, M., P. Oztas, M. N. Ilhan, B. Yal\u00e7in and N. Alli (2008). \u201cGeneralized pruritus: a prospective study concerning etiology.\u201d Am J Clin Dermatol 9(1): 39-44.","DOI":"10.2165\/00128071-200809010-00004"},{"key":"123390","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00128071-200809010-00004","DOI":"10.2165\/00128071-200809010-00004"},{"key":"123391","doi-asserted-by":"crossref","unstructured":"Ponticelli, C. and P. L. Bencini (1995). \u201cPruritus in dialysis patients: a neglected problem.\u201d Nephrol Dial Transplant 10(12): 2174-2176.","DOI":"10.1093\/ndt\/10.12.2174"},{"key":"123392","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/10.12.2174","DOI":"10.1093\/ndt\/10.12.2174"},{"key":"123393","doi-asserted-by":"crossref","unstructured":"Porzio, G., F. Aielli, L. Verna, C. Porto, M. Tudini, K. Cannita and C. Ficorella (2006). \u201cEfficacy of pregabalin in the management of cetuximab-related itch.\u201d J Pain Symptom Manage 32(5): 397-398.","DOI":"10.1016\/j.jpainsymman.2006.07.006"},{"key":"123394","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2006.07.006","DOI":"10.1016\/j.jpainsymman.2006.07.006"},{"key":"123395","doi-asserted-by":"crossref","unstructured":"Potter, P., E. Mitha, L. Barkai, G. Mezei, E. Santamaria, I. Izquierdo and M. Maurer (2016). \u201cRupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.\u201d Pediatr Allergy Immunol 27: 55-61.","DOI":"10.1111\/pai.12460"},{"key":"123396","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pai.12460","DOI":"10.1111\/pai.12460"},{"key":"123397","unstructured":"Pour-Reza-Gholi, F., A. Nasrollahi, A. Firouzan, E. N. Esfahani and F. Farrokhi (2007). \u201cLow-dose doxepin for treatment of pruritus in patients on hemodialysis.\u201d Iran J Kidney Dis 1(1): 34-37."},{"key":"123398","doi-asserted-by":"crossref","unstructured":"Powell, R. J., S. C. Leech, S. Till, P. A. J. Huber, S. M. Nasser and A. T. Clark (2015). \u201cBSACI guideline for the management of chronic urticaria and angioedema.\u201d Clin Exp Allergy 45: 547-565.","DOI":"10.1111\/cea.12494"},{"key":"123399","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/cea.12494","DOI":"10.1111\/cea.12494"},{"key":"123400","doi-asserted-by":"crossref","unstructured":"Pratyusha, K., L. Dawman, K. VInay, K. Tiewsoh and L. K. Sharawat (2021). \u201cDermatological manifestations in children with chronic kidney disease: astudy from a North Indian tertiary care institute \u201c Clin Exp Dermatol 46: 1270-1276.","DOI":"10.1111\/ced.14708"},{"key":"123401","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.14708","DOI":"10.1111\/ced.14708"},{"key":"123402","doi-asserted-by":"crossref","unstructured":"Purnamawati, S., N. Indrastuti, R. Danarti and T. Saefudin (2017). \u201cThe Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review.\u201d Clin Med Res 15(3-4): 75-87.","DOI":"10.3121\/cmr.2017.1363"},{"key":"123403","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3121\/cmr.2017.1363","DOI":"10.3121\/cmr.2017.1363"},{"key":"123404","unstructured":"Raiford, D. S. (1995). \u201cPruritus of chronic cholestasis.\u201d QJM 88(9): 603-607."},{"key":"123405","doi-asserted-by":"crossref","unstructured":"Rayner, H., J. Baharani, S. Smith, V. Suresh and I. Dasgupta (2012). \u201cUraemic pruritus: relief of itching by gabapentin and pregabalin.\u201d Nephron Clin Pract 122(3-4): 75-79.","DOI":"10.1159\/000349943"},{"key":"123406","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000349943","DOI":"10.1159\/000349943"},{"key":"123407","doi-asserted-by":"crossref","unstructured":"Rayner, H. C., M. Larkina, M. Wang, M. Graham-Brown, S. N. van der Veer and T. Ecder, et al. (2017). \u201cInternational Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.\u201d Clin J Am Soc Nephrol 12(12): 2000-2007.","DOI":"10.2215\/CJN.03280317"},{"key":"123408","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2215\/CJN.03280317","DOI":"10.2215\/CJN.03280317"},{"key":"123409","doi-asserted-by":"crossref","unstructured":"Razeghi, E., D. Eskandari, M. R. Ganji, A. P. Meysamie, M. Togha and P. Khashayar (2009). \u201cGabapentin and uremic pruritus in hemodialysis patients.\u201d Ren Fail 31(2): 85-90.","DOI":"10.1080\/08860220802595476"},{"key":"123410","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/08860220802595476","DOI":"10.1080\/08860220802595476"},{"key":"123411","doi-asserted-by":"crossref","unstructured":"Rea, J. N., M. L. Newhouse and T. Halil (1976). \u201cSkin disease in Lambeth. A community study of prevalence and use of medical care.\u201d Br J Prev Soc Med 30(2): 107-114.","DOI":"10.1136\/jech.30.2.107"},{"key":"123412","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/jech.30.2.107","DOI":"10.1136\/jech.30.2.107"},{"key":"123413","doi-asserted-by":"crossref","unstructured":"Reich, A., E. Chatzigeorkidis, C. Zeidler, N. Osada, M. Furue, K. Takamori, T. Ebata, M. Augustin, J. C. Szepietowski and S. St\u00e4nder (2017). \u201cTailoring the Cut-off Values of the Visual Analogue Scale and Numeric Rating Scale in Itch Assessment.\u201d Acta Derm Venereol 97(6): 759-760.","DOI":"10.2340\/00015555-2642"},{"key":"123414","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2642","DOI":"10.2340\/00015555-2642"},{"key":"123415","doi-asserted-by":"crossref","unstructured":"Reich, A., C. Riepe, Z. Anastasiadou, K. M\u0119drek, M. Augustin, J. C. Szepietowski and S. St\u00e4nder (2016). \u201cItch Assessment with Visual Analogue Scale and Numerical Rating Scale: Determination of Minimal Clinically Important Difference in Chronic Itch.\u201d Acta Derm Venereol 96(7): 978-980.","DOI":"10.2340\/00015555-2433"},{"key":"123416","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2433","DOI":"10.2340\/00015555-2433"},{"key":"123417","doi-asserted-by":"crossref","unstructured":"Reich, A., S. Stander and J. C. Szepietowski (2009). \u201cDrug-induced pruritus: a review.\u201d Acta Derm Venereol 89(3): 236-244.","DOI":"10.2340\/00015555-0650"},{"key":"123418","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0650","DOI":"10.2340\/00015555-0650"},{"key":"123419","doi-asserted-by":"crossref","unstructured":"Reich, A., K. Trybucka, A. Tracinska, D. Samotij, B. Jasiuk, M. Srama and J. C. Szepietowski (2008). \u201cAcne itch: do acne patients suffer from itching?\u201d Acta Derm Venereol 88(1): 38-42.","DOI":"10.2340\/00015555-0355"},{"key":"123420","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0355","DOI":"10.2340\/00015555-0355"},{"key":"123421","doi-asserted-by":"crossref","unstructured":"Reich, K., K. Kabashima, K. Peris and J. I. e. a. Silverberg (2020). \u201cEfficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.\u201d JAMA Dermatol 156(12): 1333-1343.","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"123422","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"123423","doi-asserted-by":"crossref","unstructured":"Reich, K., K. A. Papp, A. Blauvelt and R. G. e. a. Langley (2021). \u201cBimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.\u201d Lancet 397(10273): 487-498.","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"123424","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(21)00125-2","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"123425","doi-asserted-by":"crossref","unstructured":"Reich, K., J. P. Thyssen, A. Blauvelt, K. Eyerich and W. Soong, et al. (2022). \u201cEfficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.\u201d Lancet 400(10348): 273-282.","DOI":"10.1016\/S0140-6736(22)01199-0"},{"key":"123426","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(22)01199-0","DOI":"10.1016\/S0140-6736(22)01199-0"},{"key":"123427","doi-asserted-by":"crossref","unstructured":"Reimann, S., T. Luger and D. Metze (2000). \u201c[Topical administration of capsaicin in dermatology for treatment of itching and pain].\u201d Hautarzt 51(3): 164-172.","DOI":"10.1007\/s001050051014"},{"key":"123428","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s001050051014","DOI":"10.1007\/s001050051014"},{"key":"123429","doi-asserted-by":"crossref","unstructured":"Reszke, R., R. Bia\u0142ynicki-birula, K. Lindner, M. Sobieszcza\u0144ska and J. C. Szepietowski (2019). \u201cItch in Elderly People: A Cross-sectional Study.\u201d Acta Derm Venereol 99(11): 1016-1021.","DOI":"10.2340\/00015555-3271"},{"key":"123430","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3271","DOI":"10.2340\/00015555-3271"},{"key":"123431","doi-asserted-by":"crossref","unstructured":"Reszke, R., K. Kilis-Pstrusinska and J. C. Szepietowski (2021). \u201cChronic kidney disease-associated itch (CKD-aI) in children- a narrative review.\u201d Toxins 13: 450.","DOI":"10.3390\/toxins13070450"},{"key":"123432","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/toxins13070450","DOI":"10.3390\/toxins13070450"},{"key":"123433","doi-asserted-by":"crossref","unstructured":"Reszke, R. and J. C. Szepietowski (2019). \u201cCan we use psychoactive drugs to treat pruritus?\u201d Exp Dermatol 12: 1422-1431.","DOI":"10.1111\/exd.13959"},{"key":"123434","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.13959","DOI":"10.1111\/exd.13959"},{"key":"123435","doi-asserted-by":"crossref","unstructured":"Revicki, D., M. K. Willian, J.-H. Saurat, K. A. Papp, J.-P. Ortonne, C. Sexton and A. Camez (2008). \u201cImpact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.\u201d Br J Dermatol 158(3): 549-557.","DOI":"10.1111\/j.1365-2133.2007.08236.x"},{"key":"123436","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08236.x","DOI":"10.1111\/j.1365-2133.2007.08236.x"},{"key":"123437","doi-asserted-by":"crossref","unstructured":"Revicki, D. A., M. K. Willian, A. Menter and K. B. e. a. Gordon (2007). \u201cImpact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.\u201d J Dermatolog Treat 18(6): 341-350.","DOI":"10.1080\/09546630701646172"},{"key":"123438","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546630701646172","DOI":"10.1080\/09546630701646172"},{"key":"123439","doi-asserted-by":"crossref","unstructured":"Rivard, J. and H. W. Lim (2005). \u201cUltraviolet phototherapy for pruritus.\u201d Dermatol Ther 18(4): 344-354.","DOI":"10.1111\/j.1529-8019.2005.00032.x"},{"key":"123440","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1529-8019.2005.00032.x","DOI":"10.1111\/j.1529-8019.2005.00032.x"},{"key":"123441","doi-asserted-by":"crossref","unstructured":"Rodriguez, D., S. G. Kwatra, C. Dias-Barbosa, F. Zeng, Z. K. J. Lopez, C. Piketty and J. Puelles (2023). \u201cPatient Perspectives on Living With Severe Prurigo Nodularis.\u201d JAMA Dermatol 159(11): 1205-1212.","DOI":"10.1001\/jamadermatol.2023.3251"},{"key":"123442","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.3251","DOI":"10.1001\/jamadermatol.2023.3251"},{"key":"123443","doi-asserted-by":"crossref","unstructured":"Roger, D., L. Vaillant, A. Fignon, F. Pierre, Y. Dacq, J. F. Br\u00e9chot, M. C. Grangeponte and G. Lorette (1994). \u201cSpecific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women.\u201d Arch Dermatol 130: 7234-7239.","DOI":"10.1001\/archderm.1994.01690060064006"},{"key":"123444","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.1994.01690060064006","DOI":"10.1001\/archderm.1994.01690060064006"},{"key":"123445","doi-asserted-by":"crossref","unstructured":"Rombold, S., K. Lobisch, K. Katzer, T. C. Grazziotin, J. Ring and B. Eberlein (2008). \u201cEfficacy of UVA1 phototherapy in 230 patients with various skin diseases.\u201d Photodermatol Photoimmunol Photomed 24(1): 19-23.","DOI":"10.1111\/j.1600-0781.2008.00328.x"},{"key":"123446","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1600-0781.2008.00328.x","DOI":"10.1111\/j.1600-0781.2008.00328.x"},{"key":"123447","doi-asserted-by":"crossref","unstructured":"Rosenbaum, M. S. and T. Ayllon (1981). \u201cThe behavioral treatment of neurodermatitis through habit-reversal.\u201d Behav Res Ther 19(4): 313-318.","DOI":"10.1016\/0005-7967(81)90052-8"},{"key":"123448","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0005-7967(81)90052-8","DOI":"10.1016\/0005-7967(81)90052-8"},{"key":"123449","doi-asserted-by":"crossref","unstructured":"Rosner, M. H. (2006). \u201cCromolyn sodium: a potential therapy for uremic pruritus?\u201d Hemodial Int 10(2): 189-192.","DOI":"10.1111\/j.1542-4758.2006.00093.x"},{"key":"123450","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1542-4758.2006.00093.x","DOI":"10.1111\/j.1542-4758.2006.00093.x"},{"key":"123451","doi-asserted-by":"crossref","unstructured":"Rotter, G., M. Teut, R. Schleicher, M. Dell\u2019Oro, M. Ortiz, S. Binting, T. Tissen-Diabat\u00e9, S. Roll, A. Michalsen, D. Staab, B. Wolfarth and B. Brinkhaus (2023). \u201cHypnotherapy, Intermittent Fasting, and Exercise Group Programs in Atopic Dermatitis: A Randomized Controlled Explorative Clinical Trial During the COVID-19 Pandemic.\u201d J Integr Complement Med 29(2): 99-110.","DOI":"10.1089\/jicm.2022.0699"},{"key":"123452","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1089\/jicm.2022.0699","DOI":"10.1089\/jicm.2022.0699"},{"key":"123453","doi-asserted-by":"crossref","unstructured":"Rukwied, R., A. Watkinson, F. McGlone and M. Dvorak (2003). \u201cCannabinoid agonists attenuate capsaicin-induced responses in human skin.\u201d Pain 102(3): 283-288.","DOI":"10.1016\/S0304-3959(02)00401-3"},{"key":"123454","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0304-3959(02)00401-3","DOI":"10.1016\/S0304-3959(02)00401-3"},{"key":"123455","doi-asserted-by":"crossref","unstructured":"Ryczek, A. and A. Reich (2020). \u201cPrevalence of Prurigo Nodularis in Poland.\u201d Acta Derm Venereol 100(10): adv00155.","DOI":"10.2340\/00015555-3518"},{"key":"123456","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3518","DOI":"10.2340\/00015555-3518"},{"key":"123457","doi-asserted-by":"crossref","unstructured":"Sadeghi, S. and N. A. Mohandesi (2023). \u201cEfficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review.\u201d Exp Dermatol 32(5): 599-610.","DOI":"10.1111\/exd.14753"},{"key":"123458","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.14753","DOI":"10.1111\/exd.14753"},{"key":"123459","doi-asserted-by":"crossref","unstructured":"Saini, L., P. K. Gunasekaran, S. Tiwari, D. Krishna, V. Laxmi, P. Jindal and P. Kumar (2023). \u201cPatients With Chiari Malformation Type I: A Rare Phenotype.\u201d Pediatr Neurol 140: 65-67.","DOI":"10.1016\/j.pediatrneurol.2022.12.013"},{"key":"123460","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.pediatrneurol.2022.12.013","DOI":"10.1016\/j.pediatrneurol.2022.12.013"},{"key":"123461","doi-asserted-by":"crossref","unstructured":"Saini, S., A. Gim\u00e9nez-Arnau, M. Hide and M. e. a. Lebwohl (2023). \u201cFast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1\/-2 studies.\u201d Ann Allergy Asthma Immunol 131(5 [Suppl 2]): S230.","DOI":"10.1016\/j.anai.2023.10.019"},{"key":"123462","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.anai.2023.10.019","DOI":"10.1016\/j.anai.2023.10.019"},{"key":"123463","doi-asserted-by":"crossref","unstructured":"Saini, S., A. K. Jain, S. Agarwal and D. Yadav (2021). \u201cIron Deficiency and Pruritus: A Cross-Sectional Analysis to Assess Its Association and Relationship.\u201d Indian J Dermatol 66(6): 705.","DOI":"10.4103\/ijd.ijd_326_21"},{"key":"123464","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/ijd.ijd_326_21","DOI":"10.4103\/ijd.ijd_326_21"},{"key":"123465","doi-asserted-by":"crossref","unstructured":"Saki, N., S. Vahedi, M. M. Parvizi, M. Shafie\u2019ei, S. A. Hosseini and N. Ahramiyanpour (2022). \u201cTopical gabapentin 10% in the treatment of epidermolysis bullosa pruritus: A pilot, double-blind, split-site, randomized controlled trial.\u201d Dermatol Ther 35(10): e15767.","DOI":"10.1111\/dth.15767"},{"key":"123466","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15767","DOI":"10.1111\/dth.15767"},{"key":"123467","doi-asserted-by":"crossref","unstructured":"Salavastru, C. M., O. Chosidow, M. J. Boffa, M. Janier and G. S. Tiplica (2017). \u201cEuropean guideline for the management of scabies.\u201d J Eur Acad Dermatol Venereol 31(8): 1248-1253.","DOI":"10.1111\/jdv.14351"},{"key":"123468","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14351","DOI":"10.1111\/jdv.14351"},{"key":"123469","unstructured":"Saltzer, E. J. and G. Grove (1975). \u201cRelief from uremic pruritus: a therapeutic approach.\u201d Cutis 16: 298-299."},{"key":"123470","doi-asserted-by":"crossref","unstructured":"Sameni, F., B. Hajikhani, S. Yaslianifard, M. Goudarzi, P. Owlia, M. J. Nasiri, S. Shokouhi, M. Bakhtiyari and M. Dadashi (2020). \u201cCOVID-19 and Skin Manifestations: An Overview of Case Reports\/Case Series and Meta-Analysis of Prevalence Studies.\u201d Front Med 7: 573188.","DOI":"10.3389\/fmed.2020.573188"},{"key":"123471","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2020.573188","DOI":"10.3389\/fmed.2020.573188"},{"key":"123472","doi-asserted-by":"crossref","unstructured":"Samotij, D., J. Szcz\u0119ch, E. Antiga and D. e. a. Bonciani (2021). \u201cClinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study.\u201d Lupus 30(9): 1385-1393.","DOI":"10.1177\/09612033211016098"},{"key":"123473","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/09612033211016098","DOI":"10.1177\/09612033211016098"},{"key":"123474","doi-asserted-by":"crossref","unstructured":"Santer, M., I. Muller, T. Becque, B. Stuart, J. Hooper, M. Steele, S. Wilczynska, T. H. Sach, M. J. Ridd, A. Roberts, A. Ahmed, L. Yardley, P. Little, K. Greenwell, K. Sivyer, J. Nuttall, G. Griffiths, S. Lawton, S. M. Langan, L. M. Howells, P. Leighton, H. C. Williams and K. S. Thomas (2022). \u201cEczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials.\u201d BMJ 379: e072007.","DOI":"10.1136\/bmj-2022-072007"},{"key":"123475","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj-2022-072007","DOI":"10.1136\/bmj-2022-072007"},{"key":"123476","doi-asserted-by":"crossref","unstructured":"Saraceno, R., A. Chiricozzi, S. P. Nistic\u00f2, S. Tiberti and S. Chimenti (2010). \u201cAn occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.\u201d J Dermatolog Treat 21(6): 363-366.","DOI":"10.3109\/09546630903386606"},{"key":"123477","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/09546630903386606","DOI":"10.3109\/09546630903386606"},{"key":"123478","doi-asserted-by":"crossref","unstructured":"Sardana, K., A. Gupta and S. Sinha (2020). \u201cAn observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis.\u201d Clin Exp Dermatol 45(92-96).","DOI":"10.1111\/ced.14015"},{"key":"123479","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.14015","DOI":"10.1111\/ced.14015"},{"key":"123480","doi-asserted-by":"crossref","unstructured":"Sardana, K., S. R. Mathachan and D. Agrawal (2023). \u201cTreatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression.\u201d Indian J Dermatol Venereol Leprol 23: 1-3.","DOI":"10.25259\/IJDVL_362_2023"},{"key":"123481","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.25259\/IJDVL_362_2023","DOI":"10.25259\/IJDVL_362_2023"},{"key":"123482","doi-asserted-by":"crossref","unstructured":"Saverall, C., F. L. Sand and S. F. Thomsen (2015). \u201cDermatological diseases associated with pregnancy: pemphigoid gestationis, polymorphic eruption of pregnancy, intrahepatic cholestasis of pregnancy and atopic eruption of pregnancy.\u201d Dermatol Res Pract 2015: 979635.","DOI":"10.1155\/2015\/979635"},{"key":"123483","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2015\/979635","DOI":"10.1155\/2015\/979635"},{"key":"123484","doi-asserted-by":"crossref","unstructured":"Savin, J. A. (1998). \u201cHow should we define itching?\u201d J Am Acad Dermatol 39 (2 Pt 1) 268-269.","DOI":"10.1016\/S0190-9622(98)70087-8"},{"key":"123485","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(98)70087-8","DOI":"10.1016\/S0190-9622(98)70087-8"},{"key":"123486","doi-asserted-by":"crossref","unstructured":"Savk, E. (2016). \u201cNeurologic itch management.\u201d Curr Probl Dermatol 50: 116-123.","DOI":"10.1159\/000446053"},{"key":"123487","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446053","DOI":"10.1159\/000446053"},{"key":"123488","doi-asserted-by":"crossref","unstructured":"Savk, E., O. Savk, O. Bolukbasi, N. Culhaci, E. Dikicioglu, G. Karaman and N. Sendur (2000). \u201cNotalgia paresthetica: a study on pathogenesis.\u201d Int J Dermatol 39(10): 754-759.","DOI":"10.1046\/j.1365-4362.2000.00080.x"},{"key":"123489","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-4362.2000.00080.x","DOI":"10.1046\/j.1365-4362.2000.00080.x"},{"key":"123490","doi-asserted-by":"crossref","unstructured":"Savk, O. and E. Savk (2005). \u201cInvestigation of spinal pathology in notalgia paresthetica.\u201d J Am Acad Dermatol 52(6): 1085-1087.","DOI":"10.1016\/j.jaad.2005.01.138"},{"key":"123491","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2005.01.138","DOI":"10.1016\/j.jaad.2005.01.138"},{"key":"123492","doi-asserted-by":"crossref","unstructured":"Sbidian, E., A. Chaimani, I. Garcia-Doval and L. e. a. Doney (2022). \u201cSystemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.\u201d Cochrane Database Syst Rev 5(5): CD011535.","DOI":"10.1002\/14651858.CD011535.pub5"},{"key":"123493","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD011535.pub5","DOI":"10.1002\/14651858.CD011535.pub5"},{"key":"123494","doi-asserted-by":"crossref","unstructured":"Schaper-Gerhardt, K., K. Rossbach, E. Nikolouli, T. Werfel, R. Gutzmer and S. Mommert (2020). \u201cThe role of the histamine H(4) receptor in atopic dermatitis and psoriasis.\u201d Br J Pharmacol 177(3): 490-502.","DOI":"10.1111\/bph.14550"},{"key":"123495","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bph.14550","DOI":"10.1111\/bph.14550"},{"key":"123496","doi-asserted-by":"crossref","unstructured":"Schmid, Y., A. Navarini, Z. M. Thomas, B. Pfleiderer, S. Kr\u00e4henb\u00fchl and S. M. Mueller (2019). \u201cSex differences in the pharmacology of itch therapies-a narrative review.\u201d Curr Opin Pharmacol 46(122-142).","DOI":"10.1016\/j.coph.2019.05.008"},{"key":"123497","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.coph.2019.05.008","DOI":"10.1016\/j.coph.2019.05.008"},{"key":"123498","doi-asserted-by":"crossref","unstructured":"Schneider, G., G. Driesch, G. Heuft, S. Evers, T. A. Luger and S. Stander (2006). \u201cPsychosomatic cofactors and psychiatric comorbidity in patients with chronic itch.\u201d Clin Exp Dermatol 31(6): 762-767.","DOI":"10.1111\/j.1365-2230.2006.02211.x"},{"key":"123499","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2230.2006.02211.x","DOI":"10.1111\/j.1365-2230.2006.02211.x"},{"key":"123500","doi-asserted-by":"crossref","unstructured":"Schneider, G., A. Grebe, P. Bruland, G. Heuft and S. St\u00e4nder (2020). \u201cCriteria suggestive of psychological components of itch and somatoform itch: study of a large sample of patients with chronic pruritus.\u201d Acta Derm Venereol 100: adv00075.","DOI":"10.2340\/00015555-3424"},{"key":"123501","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3424","DOI":"10.2340\/00015555-3424"},{"key":"123502","doi-asserted-by":"crossref","unstructured":"Schulz, S., M. Metz, D. Siepmann, T. A. Luger, M. Maurer and S. Stander (2009). \u201c[Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series].\u201d Hautarzt 60(7): 564-568.","DOI":"10.1007\/s00105-009-1730-4"},{"key":"123503","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-009-1730-4","DOI":"10.1007\/s00105-009-1730-4"},{"key":"123504","doi-asserted-by":"crossref","unstructured":"Schut, C., S. Grossmann, U. Gieler, J. Kupfer and G. Yosipovitch (2015). \u201cContagious itch: what we know and what we would like to know.\u201d Front Hum Neurosci 11(9): 57.","DOI":"10.3389\/fnhum.2015.00057"},{"key":"123505","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fnhum.2015.00057","DOI":"10.3389\/fnhum.2015.00057"},{"key":"123506","doi-asserted-by":"crossref","unstructured":"Schworer, H. and G. Ramadori (1993). \u201cTreatment of pruritus: a new indication for serotonin type 3 receptor antagonists.\u201d Clin Investig 71(8): 659-662.","DOI":"10.1007\/BF00184497"},{"key":"123507","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/BF00184497","DOI":"10.1007\/BF00184497"},{"key":"123508","doi-asserted-by":"crossref","unstructured":"Seckin, D., Z. Demircay and O. Akin (2007). \u201cGeneralized pruritus treated with narrowband UVB.\u201d Int J Dermatol 46(4): 367-370.","DOI":"10.1111\/j.1365-4632.2007.03048.x"},{"key":"123509","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2007.03048.x","DOI":"10.1111\/j.1365-4632.2007.03048.x"},{"key":"123510","doi-asserted-by":"crossref","unstructured":"S\u00e8ne, D. (2018). \u201cSmall fiber neuropathy: Diagnosis, causes, and treatment.\u201d Joint Bone Spine 85(5): 553-559.","DOI":"10.1016\/j.jbspin.2017.11.002"},{"key":"123511","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jbspin.2017.11.002","DOI":"10.1016\/j.jbspin.2017.11.002"},{"key":"123512","doi-asserted-by":"crossref","unstructured":"Serling, S. L. C., K. Leslie and T. Maurer (2011). \u201cApproach to pruritus in the adult HIV-positive patient.\u201d Semin Cutan Med Surg 30(2): 101-106.","DOI":"10.1016\/j.sder.2011.04.004"},{"key":"123513","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.sder.2011.04.004","DOI":"10.1016\/j.sder.2011.04.004"},{"key":"123514","doi-asserted-by":"crossref","unstructured":"Sesi, J. and S. R. Feldman (2024). \u201cComparative efficacy of systemic treatments for atopic dermatitis in adults.\u201d Expert Rev Clin Immunol 20(3): 313-320.","DOI":"10.1080\/1744666X.2023.2291038"},{"key":"123515","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/1744666X.2023.2291038","DOI":"10.1080\/1744666X.2023.2291038"},{"key":"123516","doi-asserted-by":"crossref","unstructured":"Shafie\u2019ei, M., M. Jamali, Z. Akbari, N. Sarvipour, M. Ahmadzade and N. Ahramiyanpour (2022). \u201cCutaneous adverse reactions following COVID-19 vaccinations: A systematic review and meta-analysis.\u201d J Cosmet Dermatol.","DOI":"10.1111\/jocd.15261"},{"key":"123517","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jocd.15261","DOI":"10.1111\/jocd.15261"},{"key":"123518","doi-asserted-by":"crossref","unstructured":"Shahda, S., P. J. Loehrer, R. S. Clark, A. J. Spittler, S. K. Althouse and E. G. Chiorean (2016). \u201cPhase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.\u201d Oncologist 21(6): 664-665.","DOI":"10.1634\/theoncologist.2016-0071"},{"key":"123519","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0071","DOI":"10.1634\/theoncologist.2016-0071"},{"key":"123520","doi-asserted-by":"crossref","unstructured":"Shakiba, M., H. Sanadgol, H. R. Azmoude, M. A. Mashhadi and H. Sharifi (2012). \u201cEffect of sertraline on uremic pruritus improvement in ESRD patients.\u201d Int J Nephrol 2012: 363901.","DOI":"10.1155\/2012\/363901"},{"key":"123521","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2012\/363901","DOI":"10.1155\/2012\/363901"},{"key":"123522","doi-asserted-by":"crossref","unstructured":"Sharma, M., C. Bennett, S. N. Cohen and B. Carter (2014). \u201cH1-antihistamines for chronic spontaneous urticaria.\u201d Cochrane Database Syst Rev(11): CD006137.","DOI":"10.1002\/14651858.CD006137.pub2"},{"key":"123523","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD006137.pub2","DOI":"10.1002\/14651858.CD006137.pub2"},{"key":"123524","doi-asserted-by":"crossref","unstructured":"Shelley, W. B. and E. D. Shelley (1998). \u201cAquadynia: noradrenergic pain induced by bathing and responsive to clonidine.\u201d J Am Acad Dermatol 38(2 Pt 2): 357-358.","DOI":"10.1016\/S0190-9622(98)70583-3"},{"key":"123525","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(98)70583-3","DOI":"10.1016\/S0190-9622(98)70583-3"},{"key":"123526","doi-asserted-by":"crossref","unstructured":"Shelley, W. B., E. D. Shelley and N. Y. Talanin (1996). \u201cSelf-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream.\u201d J Am Acad Dermatol 34(1): 143-144.","DOI":"10.1016\/S0190-9622(96)90864-6"},{"key":"123527","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(96)90864-6","DOI":"10.1016\/S0190-9622(96)90864-6"},{"key":"123528","doi-asserted-by":"crossref","unstructured":"Shi, V. Y., T. Bhutani, L. Fonacier and M. e. a. Deleuran (2022). \u201cPhase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).\u201d J Am Acad Dermatol 87(2): 351-358.","DOI":"10.1016\/j.jaad.2022.04.009"},{"key":"123529","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2022.04.009","DOI":"10.1016\/j.jaad.2022.04.009"},{"key":"123530","doi-asserted-by":"crossref","unstructured":"Shohrati, M., S. M. Davoudi, S. Keshavarz, B. Sadr and A. Tajik (2007). \u201cCetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial.\u201d Cutan Ocul Toxicol 26(3): 249-255.","DOI":"10.1080\/15569520701212340"},{"key":"123531","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/15569520701212340","DOI":"10.1080\/15569520701212340"},{"key":"123532","doi-asserted-by":"crossref","unstructured":"Shohrati, M., A. Tajik, A. A. Harandi, S. M. Davoodi and M. Akmasi (2007). \u201cComparison of hydroxyzine and doxepin in treatment of pruritus due to sulfur mustard.\u201d Skinmed 6(2): 70-72.","DOI":"10.1111\/j.1540-9740.2007.05880.x"},{"key":"123533","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1540-9740.2007.05880.x","DOI":"10.1111\/j.1540-9740.2007.05880.x"},{"key":"123534","doi-asserted-by":"crossref","unstructured":"Sidbury, R., A. Alikhan and L. e. a. Bercovitch (2023). \u201cGuidelines of Care for the Management of Atopic Dermatitis in Adults With Topical Therapies.\u201d J Am Acad Dermatol 89(1): e1-e20.","DOI":"10.1016\/j.jaad.2022.12.029"},{"key":"123535","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2022.12.029","DOI":"10.1016\/j.jaad.2022.12.029"},{"key":"123536","doi-asserted-by":"crossref","unstructured":"Siegel, F. P., J. Tauschert and P. E. Petrides (2013). \u201cAquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients.\u201d Am J Hematol 88: 665-669.","DOI":"10.1002\/ajh.23474"},{"key":"123537","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajh.23474","DOI":"10.1002\/ajh.23474"},{"key":"123538","doi-asserted-by":"crossref","unstructured":"Siegfried, E. C., J. C. Jaworski and A. A. Hebert (2013). \u201cTopical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.\u201d Am J Clin Dermatol 14(3): 163-178.","DOI":"10.1007\/s40257-013-0020-1"},{"key":"123539","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-013-0020-1","DOI":"10.1007\/s40257-013-0020-1"},{"key":"123540","doi-asserted-by":"crossref","unstructured":"Siemens, W., C. Xander, J. J. Meerpohl, S. Buroh, G. Antes, G. Schwarzer and G. Becker (2016). \u201cPharmacological interventions for pruritus in adult palliative care patients.\u201d Cochrane Database Syst Rev 16(11): CD008320.","DOI":"10.1002\/14651858.CD008320.pub3"},{"key":"123541","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD008320.pub3","DOI":"10.1002\/14651858.CD008320.pub3"},{"key":"123542","doi-asserted-by":"crossref","unstructured":"Siepmann, D., T. Lotts, C. Blome, M. Braeutigam, N. Q. Phan, T. Butterfass-Bahloul, M. Augustin, T. A. Luger and S. St\u00e4nder (2013). \u201cEvaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.\u201d Dermatology 227(4): 353-360.","DOI":"10.1159\/000355671"},{"key":"123543","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000355671","DOI":"10.1159\/000355671"},{"key":"123544","doi-asserted-by":"crossref","unstructured":"Siepmann, D., T. A. Luger and S. Stander (2008). \u201cAntipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series.\u201d J Dtsch Dermatol Ges 6(11): 941-946.","DOI":"10.1111\/j.1610-0387.2008.06745.x"},{"key":"123545","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1610-0387.2008.06745.x","DOI":"10.1111\/j.1610-0387.2008.06745.x"},{"key":"123546","doi-asserted-by":"crossref","unstructured":"Silva, S. R., P. C. Viana, N. V. Lugon, M. Hoette, F. Ruzany and J. R. Lugon (1994). \u201cThalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial.\u201d Nephron 67(3): 270-273.","DOI":"10.1159\/000187978"},{"key":"123547","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000187978","DOI":"10.1159\/000187978"},{"key":"123548","doi-asserted-by":"crossref","unstructured":"Silverberg, J. I., E. Guttman-Yassky, D. Tha\u00e7i, A. D. Irvine and e. a. Stein Gold. L. (2023). \u201cTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.\u201d N Engl J Med 388(12): 1080-1091.","DOI":"10.1056\/NEJMoa2206714"},{"key":"123549","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2206714","DOI":"10.1056\/NEJMoa2206714"},{"key":"123550","doi-asserted-by":"crossref","unstructured":"Silverberg, J. I., A. Pinter and G. e. a. Pulka (2020). \u201cPhase 2B Randomized Study of Nemolizumab in Adults With Moderate-to-Severe Atopic Dermatitis and Severe Pruritus.\u201d J Allergy Clin Immunol 145(1): 173-182.","DOI":"10.1016\/j.jaci.2019.08.013"},{"key":"123551","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2019.08.013","DOI":"10.1016\/j.jaci.2019.08.013"},{"key":"123552","doi-asserted-by":"crossref","unstructured":"Silverberg, J. I., E. L. Simpson, J. P. Thyssen and M. e. a. Gooderham (2020). \u201cEfficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.\u201d JAMA Dermatol 156(8): 863-873.","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"123553","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"123554","doi-asserted-by":"crossref","unstructured":"Silverberg, J. I., D. Toth, T. Bieber and A. F. e. a. Alexis (2021). \u201cTralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.\u201d Br J Dermatol 184(3): 450-463.","DOI":"10.1111\/bjd.19573"},{"key":"123555","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19573","DOI":"10.1111\/bjd.19573"},{"key":"123556","doi-asserted-by":"crossref","unstructured":"Silverberg, J. I., A. Wollenberg, A. Reich and D. e. a. Tha\u00e7i (2024). \u201cNemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.\u201d Lancet 404(10451): 445-460.","DOI":"10.1016\/S0140-6736(24)01203-0"},{"key":"123557","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(24)01203-0","DOI":"10.1016\/S0140-6736(24)01203-0"},{"key":"123558","doi-asserted-by":"crossref","unstructured":"Silverberg, J. I., G. Yosipovitch, E. L. Simpson, B. S. Kim, J. J. Wu, L. Eckert, I. Guillemin, Z. Chen, M. Ardeleanu, A. Bansal, M. Kaur, A. B. Rossi, N. M. H. Graham, N. Patel and A. Gadkari (2020). \u201cDupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.\u201d J Am Acad Dermatol 82(6): 1328-1336.","DOI":"10.1016\/j.jaad.2020.02.060"},{"key":"123559","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.02.060","DOI":"10.1016\/j.jaad.2020.02.060"},{"key":"123560","doi-asserted-by":"crossref","unstructured":"Simon, D. (2011). \u201cSystemic therapy of atopic dermatitis in children and adults.\u201d Curr Probl Dermatol 41: 156-164.","DOI":"10.1159\/000323309"},{"key":"123561","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000323309","DOI":"10.1159\/000323309"},{"key":"123562","doi-asserted-by":"crossref","unstructured":"Simon, D. and T. Bieber (2014). \u201cSystemic therapy for atopic dermatitis.\u201d Allergy 69(1): 46-55.","DOI":"10.1111\/all.12339"},{"key":"123563","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.12339","DOI":"10.1111\/all.12339"},{"key":"123564","doi-asserted-by":"crossref","unstructured":"Simpson, D. and S. Noble (2005). \u201cTacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions.\u201d Drugs 65(6): 827-858.","DOI":"10.2165\/00003495-200565060-00011"},{"key":"123565","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00003495-200565060-00011","DOI":"10.2165\/00003495-200565060-00011"},{"key":"123566","doi-asserted-by":"crossref","unstructured":"Simpson, E. L., T. Bieber, E. Guttman-Yassky, L. A. Beck and A. Blauvelt, et al. (2016). \u201cTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.\u201d N Engl J Med 375(24): 2335-2348.","DOI":"10.1056\/NEJMoa1610020"},{"key":"123567","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1610020","DOI":"10.1056\/NEJMoa1610020"},{"key":"123568","doi-asserted-by":"crossref","unstructured":"Simpson, E. L., L. F. Eichenfield, J. Alonso-Llamazares and Z. D. e. a. Draelos (2024). \u201cRoflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.\u201d JAMA Dermatol 160(11): 1161-1170.","DOI":"10.1001\/jamadermatol.2024.3121"},{"key":"123569","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.3121","DOI":"10.1001\/jamadermatol.2024.3121"},{"key":"123570","doi-asserted-by":"crossref","unstructured":"Simpson, E. L., M. Gooderham, A. Wollenberg and S. e. a. Weidinger (2023). \u201cEfficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).\u201d JAMA Dermatol 159(2): 182-191.","DOI":"10.1001\/jamadermatol.2022.5534"},{"key":"123571","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.5534","DOI":"10.1001\/jamadermatol.2022.5534"},{"key":"123572","doi-asserted-by":"crossref","unstructured":"Simpson, E. L., J.-P. Lacour, L. Spelman, R. Galimberti and L. F. Eichenfield, et al. (2020). \u201cBaricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.\u201d Br J Dermatol 183(2): 242-255.","DOI":"10.1111\/bjd.18898"},{"key":"123573","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18898","DOI":"10.1111\/bjd.18898"},{"key":"123574","doi-asserted-by":"crossref","unstructured":"Simpson, E. L., A. S. Paller, E. C. Siegfried and M. e. a. Boguniewicz (2020). \u201cEfficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.\u201d JAMA Dermatol 156(1): 44-56.","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"123575","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"123576","doi-asserted-by":"crossref","unstructured":"Singer, E. M., D. B. Shin, L. A. Nattkemper, B. M. Benoit, R. S. Klein, C. A. Didigu, A. Q. Loren, T. Dentchev, M. Wysocka, G. Yosipovitch and A. H. Rook (2013). \u201cIL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus.\u201d J Invest Dermatol 133(12): 2783-2785.","DOI":"10.1038\/jid.2013.227"},{"key":"123577","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2013.227","DOI":"10.1038\/jid.2013.227"},{"key":"123578","doi-asserted-by":"crossref","unstructured":"Singh, F. and D. Rudikoff (2003). \u201cHIV-associated pruritus: etiology and management.\u201d Am J Clin Dermatol 4(3): 177-188.","DOI":"10.2165\/00128071-200304030-00004"},{"key":"123579","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00128071-200304030-00004","DOI":"10.2165\/00128071-200304030-00004"},{"key":"123580","doi-asserted-by":"crossref","unstructured":"Singleton, H., A. Hodder, O. Almilaji and S. J. e. a. Ersser (2024). \u201cEducational and psychological interventions for managing atopic dermatitis (eczema).\u201d Cochrane Database Syst Rev 2024(8): CD014932.","DOI":"10.1002\/14651858.CD014932.pub2"},{"key":"123581","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/14651858.CD014932.pub2","DOI":"10.1002\/14651858.CD014932.pub2"},{"key":"123582","doi-asserted-by":"crossref","unstructured":"Sinikumpu, S.-P., J. Jokelainen, K. Tasanen, M. Timonen and L. Huilaja (2023). \u201cAssociation between Pruritus and Psychosocial Well-being: A Population-based Study among 6,809 Subjects.\u201d Acta Derm Venereol 103: adv00837.","DOI":"10.2340\/actadv.v103.2922"},{"key":"123583","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v103.2922","DOI":"10.2340\/actadv.v103.2922"},{"key":"123584","doi-asserted-by":"crossref","unstructured":"Smith, C. H., Z. Z. N. Yiu, T. Bale and A. D. e. a. Burden (2024). \u201cBritish Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update.\u201d Br J Dermatol 190(2): 270-272.","DOI":"10.1093\/bjd\/ljad347"},{"key":"123585","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljad347","DOI":"10.1093\/bjd\/ljad347"},{"key":"123586","doi-asserted-by":"crossref","unstructured":"Sobell, J. M., P. Foley, D. Toth, U. Mrowietz, G. Girolomoni, J. Goncalves, R. M. Day, R. Chen and G. Yosipovitch (2016). \u201cEffects of apremilast on pruritus and skin discomfort\/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis.\u201d Acta Derm Venereol 96(4): 514-520.","DOI":"10.2340\/00015555-2360"},{"key":"123587","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2360","DOI":"10.2340\/00015555-2360"},{"key":"123588","doi-asserted-by":"crossref","unstructured":"Sommer, F., P. Hensen, B. Bockenholt, D. Metze, T. A. Luger and S. Stander (2007). \u201cUnderlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study.\u201d Acta Derm Venereol 87(6): 510-516.","DOI":"10.2340\/00015555-0320"},{"key":"123589","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0320","DOI":"10.2340\/00015555-0320"},{"key":"123590","doi-asserted-by":"crossref","unstructured":"Spring, P., I. Gschwind and M. Gilliet (2014). \u201cPrurigo nodularis: retrospective study of 13 cases managed with methotrexate.\u201d Clin Exp Dermatol 39(4): 468-473.","DOI":"10.1111\/ced.12365"},{"key":"123591","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.12365","DOI":"10.1111\/ced.12365"},{"key":"123592","doi-asserted-by":"crossref","unstructured":"Staab, D., T. L. Diepgen, M. Fartasch, J. Kupfer, T. Lob-Corzilius, J. Ring, S. Scheewe, R. Scheidt, G. Schmid-Ott, C. Schnopp, R. Szczepanski, T. Werfel, M. Wittenmeier, U. Wahn and U. Gieler (2006). \u201cAge related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial.\u201d BMJ 332(7547): 933-938.","DOI":"10.1136\/bmj.332.7547.933"},{"key":"123593","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.332.7547.933","DOI":"10.1136\/bmj.332.7547.933"},{"key":"123594","doi-asserted-by":"crossref","unstructured":"Staab, D., U. von Rueden, R. Kehrt, M. Erhart, K. Wenninger, P. Kamtsiuris and U. Wahn (2002). \u201cEvaluation of a parental training program for the management of childhood atopic dermatitis.\u201d Pediatr Allergy Immunol 13(2): 84-90.","DOI":"10.1034\/j.1399-3038.2002.01005.x"},{"key":"123595","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1034\/j.1399-3038.2002.01005.x","DOI":"10.1034\/j.1399-3038.2002.01005.x"},{"key":"123596","doi-asserted-by":"crossref","unstructured":"Stahle-Backdahl, M., O. Hagermark, L. E. Lins, O. Torring, M. Hilliges and O. Johansson (1989). \u201cExperimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus.\u201d J Intern Med 225(6): 411-415.","DOI":"10.1111\/j.1365-2796.1989.tb00104.x"},{"key":"123597","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2796.1989.tb00104.x","DOI":"10.1111\/j.1365-2796.1989.tb00104.x"},{"key":"123598","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., M. Augustin, A. Reich, C. Blome, T. Ebata, N. Quan Phan and J. C. Szepietowski (2013). \u201cPruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials.\u201d Acta Derm Venereol 93(5): 509-514.","DOI":"10.2340\/00015555-1620"},{"key":"123599","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1620","DOI":"10.2340\/00015555-1620"},{"key":"123600","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., M. Augustin, D. Roggenkamp, C. Blome, T. Heitkemper, A. C. Worthmann and G. Neufang (2017). \u201cNovel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double-blind, controlled, pilot study in dry skin.\u201d J Eur Acad Dermatol Venereol 31(6): 1064-1068.","DOI":"10.1111\/jdv.14041"},{"key":"123601","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14041","DOI":"10.1111\/jdv.14041"},{"key":"123602","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., B. Bockenholt, F. Schurmeyer-Horst, C. Weishaupt, G. Heuft, T. A. Luger and G. Schneider (2009). \u201cTreatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.\u201d Acta Derm Venereol 89(1): 45-51.","DOI":"10.2340\/00015555-0553"},{"key":"123603","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0553","DOI":"10.2340\/00015555-0553"},{"key":"123604","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., M. Ketz, D. Akumo, N. Kossack, M. Pignot, R. Chavda and S. Gabriel (2024). \u201cComorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: A real-world evidence claims data study.\u201d J Eur Acad Dermatol Venereol 38(5): 883-894.","DOI":"10.1111\/jdv.19700"},{"key":"123605","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19700","DOI":"10.1111\/jdv.19700"},{"key":"123606","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., P. Kwon, J. Hirman, A. J. Perlman, E. Weisshaar, M. Metz, T. A. Luger and T.-S. Group (2019). \u201cSerlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.\u201d J Am Acad Dermatol 80(5): 1395-1402.","DOI":"10.1016\/j.jaad.2019.01.052"},{"key":"123607","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.01.052","DOI":"10.1016\/j.jaad.2019.01.052"},{"key":"123608","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., T. Luger and D. Metze (2001). \u201cTreatment of prurigo nodularis with topical capsaicin.\u201d J Am Acad Dermatol 44(3): 471-478.","DOI":"10.1067\/mjd.2001.110059"},{"key":"123609","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2001.110059","DOI":"10.1067\/mjd.2001.110059"},{"key":"123610","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S. and T. A. Luger (2003). \u201c[Antipruritic effects of pimecrolimus and tacrolimus].\u201d Hautarzt 54(5): 413-417.","DOI":"10.1007\/s00105-003-0521-6"},{"key":"123611","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-003-0521-6","DOI":"10.1007\/s00105-003-0521-6"},{"key":"123612","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S. and T. A. Luger (2015). \u201cNK-1 antagonists and itch.\u201d Handb Exp Pharmacol 226: 237\u2013255.","DOI":"10.1007\/978-3-662-44605-8_14"},{"key":"123613","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/978-3-662-44605-8_14","DOI":"10.1007\/978-3-662-44605-8_14"},{"key":"123614","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., M. P. Pereira, T. Berger, C. Zeidler, M. Augustin, S. Bobko, E. Brenaut, S. C. Chen, S. Chisolm, F. J. Dalgard, J. Elberling, S. B. Elmariah, A. W. M. Evers, S. Garcovich, M. Goncalo, J. A. Halvorsen, B. S. Kim, J. Kupfer, S. Kwatra, J. Lambert, F. J. Legat, E. A. Lerner, T. A. Leslie, L. L\u00f6nndahl, A. Lvov, M. Metz, L. Misery, E. Papadavid, N. N. Potekaev, A. Reich, E. Savk, G. Schneider, C. Schut, E. Serra-Baldrich, H. F. St\u00e4nder, M. Streit, J. C. Szepietowski, M. D. Tharp, J. Wallengren, A. Nast, E. Weisshaar and G. Yosipovitch (2020). \u201cIFSI-Guideline on Chronic Prurigo including Prurigo nodularis.\u201d ITCH 5: e42.","DOI":"10.1097\/itx.0000000000000042"},{"key":"123615","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/itx.0000000000000042","DOI":"10.1097\/itx.0000000000000042"},{"key":"123616","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., M. P. Pereira and C. e. a. Zeidler (2024). \u201cEADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions.\u201d J Eur Acad Dermatol Venereol 38: 1687\u20131693.","DOI":"10.1111\/jdv.20102"},{"key":"123617","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.20102","DOI":"10.1111\/jdv.20102"},{"key":"123618","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., E. Pogatzki-Zahn, A. Stumpf, F. Fritz, B. Pfleiderer and A. Ritzkat, et al. (2015). \u201cFacing the challenges of chronic pruritus: a report from a multi-disciplinary medical itch centre in Germany.\u201d Acta Derm Venereol 95(3): 266\u2013271.","DOI":"10.2340\/00015555-1949"},{"key":"123619","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1949","DOI":"10.2340\/00015555-1949"},{"key":"123620","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., H. W. Reinhardt and T. A. Luger (2006). \u201c[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus].\u201d Hautarzt 57(9): 801\u2013807.","DOI":"10.1007\/s00105-006-1180-1"},{"key":"123621","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-006-1180-1","DOI":"10.1007\/s00105-006-1180-1"},{"key":"123622","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., M. Schmelz, E. Lerner, et al. (2025). A multidisciplinary Delphi consensus on the modern definition of pruritus: Sensation and disease. J Eur Acad Dermatol Venereol. Published online July 17, 2025.","DOI":"10.1111\/jdv.20851"},{"key":"123623","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.20851","DOI":"10.1111\/jdv.20851"},{"key":"123624","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., I. Sch\u00e4fer, N. Q. Phan, C. Blome, K. Herberger, H. Heigel and M. Augustin (2010). \u201cPrevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730.\u201d Dermatology 221(3): 229\u2013235.","DOI":"10.1159\/000319862"},{"key":"123625","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000319862","DOI":"10.1159\/000319862"},{"key":"123626","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., F. Sch\u00fcrmeyer-Horst, T. A. Luger and E. Weisshaar (2006). \u201cTreatment of pruritic diseases with topical calcineurin inhibitors.\u201d Ther Clin Risk Manag 2(2): 213\u2013218.","DOI":"10.2147\/tcrm.2006.2.2.213"},{"key":"123627","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/tcrm.2006.2.2.213","DOI":"10.2147\/tcrm.2006.2.2.213"},{"key":"123628","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., D. Siepmann, I. Herrgott, C. Sunderk\u00f6tter and T. A. Luger (2010). \u201cTargeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.\u201d PLoS One 5(6): e10968.","DOI":"10.1371\/journal.pone.0010968"},{"key":"123629","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0010968","DOI":"10.1371\/journal.pone.0010968"},{"key":"123630","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., A. Stumpf, N. Osada, S. Wilp, E. Chatzigeorgakidis and B. Pfleiderer (2013). \u201cGender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden.\u201d Br J Dermatol 168(6): 1273\u20131280.","DOI":"10.1111\/bjd.12267"},{"key":"123631","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.12267","DOI":"10.1111\/bjd.12267"},{"key":"123632","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., E. Weisshaar, T. Mettang, M. Streit, U. Darsow, G. Schneider, D. Metze and M. Schmelz (2006). \u201c[Clinical classification of chronic pruritus. Interdisciplinary consensus proposal for a diagnostic algorithm].\u201d Hautarzt 57(5): 390\u2013394.","DOI":"10.1007\/s00105-006-1122-y"},{"key":"123633","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-006-1122-y","DOI":"10.1007\/s00105-006-1122-y"},{"key":"123634","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., E. Weisshaar, T. Mettang, J. C. Szepietowski, E. Carstens, A. Ikoma, N. V. Bergasa, U. Gieler, L. Misery, J. Wallengren, U. Darsow, M. Streit, D. Metze, T. A. Luger, M. W. Greaves, M. Schmelz, G. Yosipovitch and J. D. Bernhard (2007). \u201cClinical classification of itch: a position paper of the International Forum for the Study of Itch.\u201d Acta Derm Venereol 87(4): 291\u2013294.","DOI":"10.2340\/00015555-0305"},{"key":"123635","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0305","DOI":"10.2340\/00015555-0305"},{"key":"123636","doi-asserted-by":"crossref","unstructured":"St\u00e4nder, S., G. Yosipovitch, F. J. Legat, J.-P. Lacour and C. Paul, et al. (2020). \u201cTrial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.\u201d N Engl J Med 382(8): 706\u2013716.","DOI":"10.1056\/NEJMoa1908316"},{"key":"123637","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1908316","DOI":"10.1056\/NEJMoa1908316"},{"key":"123638","doi-asserted-by":"crossref","unstructured":"Stangier, U., A. Ehlers and U. Gieler (2004). \u201cPredicting long-term outcome in group treatment of atopic dermatitis.\u201d Psychother Psychosom 73(5): 293\u2013301.","DOI":"10.1159\/000078846"},{"key":"123639","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000078846","DOI":"10.1159\/000078846"},{"key":"123640","doi-asserted-by":"crossref","unstructured":"Staubach, P., A. Peveling-Oberhag, B. M. Lang, S. Zimmer, A. Sohn and C. Mann (2020). \u201cSevere chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review.\u201d J Dermatolog Treat 26: 1\u20134.","DOI":"10.1080\/09546634.2020.1782326"},{"key":"123641","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2020.1782326","DOI":"10.1080\/09546634.2020.1782326"},{"key":"123642","unstructured":"St\u00e4ubli, M. (1981). \u201cPruritus-a little known iron-deficiency symptom.\u201d Schweiz Med Wochenschr 111(38): 1394\u20131398."},{"key":"123643","doi-asserted-by":"crossref","unstructured":"Stefaniak, A. A., R. Bia\u0142ynicki-birula, P. K. Krajewski, \u0141. Matusiak, M. Goldust and J. C. Szepietowski (2020). \u201cItch in the era of COVID-19 pandemic: An unfolding scenario.\u201d Dermatol Ther 33(5): e13477.","DOI":"10.1111\/dth.13477"},{"key":"123644","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13477","DOI":"10.1111\/dth.13477"},{"key":"123645","doi-asserted-by":"crossref","unstructured":"Stefaniak, A. A., M. P. Pereira, C. Zeidler and S. St\u00e4nder (2022). \u201cPruritus in Pregnancy.\u201d Am J Clin Dermatol 23(2): 231\u2013246.","DOI":"10.1007\/s40257-021-00668-7"},{"key":"123646","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-021-00668-7","DOI":"10.1007\/s40257-021-00668-7"},{"key":"123647","doi-asserted-by":"crossref","unstructured":"Stefaniak, A. A., A. Zubkiewicz-Kucharska, L. Matusiak, A. Noczynska and J. C. Szepietowski (2020). \u201cItch in children with type 1 diabetes: A cross sectional study.\u201d Dermatol Ther (Heidelb) 10(4): 745\u2013756.","DOI":"10.1007\/s13555-020-00403-w"},{"key":"123648","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-020-00403-w","DOI":"10.1007\/s13555-020-00403-w"},{"key":"123649","doi-asserted-by":"crossref","unstructured":"Steffens, E., M. Kaplan and E. Weisshaar (2023). \u201c[An unexpected discovery in a patient suffering from chronic prurigo].\u201d Dermatolgie (Heidelb) 74(4): 286\u2013288.","DOI":"10.1007\/s00105-023-05131-8"},{"key":"123650","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-023-05131-8","DOI":"10.1007\/s00105-023-05131-8"},{"key":"123651","doi-asserted-by":"crossref","unstructured":"Stein Gold, L., K. Papp, D. Pariser and L. e. a. Green (2022). \u201cEfficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.\u201d J Am Acad Dermatol 86(1): 77\u201385.","DOI":"10.1016\/j.jaad.2021.07.040"},{"key":"123652","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2021.07.040","DOI":"10.1016\/j.jaad.2021.07.040"},{"key":"123653","doi-asserted-by":"crossref","unstructured":"Steinhoff, M., F. Cevikbas, A. Ikoma and T. G. Berger (2011). \u201cPruritus: management algorithms and experimental therapies.\u201d Semin Cutan Med Surg 30(2): 127\u2013137.","DOI":"10.1016\/j.sder.2011.05.001"},{"key":"123654","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.sder.2011.05.001","DOI":"10.1016\/j.sder.2011.05.001"},{"key":"123655","doi-asserted-by":"crossref","unstructured":"Steinhoff, M., A. L. Oaklander, I. L. Szab\u00f3, S. St\u00e4nder and M. Schmelz (2019). \u201cNeuropathic itch.\u201d Pain 160(Suppl 1): S11-S16.","DOI":"10.1097\/j.pain.0000000000001551"},{"key":"123656","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/j.pain.0000000000001551","DOI":"10.1097\/j.pain.0000000000001551"},{"key":"123657","doi-asserted-by":"crossref","unstructured":"Steinhoff, M., M. Schmelz, I. L. Szab\u00f3 and A. L. Oaklander (2018). \u201cClinical presentation, management, and pathophysiology of neuropathic itch.\u201d Lancet Neurol 17(8): 709\u2013720.","DOI":"10.1016\/S1474-4422(18)30217-5"},{"key":"123658","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1474-4422(18)30217-5","DOI":"10.1016\/S1474-4422(18)30217-5"},{"key":"123659","doi-asserted-by":"crossref","unstructured":"Steinke, S., C. Zeidler, C. Riepe, P. Bruland, I. Soto-Rey, M. Storck, M. Augustin, S. Bobko, S. Garcovich, F. J. Legat, A. Lvov, L. Misery, N. Osada, A. Reich, E. \u015eavk, E. Serra-Baldrich, M. Streit, J. C. Szepietowski, W. Weger, M. Dugas and S. St\u00e4nder (2018). \u201cHumanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.\u201d J Am Acad Dermatol 79(3): 457\u2013463.e455.","DOI":"10.1016\/j.jaad.2018.04.044"},{"key":"123660","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.04.044","DOI":"10.1016\/j.jaad.2018.04.044"},{"key":"123661","doi-asserted-by":"crossref","unstructured":"Steinman, H. K. and M. W. Greaves (1985). \u201cAquagenic pruritus.\u201d J Am Acad Dermatol 13(1): 91\u201396.","DOI":"10.1016\/S0190-9622(85)70149-1"},{"key":"123662","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(85)70149-1","DOI":"10.1016\/S0190-9622(85)70149-1"},{"key":"123663","doi-asserted-by":"crossref","unstructured":"Stellon, A. (2002). \u201cNeurogenic pruritus: an unrecognised problem? A retrospective case series of treatment by acupuncture.\u201d Acupunct Med 20(4): 186\u2013190.","DOI":"10.1136\/aim.20.4.186"},{"key":"123664","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/aim.20.4.186","DOI":"10.1136\/aim.20.4.186"},{"key":"123665","doi-asserted-by":"crossref","unstructured":"Stern, R. S. and P. F. u. Study (2001). \u201cThe risk of melanoma in association with long-term exposure to PUVA.\u201d J Am Acad Dermatol 44(5): 755\u2013761.","DOI":"10.1067\/mjd.2001.114576"},{"key":"123666","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1067\/mjd.2001.114576","DOI":"10.1067\/mjd.2001.114576"},{"key":"123667","doi-asserted-by":"crossref","unstructured":"Stevens, M. T. and A. M. Edwards (2015). \u201cThe effect of 4% sodium cromoglicate cutaneous emulsion compared to vehicle in atopic dermatitis in children - A meta-analysis of total SCORAD scores.\u201d J Dermatolog Treat 26(3): 284\u2013290.","DOI":"10.3109\/09546634.2014.933766"},{"key":"123668","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/09546634.2014.933766","DOI":"10.3109\/09546634.2014.933766"},{"key":"123669","doi-asserted-by":"crossref","unstructured":"Stewart, K. M. A. (2010). \u201cClinical care of vulvar pruritus, with emphasis on one common cause, lichen simplex chronicus.\u201d Dermatol Clin 28(4): 669\u2013680.","DOI":"10.1016\/j.det.2010.08.004"},{"key":"123670","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.det.2010.08.004","DOI":"10.1016\/j.det.2010.08.004"},{"key":"123671","doi-asserted-by":"crossref","unstructured":"Stockenhuber, F., G. Sunder-Plassmann and P. Balcke (1987). \u201cIncreased plasma histamine levels in chronic renal failure.\u201d N Engl J Med 317(6): 386.","DOI":"10.1056\/NEJM198708063170614"},{"key":"123672","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJM198708063170614","DOI":"10.1056\/NEJM198708063170614"},{"key":"123673","doi-asserted-by":"crossref","unstructured":"Storck, M., S. Sandmann, P. Bruland, M. P. Pereira, S. Steinke, C. Riepe, I. Soto-Rey, S. Garcovich, M. Augustin, C. Blome, S. Bobko and F. J. Legat, et al. (2021). \u201cPruritus Intensity Scales across Europe: a prospective validation study.\u201d J Eur Acad Dermatol Venereol 35(5): 1176\u20131185.","DOI":"10.1111\/jdv.17111"},{"key":"123674","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17111","DOI":"10.1111\/jdv.17111"},{"key":"123675","doi-asserted-by":"crossref","unstructured":"Streit, M., V. Von Felbert and L. R. Braathen (2002). \u201c[Pruritus sine marteria. Pathophysiology, diagnostic assessment and therapy].\u201d Hautarzt 53(12): 830\u2013849.","DOI":"10.1007\/s00105-002-0455-4"},{"key":"123676","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-002-0455-4","DOI":"10.1007\/s00105-002-0455-4"},{"key":"123677","doi-asserted-by":"crossref","unstructured":"Strober, B., B. Sigurgeirsson, G. Popp, R. Sinclair, J. Krell, S. Stonkus, M. Septe, B. E. Elewski, A. B. Gottlieb, Y. Zhao, M. H. Tran, A. Karpov, L. D. McLeod, M. Mordin, C. Papavassilis and J. Nyirady, Lebwohl, M. (2016). \u201cSecukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.\u201d Int J Dermatol 55(4): 401\u2013407.","DOI":"10.1111\/ijd.13236"},{"key":"123678","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ijd.13236","DOI":"10.1111\/ijd.13236"},{"key":"123679","doi-asserted-by":"crossref","unstructured":"Stumpf, A., M. Burgmer, G. Schneider, G. Heuft and M. e. e. Schmelz (2013). \u201cSex differences in itch perception and modulation by distraction--an FMRI pilot study in healthy volunteers.\u201d PLoS One 8(11): e79123.","DOI":"10.1371\/journal.pone.0079123"},{"key":"123680","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0079123","DOI":"10.1371\/journal.pone.0079123"},{"key":"123681","doi-asserted-by":"crossref","unstructured":"Stumpf, A. and S. St\u00e4nder (2013). \u201cNeuropathic itch: diagnosis and management.\u201d Dermatol Ther 26(2): 104\u2013109.","DOI":"10.1111\/dth.12028"},{"key":"123682","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.12028","DOI":"10.1111\/dth.12028"},{"key":"123683","doi-asserted-by":"crossref","unstructured":"Su, L. N., X. Xu, L. Tang, N. Yu and Y. F. Ding (2016). \u201cUVA1 phototherapy in the treatment of palmoplantar pustulosis: a pilot prospective study.\u201d Lasers Med Sci 31(8): 1641\u20131643.","DOI":"10.1007\/s10103-016-2031-7"},{"key":"123684","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10103-016-2031-7","DOI":"10.1007\/s10103-016-2031-7"},{"key":"123685","doi-asserted-by":"crossref","unstructured":"Sun, T., X. Zhang, C. Hou, S. Yu, Y. Zhang, Z. Yu, L. Kong, C. Liu, L. Feng, D. Wang and G. Ni (2022). \u201cCold Plasma Irradiation Attenuates Atopic Dermatitis via Enhancing HIF-1\u03b1-Induced MANF Transcription Expression.\u201d Front Immunol 14(13): 941219.","DOI":"10.3389\/fimmu.2022.941219"},{"key":"123686","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2022.941219","DOI":"10.3389\/fimmu.2022.941219"},{"key":"123687","doi-asserted-by":"crossref","unstructured":"Suys, E. (2012). \u201cRandomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani.\u201d J Am Acad Dermatol 66(2): 327\u2013328.","DOI":"10.1016\/j.jaad.2011.05.024"},{"key":"123688","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2011.05.024","DOI":"10.1016\/j.jaad.2011.05.024"},{"key":"123689","unstructured":"Swanbeck, G. and G. Rajka (1970). \u201cAntipruritic effect of urea solutions. An experimental and clinical study.\u201d Acta Derm Venereol 50(3): 225\u2013227."},{"key":"123690","doi-asserted-by":"crossref","unstructured":"Swerlick, R. A. (1985). \u201cPhotochemotherapy treatment of pruritus associated with polycythemia vera.\u201d J Am Acad Dermatol 13(4): 675\u2013677.","DOI":"10.1016\/S0190-9622(85)80459-X"},{"key":"123691","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(85)80459-X","DOI":"10.1016\/S0190-9622(85)80459-X"},{"key":"123692","doi-asserted-by":"crossref","unstructured":"Symvoulakis, E. K., K. Krasagakis, I. D. Komninos, I. Kastrinakis, I. Lyronis, A. Philalithis and A. D. Tosca (2006). \u201cPrimary care and pattern of skin diseases in a Mediterranean island.\u201d BMC Fam Pract 7: 6.","DOI":"10.1186\/1471-2296-7-6"},{"key":"123693","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1471-2296-7\u20136","DOI":"10.1186\/1471-2296-7-6"},{"key":"123694","doi-asserted-by":"crossref","unstructured":"Szeimies, R. M., W. Stolz, U. Wlotzke, H. C. Korting and M. Landthaler (1994). \u201cSuccessful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin.\u201d Br J Dermatol 131(3): 380\u2013382.","DOI":"10.1111\/j.1365-2133.1994.tb08529.x"},{"key":"123695","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1994.tb08529.x","DOI":"10.1111\/j.1365-2133.1994.tb08529.x"},{"key":"123696","doi-asserted-by":"crossref","unstructured":"Szepietowski, J. C., \u0141. Matusiak, M. Szepietowska, P. K. Krajewski and R. Bia\u0142ynicki-Birula (2020). \u201cFace Mask-induced Itch: A Self-questionnaire Study of 2,315 Responders During the COVID-19 Pandemic.\u201d Acta Derm Venereol 100(10): adv00152.","DOI":"10.2340\/00015555-3536"},{"key":"123697","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3536","DOI":"10.2340\/00015555-3536"},{"key":"123698","doi-asserted-by":"crossref","unstructured":"Szepietowski, J. C., A. Morita and T. Tsuji (2002). \u201cUltraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus.\u201d Med Hypotheses 58(2): 167\u2013170.","DOI":"10.1054\/mehy.2001.1505"},{"key":"123699","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1054\/mehy.2001.1505","DOI":"10.1054\/mehy.2001.1505"},{"key":"123700","doi-asserted-by":"crossref","unstructured":"Szepietowski, J. C. and R. Reszke (2016). \u201cPsychogenic Itch Management.\u201d Curr Probl Dermatol 50: 124\u2013132.","DOI":"10.1159\/000446055"},{"key":"123701","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000446055","DOI":"10.1159\/000446055"},{"key":"123702","unstructured":"Szepietowski, J. C., T. Szepietowski and A. Reich (2005). \u201cEfficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study.\u201d Acta Dermatovenerol Croat 13(2): 97\u2013103."},{"key":"123703","doi-asserted-by":"crossref","unstructured":"Szolcsanyi, J. (2004). \u201cForty years in capsaicin research for sensory pharmacology and physiology.\u201d Neuropeptides 38(6): 377\u2013384.","DOI":"10.1016\/j.npep.2004.07.005"},{"key":"123704","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.npep.2004.07.005","DOI":"10.1016\/j.npep.2004.07.005"},{"key":"123705","doi-asserted-by":"crossref","unstructured":"Szzech, J., A. Wiatrowski, L. Hirnle and A. Reich (2017). \u201cPrevalence and Relevance of Pruritus in Pregnancy.\u201d Biomed Res Int 2017.","DOI":"10.1155\/2017\/4238139"},{"key":"123706","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2017\/4238139","DOI":"10.1155\/2017\/4238139"},{"key":"123707","doi-asserted-by":"crossref","unstructured":"Tada, Y., R. Watanabe, H. Noma, Y. Kanai, T. Nomura and K. Kaneko (2020). \u201cShort-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.\u201d J Dermatol Sci 99(1): 53\u201361.","DOI":"10.1016\/j.jdermsci.2020.06.003"},{"key":"123708","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.06.003","DOI":"10.1016\/j.jdermsci.2020.06.003"},{"key":"123709","doi-asserted-by":"crossref","unstructured":"Taghaddos, D., I. Savinova and M. Abu-Hilal (2024). \u201cClinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study.\u201d J Clin Med Surg 28(2): 141\u2013145.","DOI":"10.1177\/12034754241227808"},{"key":"123710","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/12034754241227808","DOI":"10.1177\/12034754241227808"},{"key":"123711","doi-asserted-by":"crossref","unstructured":"Tang, E. C., E. Vittinghoff, P. L. Anderson and S. E. e. a. Cohen (2018). \u201cChanges in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate\/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.\u201d J Acquir Immune Defic Syndr 77(2): 193\u2013198.","DOI":"10.1097\/QAI.0000000000001566"},{"key":"123712","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/QAI.0000000000001566","DOI":"10.1097\/QAI.0000000000001566"},{"key":"123713","doi-asserted-by":"crossref","unstructured":"Tarng, D. C., Y. L. Cho, H. N. Liu and T. P. Huang (1996). \u201cHemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream.\u201d Nephron 72(4): 617\u2013622.","DOI":"10.1159\/000188949"},{"key":"123714","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000188949","DOI":"10.1159\/000188949"},{"key":"123715","doi-asserted-by":"crossref","unstructured":"Taylor, P. C., G. Dolan, J. P. Ng, B. Paul, R. Collin and J. T. Reilly (1996). \u201cEfficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data.\u201d Br J Haematol 92(1): 55\u201359.","DOI":"10.1046\/j.1365-2141.1996.00303.x"},{"key":"123716","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2141.1996.00303.x","DOI":"10.1046\/j.1365-2141.1996.00303.x"},{"key":"123717","doi-asserted-by":"crossref","unstructured":"Tefferi, A. and R. Fonseca (2002). \u201cSelective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus.\u201d Blood 99(7): 2627.","DOI":"10.1182\/blood.V99.7.2627"},{"key":"123718","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood.V99.7.2627","DOI":"10.1182\/blood.V99.7.2627"},{"key":"123719","doi-asserted-by":"crossref","unstructured":"Tefferi, A., A. M. Vannucchi and T. Barbui (2018). \u201cPolycythemia vera treatment algorithm 2018.\u201d Blood Cancer Journal 8(1): 3.","DOI":"10.1038\/s41408-017-0042-7"},{"key":"123720","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41408-017-0042-7","DOI":"10.1038\/s41408-017-0042-7"},{"key":"123721","doi-asserted-by":"crossref","unstructured":"Teofoli, P., O. De Pita, A. Frezzolini and T. Lotti (1998). \u201cAntipruritic effect of oral cyclosporin A in essential senile pruritus.\u201d Acta Derm Venereol 78(3): 232.","DOI":"10.1080\/000155598441675"},{"key":"123722","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/000155598441675","DOI":"10.1080\/000155598441675"},{"key":"123723","doi-asserted-by":"crossref","unstructured":"Terg, R., E. Coronel, J. Sorda, A. E. Munoz and J. Findor (2002). \u201cEfficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.\u201d J Hepatol 37(6): 717\u2013722.","DOI":"10.1016\/S0168-8278(02)00318-5"},{"key":"123724","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0168-8278(02)00318-5","DOI":"10.1016\/S0168-8278(02)00318-5"},{"key":"123725","doi-asserted-by":"crossref","unstructured":"Tey, H. L. and G. Yosipovitch (2011). \u201cTargeted treatment of pruritus - a look into the future.\u201d Br J Dermatol 165(1): 5\u201317.","DOI":"10.1111\/j.1365-2133.2011.10217.x"},{"key":"123726","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10217.x","DOI":"10.1111\/j.1365-2133.2011.10217.x"},{"key":"123727","doi-asserted-by":"crossref","unstructured":"Tha\u00e7i, D., A. M. Soliman, K. Eyerich and A. e. a. Pinter (2021). \u201cPatient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-na\u00efve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.\u201d J Eur Acad Dermatol Venereol 35(8): 1686\u20131691.","DOI":"10.1111\/jdv.17109"},{"key":"123728","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17109","DOI":"10.1111\/jdv.17109"},{"key":"123729","doi-asserted-by":"crossref","unstructured":"Thaipisuttikul, Y. (1998). \u201cPruritic skin diseases in the elderly.\u201d J Dermatol 25(3): 153\u2013157.","DOI":"10.1111\/j.1346-8138.1998.tb02371.x"},{"key":"123730","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1346\u20138138.1998.tb02371.x","DOI":"10.1111\/j.1346-8138.1998.tb02371.x"},{"key":"123731","doi-asserted-by":"crossref","unstructured":"Thangam, E. B., E. A. Jemina, H. Singh, M. S. Baig, M. Khan, C. B. Mathias, M. K. Chuch and R. Saluja (2018). \u201cThe Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets.\u201d Front Immunol 9(1873).","DOI":"10.3389\/fimmu.2018.01873"},{"key":"123732","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2018.01873","DOI":"10.3389\/fimmu.2018.01873"},{"key":"123733","doi-asserted-by":"crossref","unstructured":"Th\u00e9baut, A., D. Habes, F. Gottrand, C. Rivet, J. Cohen, D. Debray, E. Jacquemin and E. Gonzales (2016). \u201cSertraline as an additional treatment for cholestatic pruritus in children.\u201d J Pediatr Gastroenterol Nutr.","DOI":"10.1097\/MPG.0000000000001385"},{"key":"123734","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/MPG.0000000000001385","DOI":"10.1097\/MPG.0000000000001385"},{"key":"123735","doi-asserted-by":"crossref","unstructured":"Th\u00e9r\u00e9n\u00e9, C., E. Brenaut, T. Barnetche and L. Misery (2018). \u201cEfficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis.\u201d J Invest Dermatol 138(1): 38\u201345.","DOI":"10.1016\/j.jid.2017.05.039"},{"key":"123736","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2017.05.039","DOI":"10.1016\/j.jid.2017.05.039"},{"key":"123737","doi-asserted-by":"crossref","unstructured":"Theodosiou, G., T. Nissen, E. Weisshaar, et al. (2022). Prevalence of Itch in German Schoolchildren: A Population-based Study. Acta Derm Venereol. 102:adv00718.","DOI":"10.2340\/actadv.v102.1063"},{"key":"123738","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v102.1063","DOI":"10.2340\/actadv.v102.1063"},{"key":"123739","doi-asserted-by":"crossref","unstructured":"Thompson, R. J., H. Arnell, R. Artan, U. Baumann and P. L. e. a. Calvo (2022). \u201cOdevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.\u201d Lancet Gastroenterol Hepatol 7(9): 830\u2013842.","DOI":"10.1016\/S2468-1253(22)00093-0"},{"key":"123740","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S2468-1253(22)00093-0","DOI":"10.1016\/S2468-1253(22)00093-0"},{"key":"123741","doi-asserted-by":"crossref","unstructured":"Thurmond, R. L. (2015). \u201cThe histamine H4 receptor: from orphan to the clinic.\u201d Front Pharmacol 6: 65.","DOI":"10.3389\/fphar.2015.00065"},{"key":"123742","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2015.00065","DOI":"10.3389\/fphar.2015.00065"},{"key":"123743","doi-asserted-by":"crossref","unstructured":"Thurmond, R. L., K. Kazerouni, S. R. Chaplan and A. J. Greenspan (2015). \u201cAntihistamines and Itch.\u201d Handb Exp Pharmacol 226: 257\u2013290.","DOI":"10.1007\/978-3-662-44605-8_15"},{"key":"123744","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/978-3-662-44605-8_15","DOI":"10.1007\/978-3-662-44605-8_15"},{"key":"123745","doi-asserted-by":"crossref","unstructured":"Tinegate, H. and J. McLelland (2002). \u201cTranscutaneous electrical nerve stimulation may improve pruritus associated with haematological disorders.\u201d Clin Lab Haematol 24(6): 389\u2013390.","DOI":"10.1046\/j.1365-2257.2002.00472.x"},{"key":"123746","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2257.2002.00472.x","DOI":"10.1046\/j.1365-2257.2002.00472.x"},{"key":"123747","doi-asserted-by":"crossref","unstructured":"Todberg, T., C. Zachariae and L. Skov (2020). \u201cTreatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study.\u201d Acta Derm Venereol 100(8): adv00119.","DOI":"10.2340\/00015555-3471"},{"key":"123748","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3471","DOI":"10.2340\/00015555-3471"},{"key":"123749","doi-asserted-by":"crossref","unstructured":"Tomas-Aragones, L., S. M. Consoli, S. G. Consoli, F. Poot, K. M. Taube, M. D. Linder, G. B. Jemec, J. C. Szepietowski, J. Korte, A. N. Lvov and U. Gieler (2016). \u201cSelf-Inflicted Lesions in Dermatology: A Management and Therapeutic Approach - A Position Paper From the European Society for Dermatology and Psychiatry.\u201d Acta Derm Venereol.","DOI":"10.2340\/00015555-2522"},{"key":"123750","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2522","DOI":"10.2340\/00015555-2522"},{"key":"123751","doi-asserted-by":"crossref","unstructured":"Tominaga, M., S. Tengara, A. Kamo, H. Ogawa and K. Takamori (2009). \u201cPsoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis.\u201d J Dermatol Sci 55(1): 40\u201346.","DOI":"10.1016\/j.jdermsci.2009.03.007"},{"key":"123752","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jdermsci.2009.03.007","DOI":"10.1016\/j.jdermsci.2009.03.007"},{"key":"123753","doi-asserted-by":"crossref","unstructured":"Topp, J., C. Apfelbacher, S. St\u00e4nder, M. Augustin and C. Blome (2022). \u201cMeasurement Properties of Patient-Reported Outcome Measures for Pruritus: An Updated Systematic Review.\u201d J Invest Dermatol 142(2): 343\u2013354.","DOI":"10.1016\/j.jid.2021.06.032"},{"key":"123754","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2021.06.032","DOI":"10.1016\/j.jid.2021.06.032"},{"key":"123755","doi-asserted-by":"crossref","unstructured":"Torres, T., I. Fernandes, M. Selores, R. Alves and M. Lima (2012). \u201cAprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.\u201d J Am Acad Dermatol 66(1): e14\u201315.","DOI":"10.1016\/j.jaad.2011.01.016"},{"key":"123756","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2011.01.016","DOI":"10.1016\/j.jaad.2011.01.016"},{"key":"123757","doi-asserted-by":"crossref","unstructured":"Treudler, R. (2010). \u201cAllergische Erkrankungen bei Schwangeren.\u201d Hautarzt 61: 1027\u20131033.","DOI":"10.1007\/s00105-010-2008-6"},{"key":"123758","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-010-2008-6","DOI":"10.1007\/s00105-010-2008-6"},{"key":"123759","doi-asserted-by":"crossref","unstructured":"Tsabouri, S., S. Arasi, B. Beken, M. K. Church, M. Alvaro-Lozano, C. Caffarelli, C. Flohr, S. R. Janmohamed, G. N. Konstantinou, S. Lau, S. Lefevre, C. G. Mortz, G. Pajno, H. Pite, K. Rutkowski, P. Staubach, L.-A. Van der Poe, T. Zuberbier and T. A. Leslie (2022). \u201cA European survey of management approaches in chronic urticaria in children : EAACI pediatric urticaria taskforce \u201c Pediatr Allergy Immunol 33: e13674.","DOI":"10.1111\/pai.13674"},{"key":"123760","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/pai.13674","DOI":"10.1111\/pai.13674"},{"key":"123761","doi-asserted-by":"crossref","unstructured":"Tsai, S. Y., W. Phipatanakul and E. B. e. a. Hawryluk (2024). \u201cComparative Safety of Oral Janus Kinase Inhibitors Versus Dupilumab in Patients With Atopic Dermatitis: A population-Based Cohort Study.\u201d J Allergy Clin Immunol 154(5): 1195\u20131203.","DOI":"10.1016\/j.jaci.2024.07.019"},{"key":"123762","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2024.07.019","DOI":"10.1016\/j.jaci.2024.07.019"},{"key":"123763","doi-asserted-by":"crossref","unstructured":"Tsianakas, A., C. Zeidler, C. Riepe, M. Borowski, C. Forner, J. Gerss, M. Metz, P. Staubach, U. Raap, M. Kaatz, M. Urban, T. A. Luger and S. St\u00e4nder (2019 [Epub ahead of print]). \u201cAprepitant in histamine-refractory chronic nodular prurigo: a multicentre, randomized, double-blind, placebo-controlled, cross-over, phase- II trial (APREPRU).\u201d Acta Derm Venereol.","DOI":"10.2340\/00015555-3120"},{"key":"123764","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3120","DOI":"10.2340\/00015555-3120"},{"key":"123765","doi-asserted-by":"crossref","unstructured":"Tupker, R. A., P. J. Coenraads and J. B. van der Meer (1992). \u201cTreatment of prurigo nodularis, chronic prurigo and neurodermatitis circumscripta with topical capsaicin.\u201d Acta Derm Venereol 72(6): 463.","DOI":"10.2340\/0001555572463"},{"key":"123766","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/0001555572463","DOI":"10.2340\/0001555572463"},{"key":"123767","doi-asserted-by":"crossref","unstructured":"Twycross, R., M. W. Greaves, H. Handwerker, E. A. Jones, S. E. Libretto, J. C. Szepietowski and Z. Zylicz (2003). \u201cItch: scratching more than the surface.\u201d QJM 96(1): 7\u201326.","DOI":"10.1093\/qjmed\/hcg002"},{"key":"123768","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/qjmed\/hcg002","DOI":"10.1093\/qjmed\/hcg002"},{"key":"123769","doi-asserted-by":"crossref","unstructured":"Umeuchi, H., Y. Togashi, T. Honda, K. Nakao, K. Okano, T. Tanaka and H. Nagase (2003). \u201cInvolvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.\u201d Eur J Pharmacol 477: 29\u201335.","DOI":"10.1016\/j.ejphar.2003.08.007"},{"key":"123770","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejphar.2003.08.007","DOI":"10.1016\/j.ejphar.2003.08.007"},{"key":"123771","doi-asserted-by":"crossref","unstructured":"Umezawa, Y., A. Asahina, S. Imafuku and Y. e. a. Tada (2021). \u201cEfficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.\u201d Dermatol Ther (Heidelb) 11(3): 943\u2013960.","DOI":"10.1007\/s13555-021-00520-0"},{"key":"123772","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-021-00520-0","DOI":"10.1007\/s13555-021-00520-0"},{"key":"123773","doi-asserted-by":"crossref","unstructured":"Uter, W., A. Bauer and A. Belloni Fortina, et al. (2021). \u201cPatch test results with the European baseline series and additions thereof in the ESSCA network, 2015-2018.\u201d Contact Dermatitis 84(2): 109\u2013120.","DOI":"10.1111\/cod.13704"},{"key":"123774","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/cod.13704","DOI":"10.1111\/cod.13704"},{"key":"123775","doi-asserted-by":"crossref","unstructured":"Valdes-Rodriguez, R., C. Stull and G. Yosipovitch (2015). \u201cChronic pruritus in the elderly: pathophysiology, diagnosis and management.\u201d Drugs Aging 32: 201\u2013215.","DOI":"10.1007\/s40266-015-0246-0"},{"key":"123776","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40266-015-0246-0","DOI":"10.1007\/s40266-015-0246-0"},{"key":"123777","doi-asserted-by":"crossref","unstructured":"van den Broek, H. (1980). \u201cTreatment of prurigo nodularis with thalidomide.\u201d Arch Dermatol 116(5): 571\u2013572.","DOI":"10.1001\/archderm.1980.01640290081018"},{"key":"123778","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.1980.01640290081018","DOI":"10.1001\/archderm.1980.01640290081018"},{"key":"123779","doi-asserted-by":"crossref","unstructured":"van Joost, T., E. Stolz and F. Heule (1987). \u201cEfficacy of low-dose cyclosporine in severe atopic skin disease.\u201d Arch Dermatol 123(2): 166\u2013167.","DOI":"10.1001\/archderm.1987.01660260034008"},{"key":"123780","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.1987.01660260034008","DOI":"10.1001\/archderm.1987.01660260034008"},{"key":"123781","doi-asserted-by":"crossref","unstructured":"van Os-Medendorp, H., W. J. Ros, P. C. Eland-de Kok, C. Kennedy, B. H. Thio, A. van der Schuur-van der Zande, M. H. Grypdonck and C. A. Bruijnzeel-Koomen (2007). \u201cEffectiveness of the nursing programme \u2018Coping with itch\u2019: a randomized controlled study in adults with chronic pruritic skin disease.\u201d Br J Dermatol 156(1235\u20131244).","DOI":"10.1111\/j.1365-2133.2007.07919.x"},{"key":"123782","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07919.x","DOI":"10.1111\/j.1365-2133.2007.07919.x"},{"key":"123783","doi-asserted-by":"crossref","unstructured":"Van Voorhees, A. S., L. Stein Gold, M. Lebwohl and B. e. a. Strober (2020). \u201cEfficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.\u201d J Am Acad Dermatol 83(1): 96\u2013103.","DOI":"10.1016\/j.jaad.2020.01.072"},{"key":"123784","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.01.072","DOI":"10.1016\/j.jaad.2020.01.072"},{"key":"123785","doi-asserted-by":"crossref","unstructured":"Vannucchi, A. M., J. J. Kiladjian, M. Griesshammer, T. Masszi, S. Durrant, F. Passamonti and C. N. e. a. Harrison (2015). \u201cRuxolitinib versus standard therapy for the treatment of polycythemia vera.\u201d N Engl J Med 372(5): 426\u2013435.","DOI":"10.1056\/NEJMoa1409002"},{"key":"123786","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1409002","DOI":"10.1056\/NEJMoa1409002"},{"key":"123787","doi-asserted-by":"crossref","unstructured":"Veien, N. K. and G. Laurberg (2011). \u201cBrachioradial pruritus: a follow-up of 76 patients.\u201d Acta Derm Venereol 91(2): 183\u2013185.","DOI":"10.2340\/00015555-1006"},{"key":"123788","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1006","DOI":"10.2340\/00015555-1006"},{"key":"123789","doi-asserted-by":"crossref","unstructured":"Verdu, E., I. Blanc-Brisset, G. Meyer, G. Le Roux, C. Bruneau and M. Deguigne (2020). \u201cSecond-generation antihistamines: a study of poisoning in children.\u201d Clin Toxicol (Phila) 58(4): 275\u2013283.","DOI":"10.1080\/15563650.2019.1634812"},{"key":"123790","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/15563650.2019.1634812","DOI":"10.1080\/15563650.2019.1634812"},{"key":"123791","doi-asserted-by":"crossref","unstructured":"Verweyen, E., S. St\u00e4nder, K. Kreitz and I. e. a. H\u00f6ben (2019). \u201cValidation of a Comprehensive Set of Pruritus Assessment Instruments: The Chronic Pruritus Tools Questionnaire PRURITOOLS.\u201d Acta Derm Venereol 99(7): 657\u2013663.","DOI":"10.2340\/00015555-3158"},{"key":"123792","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3158","DOI":"10.2340\/00015555-3158"},{"key":"123793","doi-asserted-by":"crossref","unstructured":"Vessal, G., M. M. Sagheb, S. Shilian, P. Jafari and S. M. Samani (2010). \u201cEffect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study.\u201d Nephrol Dial Transplant 25(5): 1541\u20131547.","DOI":"10.1093\/ndt\/gfp628"},{"key":"123794","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ndt\/gfp628","DOI":"10.1093\/ndt\/gfp628"},{"key":"123795","doi-asserted-by":"crossref","unstructured":"Vestergaard, C., A. Wollenberg and S. e. a. Barbarot (2019). \u201cEuropean task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period.\u201d J Eur Acad Dermatol Venereol 2019: 1644\u20131659.","DOI":"10.1111\/jdv.15709"},{"key":"123796","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15709","DOI":"10.1111\/jdv.15709"},{"key":"123797","unstructured":"Viegas, L. P., M. B. Ferreira and A. P. Kaplan (2014). \u201cThe maddening itch: an approach to chronic urticaria.\u201d J Investig Allergol Clin Immunol 24(1): 1\u20135."},{"key":"123798","doi-asserted-by":"crossref","unstructured":"Vila, T., J. Gommer and A. C. Scates (2008). \u201cRole of gabapentin in the treatment of uremic pruritus.\u201d Ann Pharmacother 42(7): 1080\u20131084.","DOI":"10.1345\/aph.1L038"},{"key":"123799","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1345\/aph.1L038","DOI":"10.1345\/aph.1L038"},{"key":"123800","doi-asserted-by":"crossref","unstructured":"Vincenzi, B., M. E. Fratto, D. Santini and G. Tonini (2010). \u201cAprepitant against pruritus in patients with solid tumours.\u201d Support Care Cancer 18(9): 1229\u20131230.","DOI":"10.1007\/s00520-010-0895-9"},{"key":"123801","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00520-010-0895-9","DOI":"10.1007\/s00520-010-0895-9"},{"key":"123802","doi-asserted-by":"crossref","unstructured":"Vincenzi, B., G. Tonini and D. Santini (2010). \u201cAprepitant for erlotinib-induced pruritus.\u201d N Engl J Med 363(4): 397\u2013398.","DOI":"10.1056\/NEJMc1003937"},{"key":"123803","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMc1003937","DOI":"10.1056\/NEJMc1003937"},{"key":"123804","doi-asserted-by":"crossref","unstructured":"Vincze, A., E. Herczeg-Lisztes, K. Szab\u00f3 and T. G. B\u00e9ldi, et al. (2023). \u201cPruritogenic molecules in the skin of patients with dermatomyositis.\u201d Front Med (Lausanne) 10: 1168359.","DOI":"10.3389\/fmed.2023.1168359"},{"key":"123805","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2023.1168359","DOI":"10.3389\/fmed.2023.1168359"},{"key":"123806","doi-asserted-by":"crossref","unstructured":"Visse, K., C. Blome, N. Q. Phan, M. Augustin and S. St\u00e4nder (2017). \u201cEfficacy of Body Lotion Containing N-palmitoylethanolamine in Subjects with Chronic Pruritus due to Dry Skin: A Dermatocosmetic Study.\u201d Acta Derm Venereol 97(5): 639\u2013641.","DOI":"10.2340\/00015555-2593"},{"key":"123807","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2593","DOI":"10.2340\/00015555-2593"},{"key":"123808","doi-asserted-by":"crossref","unstructured":"Wachholz, P. A., P. Y. Masuda, A. C. V. D. Pinto and A. C. C. Martelli (2017). \u201cImpact of drug therapy on brachioradial pruritus.\u201d An Bras Dermatol 92(2): 281\u2013282.","DOI":"10.1590\/abd1806-4841.20175321"},{"key":"123809","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1590\/abd1806-4841.20175321","DOI":"10.1590\/abd1806-4841.20175321"},{"key":"123810","doi-asserted-by":"crossref","unstructured":"Wagner, T., A. Roth-Daniek, A. Sell, J. England and K. U. Kern (2012). \u201cCapsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from \u2018real-world\u2019 clinical experience.\u201d Pain Manag 2(3): 239\u2013250.","DOI":"10.2217\/pmt.12.13"},{"key":"123811","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/pmt.12.13","DOI":"10.2217\/pmt.12.13"},{"key":"123812","unstructured":"Wahid, Z. and A. Kanjee (1998). \u201cCutaneous manifestations of diabetes mellitus.\u201d J Pak Med Assoc 48(10): 304\u2013305."},{"key":"123813","doi-asserted-by":"crossref","unstructured":"Wahlgren, C. F. (2005). \u201cChildren\u2019s rating of itch: an experimental study.\u201d Pediatr Dermatol 22(2): 97\u2013101.","DOI":"10.1111\/j.1525-1470.2005.22201.x"},{"key":"123814","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1525-1470.2005.22201.x","DOI":"10.1111\/j.1525-1470.2005.22201.x"},{"key":"123815","doi-asserted-by":"crossref","unstructured":"Wahlgren, C. F., A. Scheynius and O. Hagermark (1990). \u201cAntipruritic effect of oral cyclosporin A in atopic dermatitis.\u201d Acta Derm Venereol 70(4): 323\u2013329.","DOI":"10.2340\/0001555570323329"},{"key":"123816","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/0001555570323329","DOI":"10.2340\/0001555570323329"},{"key":"123817","doi-asserted-by":"crossref","unstructured":"Wallengren, J. (1998). \u201cBrachioradial pruritus: a recurrent solar dermopathy.\u201d J Am Acad Dermatol 39(5 Pt 1): 803\u2013806.","DOI":"10.1016\/S0190-9622(98)70058-1"},{"key":"123818","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(98)70058-1","DOI":"10.1016\/S0190-9622(98)70058-1"},{"key":"123819","doi-asserted-by":"crossref","unstructured":"Wallengren, J. (2004). \u201cPrurigo: diagnosis and management.\u201d Am J Clin Dermatol 5(2): 85\u201395.","DOI":"10.2165\/00128071-200405020-00003"},{"key":"123820","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00128071-200405020-00003","DOI":"10.2165\/00128071-200405020-00003"},{"key":"123821","doi-asserted-by":"crossref","unstructured":"Wallengren, J. (2011). \u201cTea tree oil attenuates experimental contact dermatitis.\u201d Arch Dermatol Res 303(5): 333\u2013338.","DOI":"10.1007\/s00403-010-1083-y"},{"key":"123822","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00403-010-1083-y","DOI":"10.1007\/s00403-010-1083-y"},{"key":"123823","doi-asserted-by":"crossref","unstructured":"Wallengren, J. and R. Hakanson (1992). \u201cEffects of capsaicin, bradykinin and prostaglandin E2 in the human skin.\u201d Br J Dermatol 126(2): 111\u2013117.","DOI":"10.1111\/j.1365-2133.1992.tb07806.x"},{"key":"123824","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.1992.tb07806.x","DOI":"10.1111\/j.1365-2133.1992.tb07806.x"},{"key":"123825","doi-asserted-by":"crossref","unstructured":"Wallengren, J. and M. Klinker (1995). \u201cSuccessful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study.\u201d J Am Acad Dermatol 32(2 Pt 1): 287\u2013289.","DOI":"10.1016\/0190-9622(95)90152-3"},{"key":"123826","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0190-9622(95)90152-3","DOI":"10.1016\/0190-9622(95)90152-3"},{"key":"123827","doi-asserted-by":"crossref","unstructured":"Wallengren, J. and F. Sundler (2001). \u201cCutaneous field stimulation in the treatment of severe itch.\u201d Arch Dermatol 137(10): 1323\u20131325.","DOI":"10.1001\/archderm.137.10.1323"},{"key":"123828","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archderm.137.10.1323","DOI":"10.1001\/archderm.137.10.1323"},{"key":"123829","doi-asserted-by":"crossref","unstructured":"Wallengren, J. and F. Sundler (2004). \u201cPhototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres.\u201d Acta Derm Venereol 84(2): 111\u2013115.","DOI":"10.1080\/00015550310022899"},{"key":"123830","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/00015550310022899","DOI":"10.1080\/00015550310022899"},{"key":"123831","doi-asserted-by":"crossref","unstructured":"Walt, R. P., T. K. Daneshmend, I. W. Fellows and P. J. Toghill (1988). \u201cEffect of stanozolol on itching in primary biliary cirrhosis.\u201d Br Med J (Clin Res Ed) 296(6622): 607.","DOI":"10.1136\/bmj.296.6622.607"},{"key":"123832","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.296.6622.607","DOI":"10.1136\/bmj.296.6622.607"},{"key":"123833","doi-asserted-by":"crossref","unstructured":"Wang, C. P., Y. C. Lu, I. T. Tsai, W. H. Tang, C. C. Hsu, W. C. Hung, T. H. Yu, S. C. Chen, F. M. Chung, Y. J. Lee and J. Y. Houng (2016). \u201cIncreased Levels of Total p-Cresylsulfate Are Associated with Pruritus in Patients with Chronic Kidney Disease.\u201d Dermatology 232(3): 363\u2013370.","DOI":"10.1159\/000445429"},{"key":"123834","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000445429","DOI":"10.1159\/000445429"},{"key":"123835","doi-asserted-by":"crossref","unstructured":"Wang, G. S., K. M. Reynolds, W. Banner, G. R. Bond, R. E. Kauffman, R. B. Palmer, I. M. Paul, M. Rapp-Olsson, J. L. Green and R. C. Dart (2020). \u201cAdverse Events Related to Accidental Unintentional Ingestions From Cough and Cold Medications in Children.\u201d Pediatr Emerg Care 38(1): e100-e104.","DOI":"10.1097\/PEC.0000000000002166"},{"key":"123836","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/PEC.0000000000002166","DOI":"10.1097\/PEC.0000000000002166"},{"key":"123837","doi-asserted-by":"crossref","unstructured":"Wang, H. and G. Yosipovitch (2010). \u201cNew insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma.\u201d Int J Dermatol 49(1): 1\u201311.","DOI":"10.1111\/j.1365-4632.2009.04249.x"},{"key":"123838","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04249.x","DOI":"10.1111\/j.1365-4632.2009.04249.x"},{"key":"123839","doi-asserted-by":"crossref","unstructured":"Wang, P.-F., Y. Chen, S.-Y. Song and T.-J. e. a. Wang (2017). \u201cImmune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis.\u201d Front Pharmacol 8: 730.","DOI":"10.3389\/fphar.2017.00730"},{"key":"123840","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2017.00730","DOI":"10.3389\/fphar.2017.00730"},{"key":"123841","doi-asserted-by":"crossref","unstructured":"Wang, X. D., G. Yang, Y. Bai, Y. P. Feng and H. LI (2018). \u201cThe behavioral study on the interactive aggravation between pruritus and depression.\u201d Brain Behav 8(6): e00964.","DOI":"10.1002\/brb3.964"},{"key":"123842","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/brb3.964","DOI":"10.1002\/brb3.964"},{"key":"123843","doi-asserted-by":"crossref","unstructured":"Wang, X. Y., M. Lim-Jurado, N. Prepageran, P. Tantilipikorn and W. d. Y. (2016). \u201cTreatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.\u201d Ther Clin Risk Manag 12: 585\u2013597.","DOI":"10.2147\/TCRM.S105189"},{"key":"123844","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/TCRM.S105189","DOI":"10.2147\/TCRM.S105189"},{"key":"123845","doi-asserted-by":"crossref","unstructured":"Wang, Y., D. Kong, C. Wang and J. Chen, et al. (2020). \u201cA Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.\u201d Technol Cancer Res Treat 19: 1533033820967454.","DOI":"10.1177\/1533033820967454"},{"key":"123846","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1533033820967454","DOI":"10.1177\/1533033820967454"},{"key":"123847","doi-asserted-by":"crossref","unstructured":"Weick, J. K., P. B. Donovan, Y. Najean, C. Dresch, A. V. Pisciotta, A. A. Cooperberg and J. D. Goldberg (1982). \u201cThe use of cimetidine for the treatment of pruritus in polycythemia vera.\u201d Arch Intern Med 142(2): 241\u2013242.","DOI":"10.1001\/archinte.1982.00340150041009"},{"key":"123848","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/archinte.1982.003401500410010","DOI":"10.1001\/archinte.1982.003401500410010"},{"key":"123849","doi-asserted-by":"crossref","unstructured":"Weiss, M., T. Mettang, U. Tschulena and E. Weisshaar (2016). \u201cHealth-related quality of life in haemodialysis patients suffering from chronic itch: results from GEHIS (German Epidemiology Haemodialysis Itch Study).\u201d Qual Life Res 25(12): 3097\u20133106.","DOI":"10.1007\/s11136-016-1340-4"},{"key":"123850","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11136-016-1340-4","DOI":"10.1007\/s11136-016-1340-4"},{"key":"123851","doi-asserted-by":"crossref","unstructured":"Weisshaar, E. (2008). \u201cIntractable chronic pruritus in a 67-year-old man.\u201d Acta Derm Venereol 88(5): 488\u2013490.","DOI":"10.2340\/00015555-0520"},{"key":"123852","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0520","DOI":"10.2340\/00015555-0520"},{"key":"123853","doi-asserted-by":"crossref","unstructured":"Weisshaar, E. (2015). \u201c[Genitoanal pruritus].\u201d Hautarzt 66(1): 53\u201359.","DOI":"10.1007\/s00105-014-3547-z"},{"key":"123854","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-014-3547-z","DOI":"10.1007\/s00105-014-3547-z"},{"key":"123855","doi-asserted-by":"crossref","unstructured":"Weisshaar, E. (2020). \u201c[Antihistamines for treating pruritus : The end of an era?].\u201d Hautarzt 71(7): 525\u2013527.","DOI":"10.1007\/s00105-020-04617-z"},{"key":"123856","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-020-04617-z","DOI":"10.1007\/s00105-020-04617-z"},{"key":"123857","doi-asserted-by":"crossref","unstructured":"Weisshaar, E., C. Apfelbacher, G. Jager, E. Zimmermann, T. Bruckner, T. L. Diepgen and H. Gollnick (2006). \u201cPruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients.\u201d Br J Dermatol 155(5): 957\u2013964.","DOI":"10.1111\/j.1365-2133.2006.07430.x"},{"key":"123858","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07430.x","DOI":"10.1111\/j.1365-2133.2006.07430.x"},{"key":"123859","doi-asserted-by":"crossref","unstructured":"Weisshaar, E. and F. Dalgard (2009). \u201cEpidemiology of itch: adding to the burden of skin morbidity.\u201d Acta Derm Venereol 89(4): 339\u2013350.","DOI":"10.2340\/00015555-0662"},{"key":"123860","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0662","DOI":"10.2340\/00015555-0662"},{"key":"123861","doi-asserted-by":"crossref","unstructured":"Weisshaar, E., T. L. Diepgen, T. Bruckner, M. Fartasch, J. Kupfer, T. Lob-Corzilius, J. Ring, S. Scheewe, R. Scheidt, G. Schmid-Ott, C. Schnopp, D. Staab, R. Szcepanski, T. Werfel, M. Wittenmeier, U. Wahn and U. Gieler (2008). \u201cItch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children.\u201d Acta Derm Venereol 88(3): 234\u2013239.","DOI":"10.2340\/00015555-0432"},{"key":"123862","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-0432","DOI":"10.2340\/00015555-0432"},{"key":"123863","unstructured":"Weisshaar, E., T. L. Diepgen, T. A. Luger, S. Seeliger, R. Witteler and S. Stander (2005). \u201cPruritus in pregnancy and childhood--do we really consider all relevant differential diagnoses?\u201d Eur J Dermatol 15(5): 320\u2013331."},{"key":"123864","doi-asserted-by":"crossref","unstructured":"Weisshaar, E., C. Forster, M. Dotzer and G. Heyer (1997). \u201cExperimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema.\u201d Skin Pharmacol 10(4): 183\u2013190.","DOI":"10.1159\/000211503"},{"key":"123865","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000211503","DOI":"10.1159\/000211503"},{"key":"123866","doi-asserted-by":"crossref","unstructured":"Weisshaar, E., G. Heyer, C. Forster, O. P. Hornstein and H. O. Handwerker (1996). \u201c[Antipruritic effect of antihistaminic and local anesthetic topical agents after iontophoretic histamine stimulation].\u201d Hautarzt 47(5): 355\u2013360.","DOI":"10.1007\/s001050050430"},{"key":"123867","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s001050050430","DOI":"10.1007\/s001050050430"},{"key":"123868","doi-asserted-by":"crossref","unstructured":"Weisshaar, E., J. P. Kupfer and P. e. a. Bentz (2024). \u201cValidation of the German Pruritus Questionnaire for the systematic assessment of chronic pruritus.\u201d JDDG: Journal der Deutschen Dermatologischen Gesellschaft 22: 956\u2013963.","DOI":"10.1111\/ddg.15430"},{"key":"123869","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.15430","DOI":"10.1111\/ddg.15430"},{"key":"123870","doi-asserted-by":"crossref","unstructured":"Weisshaar, E., M. Weiss, T. Mettang, G. Yosipovitch and Z. Zylicz (2015). \u201cParaneoplastic itch: An expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI).\u201d Acta Derm Ven 95: 261\u2013165.","DOI":"10.2340\/00015555-1959"},{"key":"123871","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-1959","DOI":"10.2340\/00015555-1959"},{"key":"123872","unstructured":"Welsh, A. L. (1955). Dermatologist\u2019s handbook. Springfield, Illinois, Charls C Thomas. Publisher."},{"key":"123873","doi-asserted-by":"crossref","unstructured":"Werfel, T., L. G., M. Yeadon, L. Whitlock, I. Osterloh, P. Jimenez, W. Liu, V. Lynch, A. Asher, A. Tsianakas and L. Purkins (2018). \u201cEfficacy and safety of the histamine H 4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis.\u201d J Allergy. Clin Immunol 143(5): 1830\u20131837.e1834.","DOI":"10.1016\/j.jaci.2018.07.047"},{"key":"123874","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaci.2018.07.047","DOI":"10.1016\/j.jaci.2018.07.047"},{"key":"123875","doi-asserted-by":"crossref","unstructured":"Wieczorek, A., P. Krajewski, M. Kozio\u0142-Ga\u0142czy\u0144ska and J. C. Szepietowski (2020). \u201cOpioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus.\u201d J Eur Acad Dermatol Venereol 34: 2368\u20132372.","DOI":"10.1111\/jdv.16360"},{"key":"123876","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16360","DOI":"10.1111\/jdv.16360"},{"key":"123877","doi-asserted-by":"crossref","unstructured":"Wikstrom, B., R. Gellert, S. D. Ladefoged, Y. Danda, M. Akai, K. Ide, M. Ogasawara, Y. Kawashima, K. Ueno, A. Mori and Y. Ueno (2005). \u201cKappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.\u201d J Am Soc Nephrol 16(12): 3742\u20133747.","DOI":"10.1681\/ASN.2005020152"},{"key":"123878","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1681\/ASN.2005020152","DOI":"10.1681\/ASN.2005020152"},{"key":"123879","doi-asserted-by":"crossref","unstructured":"Winkelmann, R. K., S. M. Connolly, J. A. Doyle and A. Padilha-Goncalves (1984). \u201cThalidomide treatment of prurigo nodularis.\u201d Acta Derm Venereol 64(5): 412\u2013417.","DOI":"10.2340\/0001555564412417"},{"key":"123880","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/0001555564412417","DOI":"10.2340\/0001555564412417"},{"key":"123881","doi-asserted-by":"crossref","unstructured":"Wiznia, L. E., S. W. Callahan, D. E. Cohen and S. J. Orlow (2018). \u201cRapid improvement of prurigo nodularis with cyclosporine treatment.\u201d J Am Acad Dermatol 78: 1209\u20131211.","DOI":"10.1016\/j.jaad.2018.02.024"},{"key":"123882","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.02.024","DOI":"10.1016\/j.jaad.2018.02.024"},{"key":"123883","doi-asserted-by":"crossref","unstructured":"Woelber, L., K. Prieske, W. Mendling, B. Schmalfeldt, H. J. Tietz and A. Jaeger (2019). \u201cVulvar pruritus-Causes, Diagnosis and Therapeutic Approach.\u201d Dtsch Arztebl Int 116(8): 126\u2013133.","DOI":"10.3238\/arztebl.2020.0126"},{"key":"123884","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3238\/arztebl.2020.0126","DOI":"10.3238\/arztebl.2020.0126"},{"key":"123885","doi-asserted-by":"crossref","unstructured":"Wojtowicz-Prus, E., K. Kilis-Pstrusinska, A. Reich, K. Zachwieja, M. Miklaszewska and M. Szczepanska (2016). \u201cChronic Kidney Disease-associated pruritus in children.\u201d Acta derm Venereol.","DOI":"10.2340\/00015555-2454"},{"key":"123886","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2454","DOI":"10.2340\/00015555-2454"},{"key":"123887","doi-asserted-by":"crossref","unstructured":"Wolf, R. and A. Krakowski (1988). \u201cVariations in aquagenic pruritus and treatment alternatives.\u201d J Am Acad Dermatol 18(5 Pt 1): 1081\u20131083.","DOI":"10.1016\/S0190-9622(88)70110-3"},{"key":"123888","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(88)70110-3","DOI":"10.1016\/S0190-9622(88)70110-3"},{"key":"123889","doi-asserted-by":"crossref","unstructured":"Wolfhagen, F. H., E. Sternieri, W. C. Hop, G. Vitale, M. Bertolotti and H. R. Van Buuren (1997). \u201cOral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.\u201d Gastroenterology 113(4): 1264\u20131269.","DOI":"10.1053\/gast.1997.v113.pm9322521"},{"key":"123890","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1053\/gast.1997.v113.pm9322521","DOI":"10.1053\/gast.1997.v113.pm9322521"},{"key":"123891","doi-asserted-by":"crossref","unstructured":"Wolking, S., H. Lerche and M. Dihn\u00e9 (2013). \u201cEpisodic itch in a case of spinal glioma.\u201d BMC Neurol(13): 124.","DOI":"10.1186\/1471-2377-13-124"},{"key":"123892","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1471-2377-13-124","DOI":"10.1186\/1471-2377-13-124"},{"key":"123893","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., S. Barbarot, T. Bieber, S. Christen-Zaech, M. Deleuran, A. Fink-Wagner, U. Gieler, G. Girolomoni, S. Lau, A. Muraro, M. Czarnecka-Operacz, T. Sch\u00e4fer, P. Schmid-Grendelmeier, D. Simon, Z. Szalai, J. C. Szepietowski, A. Ta\u00efeb, A. Torrelo, T. Werfel, J. Ring, t. E. D. F. (EDF), t. E. A. o. D. a. V. (EADV), t. E. A. o. A. a. C. I. (EAACI), t. E. T. F. o. A. D. (ETFAD), E. F. o. A. a. A. D. P. A. (EFA), t. E. S. f. D. a. P. (ESDaP), t. E. S. o. P. D. (ESPD), G. A. a. A. E. N. (GA2LEN) and t. E. U. o. M. S. (UEMS) (2018). \u201cConsensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.\u201d J Eur Acad Dermatol Venereol 32(5): 657\u2013682.","DOI":"10.1111\/jdv.14891"},{"key":"123894","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14891","DOI":"10.1111\/jdv.14891"},{"key":"123895","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., S. Barbarot, T. Bieber, S. Christen-Zaech, M. Deleuran, A. Fink-Wagner, U. Gieler, G. Girolomoni, S. Lau, A. Muraro, M. Czarnecka-Operacz, T. Sch\u00e4fer, P. Schmid-Grendelmeier, D. Simon, Z. Szalai, J. C. Szepietowski, A. Ta\u00efeb, A. Torrelo, T. Werfel, J. Ring, E. D. F. (EDF)., t. E. A. o. D. a. V. (EADV)., t. E. A. o. A. a. C. I. (EAACI)., t. E. T. F. o. A. D. (ETFAD)., E. F. o. A. a. A. D. P. A. (EFA)., t. E. S. f. D. a. P. (ESDaP)., t. E. S. o. P. D. (ESPD)., G. A. a. A. E. N. (GA2LEN). and t. E. U. o. M. S. (UEMS). (2018). \u201cConsensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.\u201d J Eur Acad Dermatol Venereol 32(6): 850\u2013878.","DOI":"10.1111\/jdv.14888"},{"key":"123896","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14888","DOI":"10.1111\/jdv.14888"},{"key":"123897","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., A. Blauvelt, E. Guttman-Yassky, M. Worm, C. Lynde, J. P. Lacour, L. Spelman, N. Katoh, H. Saeki, Y. Poulin, A. Lesiak, L. Kircik, S. H. Cho, P. Herranz, M. J. Cork, K. Peris, L. A. Steffensen, B. Bang, A. Kuznetsova, T. N. Jensen, M. L. \u00d8sterdal and E. L. Simpson (2021). \u201cTralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).\u201d Br J Dermatol 184(3): 437\u2013449.","DOI":"10.1111\/bjd.19574"},{"key":"123898","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19574","DOI":"10.1111\/bjd.19574"},{"key":"123899","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., S. Christen-Z\u00e4ch, A. Taieb, P. C., J. P. Thyssen, M. de Bruin-Weller, C. Vestergaard, J. Seneschal, T. Werfel, M. J. Cork, B. Kunz, R. F\u00f6lster-Holst, M. Trzeciak, U. Darsow, Z. Szalai, M. Deleuran, L. von Kobyletzki, S. Barbarot, A. Heratizadeh, U. Gieler, D. J. Hijnen, S. Weidinger, L. De Raeve, \u00c5. Svensson, D. Simon, J. F. Stalder, R. J; and E. T. F. o. A. D. E. E. T. Force (2020). \u201cETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.\u201d J Eur Acad Dermatol Venereol 34(12): 2717\u20132744.","DOI":"10.1111\/jdv.16892"},{"key":"123900","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16892","DOI":"10.1111\/jdv.16892"},{"key":"123901","doi-asserted-by":"crossref","unstructured":"Wollenberg, A. and A. Gim\u00e9nez-Arnau (2022). \u201cSensitive skin: A relevant syndrome, be aware.\u201d J Eur Acad Dermatol Venereol 36(Suppl 5): 3\u20135.","DOI":"10.1111\/jdv.17903"},{"key":"123902","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17903","DOI":"10.1111\/jdv.17903"},{"key":"123903","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., A. Oranje, M. Deleuran, D. Simon, Z. Szalai, B. Kunz, A. Svensson, S. Barbarot, L. von Kobyletzki, A. Taieb, M. de Bruin-Weller, T. Werfel, M. Trzeciak, C. Vestergard, J. Ring and U. Darsow (2016). \u201cEuropean Task Force on Atopic Dermatitis\/EADV Eczema Task Force. ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.\u201d J Eur Acad Dermatol Venereol 30(5): 729\u2013747.","DOI":"10.1111\/jdv.13599"},{"key":"123904","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.13599","DOI":"10.1111\/jdv.13599"},{"key":"123905","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., A. Oranje, M. Deleuran, D. Simon, Z. Szalai, B. Kunz, A. Svensson, S. Barbarot, L. von Kobyletzki, A. Taieb, M. de Bruin-Weller, T. Werfel, M. Trzeciak, C. Vestergard, J. Ring, U. Darsow and E. E. T. F. European Task Force on Atopic Dermatitis (2016). \u201cETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.\u201d J Eur Acad Dermatol Venereol 30(5): 729\u2013747.","DOI":"10.1111\/jdv.13599"},{"key":"123906","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.13599","DOI":"10.1111\/jdv.13599"},{"key":"123907","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., A. Oranje, M. Deleuran, D. Simon, Z. Szalai, B. Kunz, A. Svensson, S. Barbarot, L. von Kobyletzki, A. Taieb, M. de Bruin-Weller, T. Werfel, M. Trzeciak, C. Vestergard, J. Ring, U. Darsow and E. T. F. o. A. D. E. E. T. Force (2016). \u201cETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.\u201d J Eur Acad Dermatol Venereol 30(5): 729\u2013747.","DOI":"10.1111\/jdv.13599"},{"key":"123908","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.13599","DOI":"10.1111\/jdv.13599"},{"key":"123909","doi-asserted-by":"crossref","unstructured":"Wollina, U., G. Hansel, A. Koch and M. B. Abdel-Naser (2006). \u201cTopical pimecrolimus for skin disease other than atopic dermatitis.\u201d Expert Opin Pharmacother 7(14): 1967\u20131975.","DOI":"10.1517\/14656566.7.14.1967"},{"key":"123910","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1517\/14656566.7.14.1967","DOI":"10.1517\/14656566.7.14.1967"},{"key":"123911","doi-asserted-by":"crossref","unstructured":"Xifra, A., J. M. Carrascosa and C. Ferrandiz (2005). \u201cNarrow-band ultraviolet B in aquagenic pruritus.\u201d Br J Dermatol 153(6): 1233\u20131234.","DOI":"10.1111\/j.1365-2133.2005.06962.x"},{"key":"123912","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06962.x","DOI":"10.1111\/j.1365-2133.2005.06962.x"},{"key":"123913","doi-asserted-by":"crossref","unstructured":"Xu, L., H. Yu, S. Xu, Y. Wang and Y. Cao (2024). \u201cComparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis.\u201d Skin Res Technol 30(5): e13749.","DOI":"10.1111\/srt.13749"},{"key":"123914","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/srt.13749","DOI":"10.1111\/srt.13749"},{"key":"123915","doi-asserted-by":"crossref","unstructured":"Xu, S., X. Gao, J. Deng, J. Yang and F. Pan (2021). \u201cComparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.\u201d J Dtsch Dermatol Ges 19(1): 47\u201356.","DOI":"10.1111\/ddg.14308"},{"key":"123916","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14308","DOI":"10.1111\/ddg.14308"},{"key":"123917","doi-asserted-by":"crossref","unstructured":"Yagi, M., A. Tanaka, T. Namisaki, A. Takahashi, M. Abe, A. Honda, Y. Matsuzaki, H. Ohira, H. Yoshiji, H. Takikawa and J. P. S. G. (JPBCSG) (2018). \u201cIs patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.\u201d J Gastroenterol.","DOI":"10.1016\/S0168-8278(18)30672-X"},{"key":"123918","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00535-018-1465-z","DOI":"10.1007\/s00535-018-1465-z"},{"key":"123919","doi-asserted-by":"crossref","unstructured":"Yalcin, B., E. Tamer, G. G. Toy, P. Oztas, M. Hayran and N. Alli (2006). \u201cThe prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients.\u201d Int J Dermatol 45(6): 672\u2013676.","DOI":"10.1111\/j.1365-4632.2005.02607.x"},{"key":"123920","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2005.02607.x","DOI":"10.1111\/j.1365-4632.2005.02607.x"},{"key":"123921","doi-asserted-by":"crossref","unstructured":"Yang, V., T. W. Kragstrup, C. McMaster and P. e. a. Reid (2023). \u201cManaging Cardiovascular and Cancer Risk Associated with JAK Inhibitors.\u201d Drug Saf 46(11): 1049\u20131071.","DOI":"10.1007\/s40264-023-01333-0"},{"key":"123922","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40264-023-01333-0","DOI":"10.1007\/s40264-023-01333-0"},{"key":"123923","doi-asserted-by":"crossref","unstructured":"Yang, Y., Y. Sun, C. Zhu, X. Shen, J. Sun, T. Jing, S. Jun, C. Wang, G. Yu, X. Dong, M. Sheng and Z. Tang (2023). \u201cAllantoin induces pruritus by activating MrgprD in chronic kidney disease.\u201d J Cell Physiol 238(4): 813\u2013828.","DOI":"10.1002\/jcp.30977"},{"key":"123924","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/jcp.30977","DOI":"10.1002\/jcp.30977"},{"key":"123925","doi-asserted-by":"crossref","unstructured":"Yeam, C. T., T. E. Yo, Y. L. C. Tan, A. Liew and J. J. B. Seng (2021). \u201cComplementary and alternative medicine therapies for uremic pruritus - A systematic review of randomized controlled trials.\u201d Complement Ther Med 56: 102609.","DOI":"10.1016\/j.ctim.2020.102609"},{"key":"123926","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ctim.2020.102609","DOI":"10.1016\/j.ctim.2020.102609"},{"key":"123927","doi-asserted-by":"crossref","unstructured":"Yin, M., R. Wu, J. Chen and X. Dou (2022). \u201cSuccessful treatment of refractory prurigo nodularis with baricitinib.\u201d Dermatol Ther 35(8): e15642.","DOI":"10.1111\/dth.15642"},{"key":"123928","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15642","DOI":"10.1111\/dth.15642"},{"key":"123929","doi-asserted-by":"crossref","unstructured":"Yin, Q., J. Li, Y. Xia, R. Zhang, J. Wang, W. Lu, Y. Zhou, Y. Zheng, H. Abudumijiti, R. Chen, K. Chen, S. Li, T. Liu, F. Wang, J. Lu, Y. Zhou and C. Guo (2015). \u201cSystematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.\u201d Drug Des Devel Ther 9: 5407\u20135419.","DOI":"10.2147\/DDDT.S92041"},{"key":"123930","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/DDDT.S92041","DOI":"10.2147\/DDDT.S92041"},{"key":"123931","doi-asserted-by":"crossref","unstructured":"Yokozeki, H., H. Murota, T. Matsumura, H. Komazaki and f. t. N.-J. S. Group (2024). \u201cEfficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u2265 13 years.\u201d Br J Dermatol 191(2): 200\u2013208.","DOI":"10.1093\/bjd\/ljae338"},{"key":"123932","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljae131","DOI":"10.1093\/bjd\/ljae131"},{"key":"123933","doi-asserted-by":"crossref","unstructured":"Yoon, S., K. Kim, K. Shin and H.-S. e. a. Kim (2024). \u201cThe safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.\u201d J Eur Acad Dermatol Venereol 38(1): 52\u201361.","DOI":"10.1111\/jdv.19426"},{"key":"123934","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19426","DOI":"10.1111\/jdv.19426"},{"key":"123935","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G. (2010). \u201cChronic Pruritus: a Paraneoplastic Sign.\u201d dermatol Ther 23(6): 590\u2013596.","DOI":"10.1111\/j.1529-8019.2010.01366.x"},{"key":"123936","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1529-8019.2010.01366.x","DOI":"10.1111\/j.1529-8019.2010.01366.x"},{"key":"123937","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G., A. Awad, R. H. Spencer, C. Munera and F. Menzaghi (2023). \u201cA phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.\u201d J Am Acad Dermatol 89(2): 261\u2013268.","DOI":"10.1016\/j.jaad.2023.03.051"},{"key":"123938","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.051","DOI":"10.1016\/j.jaad.2023.03.051"},{"key":"123939","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G., M. I. Duque, K. Fast, A. G. Dawn and R. C. Coghill (2007). \u201cScratching and noxious heat stimuli inhibit itch in humans: a psychophysical study.\u201d Br J Dermatol 156(4): 629\u2013634.","DOI":"10.1111\/j.1365-2133.2006.07711.x"},{"key":"123940","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07711.x","DOI":"10.1111\/j.1365-2133.2006.07711.x"},{"key":"123941","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G., A. Goon, J. Wee, Y. H. Chan and C. L. Goh (2000). \u201cThe prevalence and clinical characteristics of pruritus among patients with extensive psoriasis.\u201d Br J Dermatol 143: 969\u2013973.","DOI":"10.1046\/j.1365-2133.2000.03829.x"},{"key":"123942","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.2000.03829.x","DOI":"10.1046\/j.1365-2133.2000.03829.x"},{"key":"123943","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G., N. Mollanazar, S. St\u00e4nder and S. G. e. a. Kwatra (2023). \u201cDupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.\u201d Nature Medicine 29: 1180\u20131190.","DOI":"10.1038\/s41591-023-02320-9"},{"key":"123944","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41591-023-02320-9","DOI":"10.1038\/s41591-023-02320-9"},{"key":"123945","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G., C. Szolar, X. Y. Hui and H. Maibach (1996). \u201cEffect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin.\u201d Arch Dermatol Res 288(5\u20136): 245\u2013248.","DOI":"10.1007\/BF02530092"},{"key":"123946","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/BF02530092","DOI":"10.1007\/BF02530092"},{"key":"123947","doi-asserted-by":"crossref","unstructured":"Young, T. A., T. S. Patel, F. Camacho, A. Clark, B. I. Freedman, M. Kaur, J. Fountain, L. L. Williams, G. Yosipovitch and A. B. J. Fleischer (2009). \u201cA pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients.\u201d J Dermatolog Treat 20(2): 76\u201381.","DOI":"10.1080\/09546630802441218"},{"key":"123948","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546630802441218","DOI":"10.1080\/09546630802441218"},{"key":"123949","doi-asserted-by":"crossref","unstructured":"Yuan, C., X. M. Wang, A. Guichard, Y. M. Tan, C. Y. Qian, L. J. Yang and P. Humbert (2014). \u201cN-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients.\u201d Clin Interv Aging 17(9): 1163\u20131169.","DOI":"10.2147\/CIA.S65448"},{"key":"123950","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CIA.S65448","DOI":"10.2147\/CIA.S65448"},{"key":"123951","doi-asserted-by":"crossref","unstructured":"Yue, J., S. Jiao, Y. Xiao, W. Ren, T. Zhao and J. Meng (2015). \u201cComparison of pregabalin with ondansetron in treatment of uremic pruritus in dialysis patients: a prospective, randomized, double-blind study.\u201d Int Urol Nephrol 47(1): 161\u2013167.","DOI":"10.1007\/s11255-014-0795-x"},{"key":"123952","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11255-014-0795-x","DOI":"10.1007\/s11255-014-0795-x"},{"key":"123953","doi-asserted-by":"crossref","unstructured":"Zanardelli, M., M. Kovacevic, J. McCoy, X. Wang, A. Goren and T. Lotti (2016). \u201cManagement of chronic pruritus with a UV filtering topical cream.\u201d Dermatol Ther 29(2): 101\u2013103.","DOI":"10.1111\/dth.12309"},{"key":"123954","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.12309","DOI":"10.1111\/dth.12309"},{"key":"123955","doi-asserted-by":"crossref","unstructured":"Zeidler, C., J. Kupfer and F. J. e. a. Dalgard (2024). \u201cDermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: Results from a European multi-centre study.\u201d J Eur Acad Dermatol Venereol 38: 1649\u20131661.","DOI":"10.1111\/jdv.19913"},{"key":"123956","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.19913","DOI":"10.1111\/jdv.19913"},{"key":"123957","doi-asserted-by":"crossref","unstructured":"Zeidler, C., H. L\u00fcling, A. Dieckh\u00f6fer, N. Osada, F. Schedel, S. Steinke, M. Augustin and S. St\u00e4nder (2015). \u201cCapsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus?\u201d Br J Dermatol 172(6): 1669\u20131671.","DOI":"10.1111\/bjd.13501"},{"key":"123958","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.13501","DOI":"10.1111\/bjd.13501"},{"key":"123959","doi-asserted-by":"crossref","unstructured":"Zeidler, C. and S. St\u00e4nder (2014). \u201cSecondary generalized brachioradial pruritus. An uncommon but easy-to-use differential diagnostic approach to generalized pruritus.\u201d Hautarzt 65(1): 56\u201358.","DOI":"10.1007\/s00105-013-2679-x"},{"key":"123960","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00105-013-2679-x","DOI":"10.1007\/s00105-013-2679-x"},{"key":"123961","doi-asserted-by":"crossref","unstructured":"Zeidler, C., S. Steinke, C. Riepe, P. Bruland, I. Soto-Rey, M. Storck, S. Garcovich, C. Blome, S. Bobko, F. J. Legat, N. Potekaev, A. Lvov, L. Misery, W. Weger, A. Reich, E. \u015eavk, M. Streit, E. Serra-Baldrich, J. C. Szepietowski, G. Yosipovitch, S. C. Chen, M. Dugas and S. St\u00e4nder (2019). \u201cCross-European validation of the ItchyQOL in pruritic dermatoses.\u201d J Eur Acad Dermatol Venereol 33: 391\u2013397.","DOI":"10.1111\/jdv.15225"},{"key":"123962","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15225","DOI":"10.1111\/jdv.15225"},{"key":"123963","unstructured":"Zhai, W., R. Tang, Y. Gao, H. Su, H. Mao, W. Liu, S. Ao, J. Han and F. Wang (2023). \u201cEfficacy and associated neurotransmitters of digital cognitive behavior therapy for atopic dermatitis: A comparative effectiveness research.\u201d Asian Pac J Allergy Immunol Epub ahead of print."},{"key":"123964","doi-asserted-by":"crossref","unstructured":"Zhao, Z. Q., F. Q. Huo, J. Jeffry, L. Hampton, S. Demehri, S. Kim, X. Y. Liu, D. M. Barry, L. Wan, Z. C. Liu, H. Li, A. Turkoz, K. Ma, L. A. Cornelius, R. Kopan, J. F. J. Battey, J. Zhong and Z. F. Chen (2013). \u201cChronic itch development in sensory neurons requires BRAF signaling pathways.\u201d J Clin Invest 123(11): 4769\u20134780.","DOI":"10.1172\/JCI70528"},{"key":"123965","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1172\/JCI70528","DOI":"10.1172\/JCI70528"},{"key":"123966","doi-asserted-by":"crossref","unstructured":"Zhou, T., Y. Zhang, Y. Ma, W. Ma and X. e. a. Wu (2022). \u201cComparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.\u201d Cancer 128(22): 3969\u20133976.","DOI":"10.1002\/cncr.34474"},{"key":"123967","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.34474","DOI":"10.1002\/cncr.34474"},{"key":"123968","doi-asserted-by":"crossref","unstructured":"Zhu, J., X. Zhao, A. A. Navarini and S. M. Mueller (2024). \u201cDevice-based physical therapies in chronic pruritus: A narrative review.\u201d J Am Acad Dermatol 91(4): 699\u2013705.","DOI":"10.1016\/j.jaad.2024.06.045"},{"key":"123969","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2024.06.045","DOI":"10.1016\/j.jaad.2024.06.045"},{"key":"123970","unstructured":"Zirwas MJ, B. S. (2017). \u201cAnti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream.\u201d J Drugs Dermatol 16(3): 243\u2013247."},{"key":"123971","doi-asserted-by":"crossref","unstructured":"Zuberbier, T., A. H. Abdul Latiff, M. Abuzakouk, S. Aquilina, R. Asero, D. Baker, B. Ballmer-Weber, C. Bangert, M. Ben-Shoshan, J. A. Bernstein, C. Bindslev-Jensen, K. Brockow, Z. Brzoza, C. N. H. J., M. K. Church, P. R. Criado, I. V. Danilycheva, C. Dressler, L. F. Ensina and L. e. a. Fonacier (2021). \u201cThe international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.\u201d Allergy.","DOI":"10.26416\/Aler.6.4.2021.5815"},{"key":"123972","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.26416\/Aler.6.4.2021.5815","DOI":"10.26416\/Aler.6.4.2021.5815"},{"key":"123973","doi-asserted-by":"crossref","unstructured":"Zuberbier, T., W. Aberer, R. Asero, A. H. Abdul Latiff, D. Baker, B. Ballmer-Weber, J. A. Bernstein, C. Bindslev-Jensen, Z. Brzoza, R. Buense Bedrikow, G. W. Canonica, M. K. Church, T. Craig, I. V. Danilycheva, C. Dressler, L. F. Ensina, A. Gim\u00e9nez-Arnau, K. Godse, M. Gon\u00e7alo, C. Grattan, J. Hebert, M. Hide, A. Kaplan, A. Kapp, C. H. Katelaris, E. Kocat\u00fcrk, K. Kulthanan, D. Larenas-Linnemann, T. A. Leslie, M. Magerl, P. Mathelier-Fusade, R. Y. Meshkova, M. Metz, A. Nast, E. Nettis, H. Oude-Elberink, S. Rosumeck, S. S. Saini, M. S\u00e1nchez-Borges, P. Schmid-Grendelmeier, P. Staubach, G. Sussman, E. Toubi, G. A. Vena, C. Vestergaard, B. Wedi, R. N. Werner, Z. Zhao and M. Maurer (2018). \u201cThe EAACI\/GA\u00b2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria.\u201d Allergy 3(7): 1393\u20131414.","DOI":"10.1111\/all.13397"},{"key":"123974","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.13397","DOI":"10.1111\/all.13397"},{"key":"123975","unstructured":"Zuberbier, T., W. Aberer, R. Asero, A. H. Abdul Latiff, D. Baker, B. Ballmer-Weber, J. A. Bernstein, C. Bindslev-Jensen, Z. Brzoza, R. Buense Bedrikow, G. W. Canonica, M. K. Church, T. Craig, I. V. Danilycheva, C. Dressler, L. F. Ensina, A. Gim\u00e9nez-Arnau, K. Godse, M. Gon\u00e7alo, C. Grattan, J. Hebert, M. Hide, A. Kaplan, A. Kapp, C. H. Katelaris, E. Kocat\u00fcrk, K. Kulthanan, D. Larenas-Linnemann, T. A. Leslie, M. Magerl, P. Mathelier-Fusade, R. Y. Meshkova, M. Metz, A. Nast, E. Nettis, H. Oude-Elberink, S. Rosumeck, S. S. Saini, M. S\u00e1nchez-Borges, P. Schmid-Grendelmeier, P. Staubach, G. Sussman, E. Toubi, G. A. Vena, C. Vestergaard, B. Wedi, R. N. Werner, Z. Zhao and M. Maurer (2018). \u201cThe EAACI\/GA\u00b2LEN\/EDF\/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update.\u201d Allergy."},{"key":"#cr-split#-123976.1","unstructured":"Zuberbier, T., W. Aberer, R. Asero, C. Bindslev-Jensen, Z. Brzoza, G. W. Canonica, M. K. Church, L. F. Ensina, A. Gimenez-Arnau, K. Godse, M. Gon\u00e7alo, C. Grattan, J. Hebert, M. Hide, A. Kaplan, A. Kapp, A. H. Abdul Latiff, P. Mathelier-Fusade, M. Metz, Nast, A., Saini, S. S., M. Sanchez-Borges, P. Schmid-Grendelmeier, F. E. R. Simons, P. Staubach, G. Sussman, E. Toubi, G. A. Vena, B. Wedi, X. J. Zhu and M. Maurer (2014). \"The EAACI\/GA"},{"key":"#cr-split#-123976.2","doi-asserted-by":"crossref","unstructured":"(2) LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.\" Allergy 69: 868-887.","DOI":"10.1111\/all.12313"},{"key":"123977","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/all.12313","DOI":"10.1111\/all.12313"},{"key":"123978","doi-asserted-by":"crossref","unstructured":"Zuberbier, T., C. Bindslev-Jensen, W. Canonica, C. E. Grattan, M. W. Greaves, B. M. Henz, A. Kapp, M. M. Kozel, M. Maurer, H. F. Merk, T. Schafer, D. Simon, G. A. Vena, B. Wedi and Eaaci\/Ga2Len\/Edf (2006). \u201cEAACI\/GA2LEN\/EDF guideline: management of urticaria.\u201d Allergy 61(3): 321\u2013331.","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"key":"123979","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1398-9995.2005.00962.x","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"key":"123980","doi-asserted-by":"crossref","unstructured":"Zylicz, Z., M. Krajnik, A. A. Sorge and M. Costantini (2003). \u201cParoxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial.\u201d J Pain Symptom Manage 26(6): 1105\u20131112.","DOI":"10.1016\/j.jpainsymman.2003.05.004"},{"key":"123981","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2003.05.004","DOI":"10.1016\/j.jpainsymman.2003.05.004"},{"key":"123982","unstructured":"Zylicz, Z., C. Smits and M. Krajnik (1998). \u201cParoxetine for pruritus in advanced cancer.\u201d J Pain Symptom Manage 16(2): 121\u2013124."},{"key":"123983","doi-asserted-by":"crossref","unstructured":"Zylicz, Z., R. Twycross and E. A. Jones (2004). Pruritus in advanced disease. Oxford, Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780198525103.001.0001"},{"key":"123984","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/acprof:oso\/9780198525103.001.0001","DOI":"10.1093\/acprof:oso\/9780198525103.001.0001"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44220\/51149","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44220\/51149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T09:58:20Z","timestamp":1755856700000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/44220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":1624,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.44220","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}